
<html lang="en"     class="pb-page"  data-request-id="c486b22b-3016-4b68-b889-319c20fc59c9"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.0c02254;requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2021.64.issue-11;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of Novel Benzothiazepinones as Irreversible Covalent Glycogen Synthase Kinase 3β Inhibitors for the Treatment of Acute Promyelocytic Leukemia" /></meta><meta name="dc.Creator" content="Peng  Zhang" /></meta><meta name="dc.Creator" content="Zhihui  Min" /></meta><meta name="dc.Creator" content="Yang  Gao" /></meta><meta name="dc.Creator" content="Jiang  Bian" /></meta><meta name="dc.Creator" content="Xin  Lin" /></meta><meta name="dc.Creator" content="Jie  He" /></meta><meta name="dc.Creator" content="Deyong  Ye" /></meta><meta name="dc.Creator" content="Yilin  Li" /></meta><meta name="dc.Creator" content="Chao  Peng" /></meta><meta name="dc.Creator" content="Yunfeng  Cheng" /></meta><meta name="dc.Creator" content="Yong  Chu" /></meta><meta name="dc.Description" content="Recently, irreversible inhibitors have attracted great interest in antitumors due to their advantages of forming covalent bonds to target proteins. Herein, some benzothiazepinone compounds (BTZs) h..." /></meta><meta name="Description" content="Recently, irreversible inhibitors have attracted great interest in antitumors due to their advantages of forming covalent bonds to target proteins. Herein, some benzothiazepinone compounds (BTZs) h..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 24, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c02254" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02254" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c02254" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02254" /></link>
        
    
    

<title>Discovery of Novel Benzothiazepinones as Irreversible Covalent Glycogen Synthase Kinase 3β Inhibitors for the Treatment of Acute Promyelocytic Leukemia | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c02254" /></meta><meta property="og:title" content="Discovery of Novel Benzothiazepinones as Irreversible Covalent Glycogen Synthase Kinase 3β Inhibitors for the Treatment of Acute Promyelocytic Leukemia" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0016.jpeg" /></meta><meta property="og:description" content="Recently, irreversible inhibitors have attracted great interest in antitumors due to their advantages of forming covalent bonds to target proteins. Herein, some benzothiazepinone compounds (BTZs) have been designed and synthesized as novel covalent GSK-3β inhibitors with high selectivity for the kinase panel. The irreversible covalent binding mode was identified by kinetics and mass spectrometry, and the main labeled residue was confirmed to be the unique Cys14 that exists only in GSK-3β. The candidate 4-3 (IC50 = 6.6 μM) showed good proliferation inhibition and apoptosis-inducing ability to leukemia cell lines, low cytotoxicity on normal cell lines, and no hERG inhibition, which hinted the potential efficacy and safety. Furthermore, 4-3 exhibited decent pharmacokinetic properties in vivo and remarkably inhibited tumor growth in the acute promyelocytic leukemia (APL) mouse model. All the results suggest that these newly irreversible BTZ compounds might be useful in the treatment of cancer such as APL." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c02254"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02254">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c02254&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c02254&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c02254&amp;href=/doi/10.1021/acs.jmedchem.0c02254" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 11</span><span class="cit-fg-pageRange">, 7341-7358</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/11" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c02186" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c02257" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Novel Benzothiazepinones as Irreversible Covalent Glycogen Synthase Kinase 3β Inhibitors for the Treatment of Acute Promyelocytic Leukemia</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Peng Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peng Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China</div><div class="loa-info-affiliations-info">State Key Lab of New Drug & Pharmaceutical Process, Shanghai Key Lab of Anti-Infectives, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peng++Zhang">Peng Zhang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-2703-6009" title="Orcid link">https://orcid.org/0000-0002-2703-6009</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhihui Min</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhihui Min</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai 200032, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhihui++Min">Zhihui Min</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yang Gao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yang Gao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yang++Gao">Yang Gao</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-9131-3541" title="Orcid link">https://orcid.org/0000-0002-9131-3541</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jiang Bian</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jiang Bian</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jiang++Bian">Jiang Bian</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xin Lin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xin Lin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xin++Lin">Xin Lin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jie He</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jie He</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jie++He">Jie He</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Deyong Ye</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Deyong Ye</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Deyong++Ye">Deyong Ye</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-0498-3019" title="Orcid link">https://orcid.org/0000-0003-0498-3019</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yilin Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yilin Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National Facility for Protein Science in Shanghai, Zhangjiang Lab, Shanghai Advanced Research Institute, Chinese Academy of Science, Shanghai 201210, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yilin++Li">Yilin Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chao Peng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chao Peng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National Facility for Protein Science in Shanghai, Zhangjiang Lab, Shanghai Advanced Research Institute, Chinese Academy of Science, Shanghai 201210, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chao++Peng">Chao Peng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yunfeng Cheng</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yunfeng Cheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai 200032, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#4f36292c272a21280f293a2b2e21612a2b3a612c21"><span class="__cf_email__" data-cfemail="0178676269646f6641677465606f2f6465742f626f">[email protected]</span></a>. Phone: +86-21-60267312. Fax: +86-21-60267312.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yunfeng++Cheng">Yunfeng Cheng</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Yong Chu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yong Chu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#9af9e3ababaadafceffefbf4b4fffeefb4f9f4"><span class="__cf_email__" data-cfemail="b0d3c9818180f0d6c5d4d1de9ed5d4c59ed3de">[email protected]</span></a>. Phone: +86-21-51980125. Fax: +86-21-51980125.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yong++Chu">Yong Chu</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02254&amp;href=/doi/10.1021%2Facs.jmedchem.0c02254" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 11</span><span class="cit-pageRange">, 7341–7358</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 24, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>29 December 2020</li><li><span class="item_label"><b>Published</b> online</span>24 May 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 June 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c02254" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02254</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7341%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DPeng%2BZhang%252C%2BZhihui%2BMin%252C%2BYang%2BGao%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D11%26contentID%3Dacs.jmedchem.0c02254%26title%3DDiscovery%2Bof%2BNovel%2BBenzothiazepinones%2Bas%2BIrreversible%2BCovalent%2BGlycogen%2BSynthase%2BKinase%2B3%25CE%25B2%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BAcute%2BPromyelocytic%2BLeukemia%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7358%26publicationDate%3DJune%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c02254"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">932</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c02254" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Novel Benzothiazepinones as Irreversible Covalent Glycogen Synthase Kinase 3β Inhibitors for the Treatment of Acute Promyelocytic Leukemia&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Peng&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Zhihui&quot;,&quot;last_name&quot;:&quot;Min&quot;},{&quot;first_name&quot;:&quot;Yang&quot;,&quot;last_name&quot;:&quot;Gao&quot;},{&quot;first_name&quot;:&quot;Jiang&quot;,&quot;last_name&quot;:&quot;Bian&quot;},{&quot;first_name&quot;:&quot;Xin&quot;,&quot;last_name&quot;:&quot;Lin&quot;},{&quot;first_name&quot;:&quot;Jie&quot;,&quot;last_name&quot;:&quot;He&quot;},{&quot;first_name&quot;:&quot;Deyong&quot;,&quot;last_name&quot;:&quot;Ye&quot;},{&quot;first_name&quot;:&quot;Yilin&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Chao&quot;,&quot;last_name&quot;:&quot;Peng&quot;},{&quot;first_name&quot;:&quot;Yunfeng&quot;,&quot;last_name&quot;:&quot;Cheng&quot;},{&quot;first_name&quot;:&quot;Yong&quot;,&quot;last_name&quot;:&quot;Chu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;24&quot;,&quot;issue&quot;:&quot;11&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;7341-7358&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c02254&quot;},&quot;abstract&quot;:&quot;Recently, irreversible inhibitors have attracted great interest in antitumors due to their advantages of forming covalent bonds to target proteins. Herein, some benzothiazepinone compounds (BTZs) have been designed and synthesized as novel covalent GSK-3β inhibitors with high selectivity for the kinase panel. The irreversible covalent binding mode was identified by kinetics and mass spectrometry, and the main labeled residue was confirmed to be the unique Cys14 that exists only in GSK-3β. The candidate 4-3 (IC50 = 6.6 μM) showed good proliferation inhibition and apoptosis-inducing ability to leukemia cell lines, low cytotoxicity on normal cell lines, and no hERG inhibition, which hinted the potential efficacy and safety. Furthermore, 4-3 exhibited decent pharmacokinetic properties in vivo and remarkably inhibited tumor growth in the acute promyelocytic leukemia (APL) mouse model. All the results suggest that these newly irreversible BTZ compounds might be useful in the treatment of cancer such as APL.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02254&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02254" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02254&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02254" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02254&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02254" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02254&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02254&amp;href=/doi/10.1021/acs.jmedchem.0c02254" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c02254" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c02254" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c02254%26sid%3Dliteratum%253Aachs%26pmid%3D34027661%26genre%3Darticle%26aulast%3DZhang%26date%3D2021%26atitle%3DDiscovery%2Bof%2BNovel%2BBenzothiazepinones%2Bas%2BIrreversible%2BCovalent%2BGlycogen%2BSynthase%2BKinase%2B3%25CE%25B2%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BAcute%2BPromyelocytic%2BLeukemia%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D11%26spage%3D7341%26epage%3D7358%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291149" title="Apoptosis">Apoptosis</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/11" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/jmcmar.2021.64.issue-11/20210610/jmcmar.2021.64.issue-11.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/medium/jm0c02254_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02254&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Recently, irreversible inhibitors have attracted great interest in antitumors due to their advantages of forming covalent bonds to target proteins. Herein, some benzothiazepinone compounds (BTZs) have been designed and synthesized as novel covalent GSK-3β inhibitors with high selectivity for the kinase panel. The irreversible covalent binding mode was identified by kinetics and mass spectrometry, and the main labeled residue was confirmed to be the unique Cys14 that exists only in GSK-3β. The candidate <b>4</b>-<b>3</b> (IC<sub>50</sub> = 6.6 μM) showed good proliferation inhibition and apoptosis-inducing ability to leukemia cell lines, low cytotoxicity on normal cell lines, and no hERG inhibition, which hinted the potential efficacy and safety. Furthermore, <b>4</b>-<b>3</b> exhibited decent pharmacokinetic properties <i>in vivo</i> and remarkably inhibited tumor growth in the acute promyelocytic leukemia (APL) mouse model. All the results suggest that these newly irreversible BTZ compounds might be useful in the treatment of cancer such as APL.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85061" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85061" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The malignant tumor remains the second leading cause of death worldwide, and aberrant protein kinase regulation is believed to be responsible for the occurrence of various cancers. Consequently, kinases have been very promising targets for anticancer drugs. However, most of the reported protein kinase inhibitors are reversible ATP competitive inhibitors. Due to the abundance of kinases and their high sequence conservation in the ATP-binding site, the discovery of potential drugs with high kinase selectivity has proved extremely challenging.</div><div class="NLM_p">Irreversible covalent kinase inhibitors have drawn increasing attention mainly due to their advantages over reversible non-covalent inhibitors, including (1) higher binding affinity to target, (2) longer interaction time with kinase, (3) higher therapeutic index, and (4) prevention of emergence of drug resistance.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a> To date, two covalent Bruton’s tyrosine kinase (BTK) inhibitors of Ibrutinib and Acalabrutinib and two covalent epidermal growth factor receptor (EGFR) inhibitors of Afatinib and Osimertinib have been approved by the FDA in the treatment of B-cell malignancies and non-small cell lung carcinoma (NSCLC) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), thus resulting in the development of more covalent kinase inhibitors.<a onclick="showRef(event, 'ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6 ref7">(4−7)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/medium/jm0c02254_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative covalent kinase inhibitors approved by the FDA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02254&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Glycogen synthase kinase-3 (GSK-3) is a highly conserved serine/threonine-protein kinase.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> In mammals, GSK-3 has two highly related subtypes named GSK-3α and GSK-3β that share amino acid sequence identity in 85% overall and 98% especially within their kinase domains.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Recent studies have confirmed that GSK-3β is the dominant subtype both physiologically and pathologically; therefore, the research work of GSK-3 mainly focuses on the β subtype.</div><div class="NLM_p">GSK-3β is critical in the regulation of transcription factors and signaling pathways that modulates gene transcription, cell growth, differentiation, and apoptosis.<a onclick="showRef(event, 'ref10 ref11 ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12 ref13 ref14">(10−14)</a> Thus, inhibition of GSK-3β might offer a new potential treatment for severe human diseases, such as Alzheimer’s disease,<a onclick="showRef(event, 'ref15 ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17 ref18">(15−18)</a> type II diabetes,<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> chronic inflammatory disease,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and cancer.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> Lately, emerging data revealed that GSK-3β might be a novel modulator of antitumor immune responses and is thought to be a novel checkpoint regulator for cancer, which further highlights the potential applications of GSK-3β inhibitors in cancer therapy.<a onclick="showRef(event, 'ref24 ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26 ref27">(24−27)</a></div><div class="NLM_p">To the best of our knowledge, though lots of small molecules with different structures have been published to inhibit GSK-3β,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> only thiadiazolidinones (TDZDs)<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> and halomethyl ketones<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a> have been reported to inhibit GSK-3β as irreversible inhibitors with 1–10 μM (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). One compound of TDZDs named tideglusib (NP-12) is undergoing phase IIb clinical trials in Europe for the evaluation of curative effects on orphan tauopathy and Alzheimer’s disease.<a onclick="showRef(event, 'ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34">(32−34)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/medium/jm0c02254_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Novel irreversible GSK-3β inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02254&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In the previous work, we found that benzothiazepinones (BTZs) were a novel family of GSK-3β inhibitors. After that, further investigations were performed over this skeleton to study the influence of structural modifications on biological activity. After an extensive study among different substituent groups on the core BTZ ring, herein we describe a successful strategy of introducing an electrophilic warhead into the core skeleton to build a new type of BTZ compounds as highly selective irreversible GSK-3β inhibitors. These new compounds were biophysically identified to work in an irreversible covalent manner and showed a good inhibitory activity to GSK-3β at the sub-micromolar level. They also showed good selectivity to GSK-3α and other kinases. Moreover, we assayed and discussed the proliferation inhibition and apoptosis-inducing ability of these compounds on some cancer and normal cell lines. Finally, we evaluated <i>in vivo</i> therapeutic efficacy in a localized leukemia xenograft mouse model. The observed results, including good features of pharmacokinetics (PKs) and hERG value, suggested that the newly irreversible BTZ compounds might be potentially powerful candidates with good safety for the treatment of cancer such as acute promyelocytic leukemia (APL).</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68060" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68060" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The general synthesis of target compounds <b>4</b> is outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The intermediate acids <b>2</b>-<b>1</b> to <b>2</b>-<b>16</b> were synthesized based on Knoevenagel condensation, in which a mixture of propanedioic acid and different aromatic formaldehydes <b>1</b>-<b>1</b> to <b>1</b>-<b>16</b> was heated to reflux in the presence of a base such as piperidine or pyridine. Compounds <b>2</b>-<b>17</b> and <b>2</b>-<b>18</b> were purchased commercially. An optimized reaction was applied to prepare the key intermediates <b>3</b>, in which cyclization of 2-aminobenzenethiol with various acids <b>2</b> was performed at 80 °C without any solvent but tetra-<i>n</i>-butylammonium fluoride (TBAF).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Finally, benzothiazepinone analogues <b>3</b>-<b>1</b> to <b>3</b>-<b>18</b> were successfully obtained from recrystallization in accepted yields. Based on the acylation of <b>3</b> with acryloyl chloride catalyzed by DIPEA, the object BTZ compounds <b>4</b> were obtained, in which the acryloyl group was introduced to the framework in 5-position.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/medium/jm0c02254_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0014.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Reagents and Conditions: (a) Malonic Acid, Piperidine, Pyridine, Reflux, 4 h; (b) 2-Aminothiophenol, TBAF·3H<sub>2</sub>O, 80 °C, 24 h; and (c) Acrolyl Chloride, DIPEA, DCM, rt, 24 h</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02254&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47438" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47438" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Design and Identification of BTZ Compounds as Potent GSK-3β Inhibitors</h3><div class="NLM_p">Because the acryloyl group is a good warhead used in covalent drugs, we introduce it into our BTZ skeleton to make an irreversible mode (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). We first synthesized compounds <b>4</b>-<b>1</b>, <b>6</b>, and <b>7</b> to check the best binding position. Both compounds <b>6</b> and <b>7</b> showed no inhibition to GSK-3β at even 100 μM concentration, while <b>4</b>-<b>1</b> showed good inhibition at an IC<sub>50</sub> value of 4.9 μM, which suggested that the direct introduction of the acryloyl group at the 5-position of the BTZ ring should be very crucial to maintain the inhibitory activity. To further examine the influence mode of the acryloyl moiety in <b>4</b>-<b>1</b>, compound <b>5</b> with the corresponding saturated propionyl moiety was synthesized. The biological test showed that no GSK-3β inhibitory activity was observed for compound <b>5</b> at even a high concentration of 100 μM, which indicated that the covalent reaction could happen at the carbon–carbon double bond of the acryloyl group in compound <b>4</b>-<b>1</b>.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/medium/jm0c02254_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compounds for identification of acryloyl attaching position and reactive mode.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02254&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Based on that results, we designed and synthesized some analogues of <b>4</b>-<b>1</b>, in which a variety of aryl, substituted aryl, and alkyl groups were substituted in the 2-position of the <b>BTZ</b> ring (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). The GSK-3β inhibitory activities of the newly prepared BTZ compounds were evaluated by a non-radioactive method described in our previous work according to the reported assay.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Briefly, after co-incubation of GSK-3β, substrate GS-2 peptide, and ATP in the presence/absence of the test compounds, the activity was calculated based on the unreacted ATP left in solution by the Kinase-Glo luminescent kinase assay. The members of this new family showed good GSK-3β inhibitory activities between 2.5 and 20 μM. Nearly all of them except compounds substituted with groups of 4-CF<sub>3</sub>-Ph, 4-morpholino-Ph, hydrogen, or methyl (<b>4</b>-<b>10</b>, <b>4</b>-<b>16</b> ∼ <b>4</b>-<b>18</b>) showed the IC<sub>50</sub> values for GSK-3β around 5 μM, which is nearly equal to that of the best reported irreversible inhibitors, such as TDZD-8.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Structure–Activity Relationship Studies</h3><div class="NLM_p">A preliminary structure–activity relationship (SAR) was analyzed according to the preceding <i>in vitro</i> data (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The acryloyl group substituted in the N5 position of the BTZ ring seemed to be critical for activity retention because the acryloyl moiety could act as a Michael addition acceptor to form a covalent bond with a specific cysteine residue of the targeted protein (<b>4</b>-<b>1</b> vs <b>5</b>, <b>6</b>, and <b>7</b>). Besides, the nature and size of C2-R groups should also be crucial for activity. The inhibition dramatically decreased (<b>4</b>-<b>17</b> and <b>4</b>-<b>18</b>) as the R is hydrogen or methyl, while increased greatly when aromatic groups were introduced into. Both electron-donating and electron-withdrawing groups substituted at the aromatic ring could inhibit the enzymatic activity at the low-micromole level (<10 μM) except the morpholino substituent, suggesting that a relatively large hydrophobic pocket could exist in the enzyme.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Inhibition of <b>BTZs</b> to GSK-3β and Cancer Cells</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd.</th><th class="colsep0 rowsep0" align="center" char=".">GSK-3β IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">NB4 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">Molt4 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">HL60 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">Raji IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b>-<b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">4.9</td><td class="colsep0 rowsep0" align="char" char=".">765.3</td><td class="colsep0 rowsep0" align="char" char=".">556.72</td><td class="colsep0 rowsep0" align="char" char=".">695.47</td><td class="colsep0 rowsep0" align="char" char=".">659.35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b>-<b>2</b></td><td class="colsep0 rowsep0" align="char" char=".">6.6</td><td class="colsep0 rowsep0" align="char" char=".">35.52</td><td class="colsep0 rowsep0" align="char" char=".">85.92</td><td class="colsep0 rowsep0" align="char" char=".">97.38</td><td class="colsep0 rowsep0" align="char" char=".">74.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b>-<b>3</b></td><td class="colsep0 rowsep0" align="char" char=".">6.6</td><td class="colsep0 rowsep0" align="char" char=".">19.56</td><td class="colsep0 rowsep0" align="char" char=".">75.58</td><td class="colsep0 rowsep0" align="char" char=".">86.3</td><td class="colsep0 rowsep0" align="char" char=".">28.45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b>-<b>4</b></td><td class="colsep0 rowsep0" align="char" char=".">6.7</td><td class="colsep0 rowsep0" align="char" char=".">22.62</td><td class="colsep0 rowsep0" align="char" char=".">82.36</td><td class="colsep0 rowsep0" align="char" char=".">95.71</td><td class="colsep0 rowsep0" align="char" char=".">18.39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b>-<b>5</b></td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">31.65</td><td class="colsep0 rowsep0" align="char" char=".">77.52</td><td class="colsep0 rowsep0" align="char" char=".">93.14</td><td class="colsep0 rowsep0" align="char" char=".">47.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b>-<b>6</b></td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="char" char=".">33.84</td><td class="colsep0 rowsep0" align="char" char=".">80.27</td><td class="colsep0 rowsep0" align="char" char=".">91.43</td><td class="colsep0 rowsep0" align="char" char=".">50.39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b>-<b>7</b></td><td class="colsep0 rowsep0" align="char" char=".">6.4</td><td class="colsep0 rowsep0" align="char" char=".">59.37</td><td class="colsep0 rowsep0" align="char" char=".">106.35</td><td class="colsep0 rowsep0" align="char" char=".">126.04</td><td class="colsep0 rowsep0" align="char" char=".">51.28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b>-<b>8</b></td><td class="colsep0 rowsep0" align="char" char=".">4.8</td><td class="colsep0 rowsep0" align="char" char=".">37.28</td><td class="colsep0 rowsep0" align="char" char=".">87.61</td><td class="colsep0 rowsep0" align="char" char=".">94.35</td><td class="colsep0 rowsep0" align="char" char=".">75.53</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b>-<b>9</b></td><td class="colsep0 rowsep0" align="char" char=".">6.2</td><td class="colsep0 rowsep0" align="char" char=".">32.94</td><td class="colsep0 rowsep0" align="char" char=".">83.16</td><td class="colsep0 rowsep0" align="char" char=".">92.07</td><td class="colsep0 rowsep0" align="char" char=".">43.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b>-<b>10</b></td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">38.55</td><td class="colsep0 rowsep0" align="char" char=".">76.31</td><td class="colsep0 rowsep0" align="char" char=".">106.04</td><td class="colsep0 rowsep0" align="char" char=".">47.60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b>-<b>11</b></td><td class="colsep0 rowsep0" align="char" char=".">2.8</td><td class="colsep0 rowsep0" align="char" char=".">35.21</td><td class="colsep0 rowsep0" align="char" char=".">84.43</td><td class="colsep0 rowsep0" align="char" char=".">96.38</td><td class="colsep0 rowsep0" align="char" char=".">50.28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b>-<b>12</b></td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="char" char=".">24.41</td><td class="colsep0 rowsep0" align="char" char=".">79.64</td><td class="colsep0 rowsep0" align="char" char=".">101.75</td><td class="colsep0 rowsep0" align="char" char=".">89.56</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b>-<b>13</b></td><td class="colsep0 rowsep0" align="char" char=".">7.5</td><td class="colsep0 rowsep0" align="char" char=".">37.65</td><td class="colsep0 rowsep0" align="char" char=".">91.50</td><td class="colsep0 rowsep0" align="char" char=".">106.87</td><td class="colsep0 rowsep0" align="char" char=".">34.84</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b>-<b>14</b></td><td class="colsep0 rowsep0" align="char" char=".">6.2</td><td class="colsep0 rowsep0" align="char" char=".">62.37</td><td class="colsep0 rowsep0" align="char" char=".">88.72</td><td class="colsep0 rowsep0" align="char" char=".">115.06</td><td class="colsep0 rowsep0" align="char" char=".">84.50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b>-<b>15</b></td><td class="colsep0 rowsep0" align="char" char=".">5.8</td><td class="colsep0 rowsep0" align="char" char=".">57.68</td><td class="colsep0 rowsep0" align="char" char=".">97.54</td><td class="colsep0 rowsep0" align="char" char=".">117.66</td><td class="colsep0 rowsep0" align="char" char=".">56.34</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b>-<b>16</b></td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">42.37</td><td class="colsep0 rowsep0" align="char" char=".">65.03</td><td class="colsep0 rowsep0" align="char" char=".">97.95</td><td class="colsep0 rowsep0" align="char" char=".">56.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b>-<b>17</b></td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="char" char=".">22.37</td><td class="colsep0 rowsep0" align="char" char=".">565.4</td><td class="colsep0 rowsep0" align="char" char=".">44.76</td><td class="colsep0 rowsep0" align="char" char=".">581.36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b>-<b>18</b></td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">226.51</td><td class="colsep0 rowsep0" align="char" char=".">729.84</td><td class="colsep0 rowsep0" align="char" char=".">198.52</td><td class="colsep0 rowsep0" align="char" char=".">837.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>TDZD</b>-<b>8</b><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub>, the mean value of at least two separate determinations, each determination was means of triplicate experiments.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">TDZD-8, the reference compound.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">IC<sub>50</sub>, the mean value of at least three independent experiments, each determination was means of triplicate experiments.</p></div></div></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Validation of Selectivity</h3><div class="NLM_p">Selectivity is very important for kinase inhibitor development. Recent studies have suggested that toxicities may be linked to the inhibition of both GSK3 paralogs. To examine the selectivity of these new BTZs to GSK-3 isoforms, they were tested against GSK-3α by mobility shift assay at ChemPartner (Shanghai, China). The results (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) indicated that most of them showed little inhibitory activity even at a very high concentration of 100 μM, which suggested their good sub-type specificity to GSK-3.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. GSK-3α Inhibitory Activity of BTZ Compounds at 100 μM</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd.</th><th class="colsep0 rowsep0" align="center" char=".">4-3</th><th class="colsep0 rowsep0" align="center" char=".">4-4</th><th class="colsep0 rowsep0" align="center" char=".">4-6</th><th class="colsep0 rowsep0" align="center" char=".">4-7</th><th class="colsep0 rowsep0" align="center" char=".">4-8</th><th class="colsep0 rowsep0" align="center" char=".">4-10</th><th class="colsep0 rowsep0" align="center" char=".">4-11</th><th class="colsep0 rowsep0" align="center" char=".">4-13</th><th class="colsep0 rowsep0" align="center" char=".">4-14</th><th class="colsep0 rowsep0" align="center" char=".">4-15</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">% inhibition</td><td class="colsep0 rowsep0" align="char" char=".">87.3</td><td class="colsep0 rowsep0" align="char" char=".">46.7</td><td class="colsep0 rowsep0" align="char" char=".">61.8</td><td class="colsep0 rowsep0" align="char" char=".">33.4</td><td class="colsep0 rowsep0" align="char" char=".">30.0</td><td class="colsep0 rowsep0" align="char" char=".">20.0</td><td class="colsep0 rowsep0" align="char" char=".">32.0</td><td class="colsep0 rowsep0" align="char" char=".">50.7</td><td class="colsep0 rowsep0" align="char" char=".">92.9</td><td class="colsep0 rowsep0" align="char" char=".">13.4</td></tr></tbody></table></div></div><div class="NLM_p">Three key compounds were further evaluated for their selectivity on 14 tyrosine and serine/threonine kinases, which are key regulatory factors in the signaling process of tumor pathogenesis. A high concentration of 100 μM was applied for three compounds in all tests, which were performed by ELISA for tyrosine kinases and by Kinase Profiler service of Millipore Corporation (Dundee, UK) for serine/threonine kinases (CK2 and PKA), respectively. The results (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>) showed that the selected compounds nearly displayed no inhibition to the whole tested kinases. All results to some extent demonstrate that these BTZ compounds might be highly selective to GSK-3β as we had expected.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Inhibitory Activity (% Inhibition) of Representative Compounds at 100 μM against Several Protein Kinases<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd.</th><th class="colsep0 rowsep0" align="center" char=".">4-1</th><th class="colsep0 rowsep0" align="center">4-2</th><th class="colsep0 rowsep0" align="center" char=".">4-4</th><th class="colsep0 rowsep0" align="center">Su11248<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">BBIBW2992<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">Dasatinib<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">AP24534<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CK2</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="left">—</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PKA</td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="left">—</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Flt-1</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="char" char=".">7.4</td><td class="colsep0 rowsep0" align="left">74.8</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="left">—</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KDR</td><td class="colsep0 rowsep0" align="char" char=".">3.1</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="left">1.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR1</td><td class="colsep0 rowsep0" align="char" char=".">18.8</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="char" char=".">88.3</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="left">0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">c-Kit</td><td class="colsep0 rowsep0" align="char" char=".">26.3</td><td class="colsep0 rowsep0" align="left">26.9</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="left">49.4</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="left">—</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFR-α</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">6.5</td><td class="colsep0 rowsep0" align="char" char=".">11.1</td><td class="colsep0 rowsep0" align="left">71.4</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="left">—</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFR-β</td><td class="colsep0 rowsep0" align="char" char=".">7.8</td><td class="colsep0 rowsep0" align="left">2.7</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">70.6</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="left">—</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EPH-A2</td><td class="colsep0 rowsep0" align="char" char=".">15.4</td><td class="colsep0 rowsep0" align="left">13.0</td><td class="colsep0 rowsep0" align="char" char=".">5.5</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="left">94.8</td><td class="colsep0 rowsep0" align="left">—</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="char" char=".">21.9</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="left">89</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">—</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RET</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="char" char=".">73.9</td><td class="colsep0 rowsep0" align="left">97</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">—</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ErbB4</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="left">88.1</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">—</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">C-Src</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="char" char=".">12.2</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="left">94</td><td class="colsep0 rowsep0" align="left">—</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ABL</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">39.8</td><td class="colsep0 rowsep0" align="char" char=".">53.8</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="left">—</td><td class="colsep0 rowsep0" align="left">93.2</td><td class="colsep0 rowsep0" align="left">—</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Corresponding data is the IC<sub>50</sub> value and the symbol “—″ indicates no test operated.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last"><b>Su11248</b> has been used as a reference inhibitor for PDGFR-β, KDR, Flt-1, and c-Kit.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last"><b>BIBW2992</b> has been used as a reference inhibitor for ErbB4 and EGFR.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last"><b>Dasatinib</b> has been used as a reference inhibitor for C-Src, ABL, and EPH-A2.</p></div><div class="footnote" id="t3fn5"><sup><sup>e</sup></sup><p class="last"><b>AP24534</b> has been used as a reference inhibitor for FGFR1 and KDR.</p></div></div></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Validation of Target Engagement and Binding Mechanism</h3><div class="NLM_p">To test the reactivity of BTZ compounds to thiol groups, we analyzed the reaction of <b>4</b>-<b>2</b> with 2-mercaptoethanol by stirring them at room temperature in a mixture of MeOH and H<sub>2</sub>O for 24 h (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). 2-Mercaptoethanol is a simple compound that could mimic the reactivity of cysteine. The reaction afforded a 64% yield of the S-alkylated product <b>8</b>, which was identified by <sup>1</sup>H NMR. It clearly showed that the peaks of two hydrogens from olefin in <b>4</b>-<b>2</b> disappeared in the spectrum of compound <b>8</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/medium/jm0c02254_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. <sup>1</sup>H NMR spectra of compounds <b>4</b>-<b>2</b> and <b>8</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02254&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/medium/jm0c02254_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0015.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Reagents and Conditions: MeOH, H<sub>2</sub>O, rt, 24 h, Yield: 64%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02254&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As a representative, the kinetic features of compound <b>4</b>-<b>2</b> were studied for exploration of the mechanism of these new BTZ derivatives. First, it was checked whether a competitive relationship exists between <b>4</b>-<b>2</b> and ATP. The measurement was carried out for <b>4</b>-<b>2</b> to inhibit the enzyme at 2 and 4 μM separately while keeping the GS-2 concentration constant with different ATP concentrations. The results showed that <b>4</b>-<b>2</b> acts in a non-ATP competitive manner (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). Second, similar tests were performed to see if <b>4</b>-<b>2</b> competes with GS-2. Its inhibition was measured at the same concentrations of 2 and 4 μM separately, while in turn keeping the ATP concentration constant with different GS-2 concentrations. The results indicate that compound <b>4</b>-<b>2</b> acts in a non-GS-2 competitive manner (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B).</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/medium/jm0c02254_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Double-reciprocal plot of kinetic data for the GSK-3β assay at different <b>4</b>-<b>2</b> concentrations. (A) ATP concentrations varied from 0.5 to 8 μM in the final reaction mixture. The GS-2 concentration was kept at 6.25 μM constant in all of the tests. (B) GS-2 concentrations varied from 0.78 to 12.5 μM in the final reaction mixture. The ATP concentration was kept 2 μM constant in all of the tests. (C) Time-dependent inhibition to GSK-3β for <b>4</b>-<b>2</b>. Each point was the mean of two separate experiments, which were performed in triplicate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02254&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The interaction characteristics between <b>4</b>-<b>2</b> and the target enzyme were further investigated. Normally, different incubation times do not affect the inhibition of reversible inhibitors, but for an irreversible inhibitor, its inhibition percentage increases as the co-incubation time with the enzyme increases. As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C, the inhibition increased with more pre-incubation time, which indicates <b>4</b>-<b>2</b> irreversibly inhibiting GSK-3β.</div><div class="NLM_p">To confirm the binding mode, the mass spectrometry (MS) analyses proceeded after co-incubation of compound <b>4</b>-<b>3</b> with the GSK-3β enzyme under the same condition for activity test. According to mass results, only the mass corresponding to GSK-3β (48919.9907 Da) was detected when using only pure enzyme without <b>4</b>-<b>3</b>, whereas it showed a mass peak of 49247.9014 Da after adding inhibitor <b>4</b>-<b>3</b>, which confirms the formation of a covalent bond between <b>4</b>-<b>3</b> and the enzyme (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/medium/jm0c02254_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. TOF MS spectra. (A) Pure GSK-3β enzyme (MW = 48919.99) without <b>4</b>-<b>3</b> as a control showed a 48919.9907 mass peak. (B) GSK-3β with inhibitor <b>4</b>-<b>3</b> (MW = 327.37) showed a 49247.9014 mass peak corresponding to the C–S bond covalently formed between inhibitor <b>4</b>-<b>3</b> and the GSK-3β enzyme.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02254&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Subsequent protease digestion and MS/MS experiments identified the modified peptides and localized the sites of modification predominately to Cys14 and slightly to Cys199 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Cumulatively, these results provide strong evidence that <b>4</b>-<b>3</b> is an irreversible, covalent inhibitor and that unique Cys14 of GSK-3β is the main labeled site.</div><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/medium/jm0c02254_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Higher-energy collisional dissociation MS/MS spectrum of GSK-3β peptide-modified <b>4</b>-<b>3</b>. The above listed are predicted b- and y-type ions (not including all) and below listed is the peptide sequence. C* means the cysteine labeled by <b>4</b>-<b>3.</b> (A) The data was recorded on the [M + H]<sup>2+</sup> ion at <i>m</i>/<i>z</i> 1279.5638 of the GSK-3β peptide TTSFAES(C*)KPVQQPSAFGSMK (residues 7–27) harboring a modification(C<sub>18</sub>H<sub>14</sub>FNO<sub>2</sub>S) on Cys14. The spec count value is 12. (B) The data was recorded on the [M + H]<sup>3+</sup> ion at <i>m</i>/<i>z</i> 1014.5118 of the GSK-3β peptide DIKPQNLLLDPDTAVLKL(C*)DFGSAK (residues 181–205) harboring a modification (C<sub>18</sub>H<sub>14</sub>FNO<sub>2</sub>S) on Cys199. The spec count value is 1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02254&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Validation in Cells</h3><div class="NLM_p">Inspired by the good activity and selectivity of BTZs to the enzyme, especially the irreversible action mode shown in these compounds, we further conducted a cell-based screening to evaluate their effects on the viability of cancer cells. Various patient-derived cell lines were exposed to GSK-3β inhibitors in different concentrations (0–1000 μM) for 24 h. The values of IC<sub>50</sub> were determined by the CCK-8 assay. The results listed in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> showed that these compounds inhibited NB4 cells greater than the other three cell lines such as Molt4, HL-60, and lymphoma cell Raji. Therefore, we chose NB4 and NB4-R1 cells as the subject of further study for three candidates of <b>4</b>-<b>3</b>, <b>4</b>-<b>4</b>, and <b>4</b>-<b>12</b>.</div><div class="NLM_p">Similarly, various cell lines were exposed to different concentrations of <b>4</b>-<b>3</b>, <b>4</b>-<b>4</b>, and <b>4</b>-<b>12</b> (0–100 μM) for 24–48 h. Cell viability was determined by the CCK-8 assay. All the three inhibitors showed marked growth inhibition to NB4 and NB4-R1 cells in a dose-dependent manner (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A,B). With the increase of concentrations, the inhibition activity of <b>4</b>-<b>3</b> was higher than that of the other two inhibitors <b>4</b>-<b>4</b> and <b>4</b>-<b>12</b> with IC<sub>50</sub> of 19.56, 22.62, and 24.41 μM in NB4 cells at 24 h and with IC<sub>50</sub> of 26.42, 48.27, and 93.06 μM in NB4-R1 cells at 24 h, respectively, which suggested that <b>4</b>-<b>3</b> displayed the strongest proliferation inhibitory effects on both NB4 and NB4-R1 cells. Furthermore, the proliferation inhibitory effects of <b>4</b>-<b>3</b> were not significantly different at 24 and 48 h in NB4 (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>C) and NB4-R1 cells (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>D), respectively. Accordingly, we chose 24 h as a subsequent time point.</div><figure id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/medium/jm0c02254_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Proliferation inhibition of three GSK-3β inhibitors in NB4 and NB4-R1 cells and their cytotoxicity to normal cell lines by the CCK-8 assay. (A) Proliferation inhibition rate of NB4 cells after exposure to three inhibitors at various concentrations for 24 h. (B) Proliferation inhibition rate of NB4-R1 cells after exposure to three inhibitors at various concentrations for 24 h. Inhibition rate of NB4 cells (C) and NB4-R1 cells (D) after exposure to <b>4</b>-<b>3</b> at various concentrations for 24 and 48 h. Viability of two normal cell lines HUVECs (E) and LO<sub>2</sub> cells (F) after exposure to three inhibitors at various concentrations for 24 h. Data are presented as mean ± standard error of the mean (SEM) of three independent experiments and significant differences are indicated as *<i>P</i> < 0.01 vs control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02254&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">For evaluating the possible cytotoxicity, we examined the affection of the three inhibitors to human normal liver cells (LO<sub>2</sub>) and human umbilical vein endothelial cells (HUVECs). The data exhibited that the viability percentages of the two cell lines were over 80% compared to the control after incubated with three compounds (0–50 μM) for 24 h (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>E,F). When the inhibition concentration reached 100 μM, there still had above 70% cell viability for <b>4</b>-<b>3</b> in both HUVEC and LO<sub>2</sub> cells, which indicated that <b>4</b>-<b>3</b> had little cytotoxicity.</div><div class="NLM_p">Next, apoptotic cells were determined by Annexin V/propidium iodide (PI) staining and flow cytometric analysis. The percentage of apoptosis in NB4 and NB4-R1 cells treated with three inhibitors for 24 h was all significantly increased in a dose-dependent pattern when compared to the control with <i>p</i> < 0.01, and the highest percentage of apoptosis among the three inhibitors was promoted by <b>4</b>-<b>3</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A,B). Moreover, the percentage of apoptosis induced by <b>4</b>-<b>3</b> in NB4 cells was higher than that in NB4-R1 cells, which was consistent with the CCK-8 result above.</div><figure id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/medium/jm0c02254_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Induction of cell apoptosis by three inhibitors of GSK-3β. Apoptosis of NB4 cells (A) and NB4-R1 cells (B) exposed to different concentrations of three inhibitors for 24 h. Apoptotic cells were detected by a flow cytometer using Annexin V/PI double staining. (C) Representative scatter plot for a flow cytometer. <b>4</b>-<b>3</b> induced apoptosis in NB4 cells in combination with Z-VAD-FMK (irreversible pan-caspase inhibitor) in a dose-dependent manner. (D) Percentages of apoptotic NB4 cells treated with indicated inhibitor <b>4</b>-<b>3</b> or in combination with Z-VAD-FMK for 24 h. (E,F) Representative scatter plots for flow cytometer in NB4-R1 cells. Apoptosis of NB4-R1 cells exposed to different concentrations of <b>4</b>-<b>3</b> or in combination with Z-VAD-FMK for 24 h. The data shown are representative of values from at least three independent experiments (mean ± SEM; ** <i>P</i> < 0.05; * <i>P</i> < 0.01 vs control).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02254&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To assess whether caspase would take part in the apoptosis induced by <b>4</b>-<b>3</b>, Z-VAD-FMK, an irreversible pan-caspase inhibitor with good cell permeability was selected to block caspase activation of apoptotic cells. As shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>C,D, pretreated with 10 μM of Z-VAD-FMK for 4 h before the indicated <b>4</b>-<b>3</b> processing, the apoptosis percentages of NB4 cells were obviously reduced (about 2–4 fold change) compared with the corresponding cells that were unpretreated (14.56% ± 1.15 vs 11.95% ± 0.97 at 12.5 μM, <i>p</i> < 0.05, 48.70% ± 2.58 vs 18.62% ± 2.75 at 25 μM, 81.40% ± 3.52 vs 19.88% ± 2.26 at 50 μM, and 90.60% ± 1.55 vs 24.98% ± 3.04 at 100 μM, <i>p</i> < 0.01, respectively). A similar tendency was observed in NB4-R1 cells, which also presented a marked reduction of apoptosis percentages when pretreated for Z-VAD-FMK at the same time (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>E,F). Thus, the results confirmed that caspase participated in the <b>4</b>-<b>3</b>-induced cell apoptosis.<named-content content-type="anchor" rid="fig6" type="simple"></named-content><named-content content-type="anchor" rid="fig7" type="simple"></named-content><named-content content-type="anchor" rid="fig8" type="simple"></named-content><named-content content-type="anchor" rid="fig9" type="simple"></named-content></div><div class="NLM_p">In summary, candidate <b>4</b>-<b>3</b> produced stronger growth inhibition to NB4 and NB4-R1 cells than other cell lines such as Molt4, HL-60, and Raji cells (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A). As is well known, lithium chloride (LiCl), as a classical GSK-3β inhibitor, had been much reported to have potent anti-leukemic activity in MLL-associated leukemia<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> and in AML- or RA-sensitive APL cells.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Under the same conditions, we assessed the inhibition percentages of LiCl to NB4 and NB4-R1 cells by the CCK-8 test. Compared with the control group, LiCl showed more significant inhibitory effects on NB4 cells than on NB4-R1 cells, and the IC<sub>50</sub> value at 24 h was 5.32 mM and 42.50 mM for NB4 and NB4-R1 cells, respectively (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>B). Exhilaratingly, the inhibition of <b>4</b>-<b>3</b> is stronger than LiCl 270-fold on NB4 and 1600-fold on NB4-R1 cells, respectively, indicating that <b>4</b>-<b>3</b> might be a potentially powerful candidate for leukemia treatment.</div><figure id="fig10" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/medium/jm0c02254_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Cell proliferation and viability of <b>4</b>-<b>3</b> and LiCl. (A) IC<sub>50</sub> of <b>4</b>-<b>3</b> for several tumor cells. (B) Proliferation inhibition of NB4 and NB4-R1cells exposed to different concentrations of LiCl for 24 h by the CCK-8 assay. The data shown are representative of values from at least three independent experiments (mean ± SEM; *, <i>P</i> < 0.01 vs control).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02254&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To assign the observed results to GSK-3β, <b>4</b>-<b>3</b> was treated with NB4 and NB4-R1 cells to check its effects on glycogen synthase (GS) phosphorylation. GS is a well-known downstream physiological target that can be directly phosphorylated by GSK-3β and thereby inactivated. The phospho-GS (p-GS) was detected by western blotting after <b>4</b>-<b>3</b> co-incubated with cells for 24 h (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>A). The bands were quantified by gray analysis, and the data showed that <b>4</b>-<b>3</b> decreased the ratio of p-GS/GS both in two cells in a dose-dependent manner (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>B), indicating that the inhibition was produced by targeting GSK-3β in both cells.</div><figure id="fig11" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/medium/jm0c02254_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. (A) The western blot analysis of p-GS and GS expression of NB4 and NB4-R1 cells was obtained after 24 h of treatment with <b>4</b>-<b>3</b>, and the representative bands were shown. (B) Values denoted the relative protein intensity as ratios of p-GS to GS. Data were represented as means ± SEM (<i>n</i> = 3), and significant differences were indicated as **, <i>P</i> < 0.05; *, <i>P</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02254&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In the hERG assay, the calculated IC<sub>50</sub> value of <b>4</b>-<b>3</b> was 37.5 μM, and it suggests that <b>4</b>-<b>3</b> is not an inhibitor to the hERG channel showing good heart safety (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02254/suppl_file/jm0c02254_si_001.pdf" class="ext-link">Supporting Information</a>, Figure S1).</div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Mouse PK Properties and Pharmacodynamic Studies</h3><div class="NLM_p">Based on its good activity in the cellular assay and unique mode of action, compound <b>4</b>-<b>3</b> was further profiled <i>in vivo</i> PKs and pharmacodynamics (PDs). After intraperitoneal injection (i.p.) of <b>4</b>-<b>3</b> at a dose of 15 mg/kg in mice, the compound demonstrated good PK properties (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02254/suppl_file/jm0c02254_si_001.pdf" class="ext-link">Figure S2</a>), with long <i>T</i><sub>1/2</sub> of 14.2 h, high AUC values, and maximum concentration (<i>C</i><sub>max</sub>) was reached quickly at 1.0 h (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. PK Parameters of <b>4</b>-<b>3</b> Following a Single Administration to Mice</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center">route</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (ng/mL)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>last</sub> (ng/mL·h)<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>inf</sub> (ng/mL·h)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i>1/2 (h)<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">i.p.</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">515</td><td class="colsep0 rowsep0" align="char" char=".">3503.42</td><td class="colsep0 rowsep0" align="char" char=".">10838.33</td><td class="colsep0 rowsep0" align="char" char=".">14.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Time for peak plasma concentrations.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Peak plasma concentrations.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">Area under the concentration–time curve.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">Terminal half-life.</p></div></div></div><div class="NLM_p">The APL mouse model was selected for the PD study. Balb/c nude mice bearing subcutaneous xenografts of NB4 cells were treated with <b>4</b>-<b>3</b> (15 mg/kg/d) for 2 weeks, and the effects of <b>4</b>-<b>3</b> on the growth of xenografts of human APL NB4 cells were evaluated. The results showed that <b>4</b>-<b>3</b> inhibited tumor growth by 75.97% relative to vehicle control (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>A). In addition, the mice treated with <b>4</b>-<b>3</b> had mild weight loss compared with control (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>B). The treated mice were killed at the end of therapy, and dissection of tumor tissue displayed that <b>4</b>-<b>3</b>-treated mice had much smaller tumor masses compared with control (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>C). The gross tumor tissues were presented in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>D. These results indicated that GSK-3β inhibition by <b>4</b>-<b>3</b> had antitumor activity and therapeutic efficacy in localized leukemia xenograft models.</div><figure id="fig12" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/medium/jm0c02254_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. <i>In vivo</i> activity of <b>4</b>-<b>3</b>. (A). <b>4</b>-<b>3</b> inhibition of localized growth in NB4 cells. NB4 cells were transplanted into the right flanks of nude mice, which were intraperitoneally injected daily with <b>4</b>-<b>3</b> (15 mg/kg/d) for 2 weeks. Tumor volumes were measured (mean ± SEM, <i>n</i> = 5; *, <i>P</i> < 0.01 vs control). (B). The body weight of mice recorded during the treatment period. Data were recorded as the mean ± SEM, <i>n</i> = 5; **, <i>P</i> < 0.05 vs control. (C). Weights of tumors dissected from mice treated with <b>4</b>-<b>3</b> or control (mean ± SEM, <i>n</i> = 5; *, <i>P</i> < 0.01 vs control). (D). The gross subcutaneous xenografts of NB4 cells were determined.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02254&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16178" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16178" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Irreversible GSK-3β covalent inhibitors should be clinically more therapeutic benefits to overcome the resistance. Herein, we found a new kind of irreversible GSK-3β inhibitors with the advantage of high selectivity over kinases. Their IC<sub>50</sub> values were mostly around 5 μM, which is comparable to the well-known covalent GSK-3β inhibitor TDZD-8 undergoing clinical trials. The covalent binding mode was confirmed biophysically by kinetic and MS studies, where incubation of recombinant GSK-3β kinase with <b>4</b>-<b>3</b> resulted in an addition of the expected molecular weight. Furthermore, the labeled cysteines of Cys14 and Cys199 in GSK-3β were identified by MS/MS analysis.</div><div class="NLM_p">Subsequently, we investigated the inhibitors for their effects on human APL cell lines followed in a xenograft model. Interestingly, our inhibitors exerted anti-proliferation and inducing apoptosis not only on ATRA-sensitive APL cells but also on ATRA-resistant cells in a dose-dependent manner with less cytotoxicity in cells. The western blotting analysis assigned the cellular activity to the GSK-3β inhibition. The potential mechanism of inducing apoptosis possibly could be related to the caspase cascade, which confirmed a previous study of ATP-competitive GSK-3β inhibitor on B- and T-ALL cell lines.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Among the inhibitors, compound <b>4</b>-<b>3</b> showed much more sensitivity to NB4 and NB4-R1 cells than to Molt4, HL-60, and Raji cells. Therefore, we selected NB4 and NB4-R1 cells as the main subject for further study.</div><div class="NLM_p">LiCl is a classical GSK-3β inhibitor with potent anti-leukemic activity in MLL-associated leukemia<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> and in AML- or RA-sensitive APL cells,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> but much serious side effects from high-dosage use limited its clinical application.<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40,41)</a> Our results confirmed that <b>4</b>-<b>3</b> could depress NB4 and NB4-R1 cell proliferation at low μM level while LiCl worked at high mM level, suggesting that <b>4</b>-<b>3</b> is much superior to LiCl in the treatment of leukemia. Moreover, the benefits from <b>4</b>-<b>3</b> in cells were close to or even higher than that of classical As<sub>2</sub>O<sub>3</sub>-induced NB4 cells reported in previous study<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> and particularly on ATRA-resistant NB4-R1 cells.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Moreover, <b>4</b>-<b>3</b> had good PK features in mice with rapid onset, high exposure, and long duration. In APL xenograft nude mice, <b>4</b>-<b>3</b> developed lower tumor volume than control and no significant weight loss. Moreover, <b>4</b>-<b>3</b> showed low cytotoxicity on normal cell lines and no inhibition in the hERG test. All the results illustrated the potential safety and therapeutic efficacy of <b>4</b>-<b>3</b> in leukemia. Since <b>4</b>-<b>3</b> represents a new scaffold and interaction unreported before, it should be a promising candidate to offer more therapeutic possibilities due to the advantages of irreversible covalent inhibition, such as high activity, good safety, and high selectivity.</div><div class="NLM_p">GSK-3 has two highly conserved isoforms α and β. Recent studies suggested that toxicities may be linked to the inhibition of both GSK3 paralogs. In our study, <b>4</b>-<b>3</b> was confirmed to bind mainly to the unique residues of Cys14 and slightly to Cys199 of GSK-3β in covalent modes with spec count values of 12 and 1, respectively. It roughly indicated that the binding of <b>4</b>-<b>3</b> on Cys14 is 12-fold stronger than that on Cys199. Because the unique Cys14 residue only exists in β isoform and not in α isoform for GSK-3, and the Cys199 residue was also replaced by other residues in other structurally related kinases, such as the CDK family, the specific binding mechanism to Cys14 and Cys199 well explained the selectivity of <b>4</b>-<b>3</b> to both GSK-3α and other related kinases in our test. These results can also be expected for the high selectivity of other BTZ compounds, which had been partly confirmed by the measured results.</div><div class="NLM_p last">Recently, computational tools have emerged to accelerate the rational discovery of new inhibitors. Wagner rationally designed the isoform selectivity based on a single amino acid difference in the ATP-binding domain of GSK-3α (Glu196) and GSK-3β (Asp133).<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Liu proposed a strategy based on the assessment of p<i>K</i><sub>a</sub> values to screen reactive amino acid residues for designing targeted covalent kinase inhibitors.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> These studies demonstrate the feasibility of isoform-selective inhibition. According to that way, much work is worth doing in our future study, such as confirming the functional selectivity or activity of Cys14 and Cys199 residues via point mutations, careful assessments of the reactivities for targetable residues in GSK-3 by calculating their p<i>K</i><sub>a</sub> values, and prediction of the binding modes through docking or molecular dynamics simulations. The deep understanding of the biochemical functions, topological features, and interaction modes would help to bind specifically to Cys14 or other unique cysteine residues by fine modification of the structures and reactivities of our compounds, which can predictably improve the paralog selectivity and off-target inhibition against other kinases.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01510" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01510" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Chemistry</h3><div class="NLM_p">All chemical reagents and solvents used in experiments were purchased from commercial suppliers and used without further purification. The silica gel (200–300 mesh) used for column chromatography and the thin-layer chromatograph used to monitor the progress of the reaction were purchased from Qingdao Haiyang Chemical Co., Ltd. <sup>1</sup>H NMR spectra were performed on the Mercury Plus 400 spectrometer at 400 MHz and <sup>13</sup>C NMR spectra at 100 or 151 MHz, respectively. Chemical shifts (δ) are reported in parts per million (ppm) relative to internal tetramethylsilane, and <i>J</i> values are reported in hertz. The low-resolution mass spectra (LC–MS) were recorded using the Agilent LC–MS 1100 instrument with an ESI mass selective detector. HRMS (EI) experiments were performed using an AB 5600+ Q-TOF spectrometer. Melting points were determined by the SGW X-4 thermometer and were uncorrected. The purity of final compounds was analyzed by high-performance liquid chromatography (HPLC) (Hewlett-Packard 1100), with the purity of all compounds being over 95%. The HPLC instrument was equipped with a photodiode array detector using a Zorbax RP-18 column (5 μm, 4.6 mm × 250 mm, reverse phase column). The mobile phases A and B were acetonitrile and the solution of 10 mM ammonium acetate in purified water (pH = 6.0), respectively.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> General Procedure for the Synthesis of 3-Substituted Acrylic Acid</h4><div class="NLM_p last">A mixture of substituted carbaldehyde (200 mmol), propenedioic acid (20.8 g, 200 mmol) in a solution of pyridine (10 mL 120 mmol), and piperidine (1 mL) was warmed at reflux for 2 h. The resultant solution was poured into 2 M HCl aq. and then cooled to room temperature. The present solid was collected by filtration, washed with water, and recrystallized from ethanol/water.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 3-(2-Thienyl)acrylic Acid (<b>2</b>-<b>1</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 2-thenaldehyde. Yellow solid. Yield: 85%. mp 158.2–159.6 °C.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 3-Phenylacrylic Acid (<b>2</b>-<b>2</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from benzaldehyde. White solid. Yield: 91%. mp: 134.6–135.7 °C.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 3-(4-Fluorophenyl)acrylic Acid (<b>2</b>-<b>3</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 4-fluorobenzaldehyde. White solid. Yield: 88%. mp 205.8–207.4 °C.</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 3-(4-Chlorophenyl)acrylic Acid (<b>2</b>-<b>4</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 4-chlorobenzaldehyde. White solid. Yield: 95%. mp 247.1–250.5 °C.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 3-(3-Chlorophenyl)acrylic Acid (<b>2</b>-<b>5</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 3-chlorobenzaldehyde. White solid. Yield: 94%. mp 179.1–182.5 °C.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 3-(2-Chlorophenyl)acrylic Acid (<b>2</b>-<b>6</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 2-chlorobenzaldehyde. White solid. Yield: 93%. mp 212.5–214.2 °C.</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 3-(4-Bromophenyl)acrylic Acid (<b>2</b>-<b>7</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 4-bromobenzaldehyde. White solid. Yield: 85%. mp 255.9–257.6 °C.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 3-(4-Methylphenyl)acrylic Acid (<b>2</b>-<b>8</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 4-methyl benzaldehyde. White solid. Yield: 91%. mp 208.2–211.3 °C.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 3-(4-Methoxyphenyl)acrylic Acid (<b>2</b>-<b>9</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 4-methoxybenzaldehyde. White solid. Yield: 93%. mp 218.9–220.5 °C.</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 3-(4-Trifluoromethylphenyl)acrylic Acid (<b>2</b>-<b>10</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 4-trifluoromethylbenzaldehyde. White solid. Yield: 88%. mp 208.9–210.6 °C.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 3-(2-Trifluoromethylphenyl)acrylic Acid (<b>2</b>-<b>11</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 2-trifluoromethylbenzaldehyde. White solid. Yield: 91%. mp 205.4–206.2 °C.</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 3-(4-Methoxycarbonylphenyl)acrylic Acid (<b>2</b>-<b>12</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 4-trifluoromethylbenzaldehyde. White solid. Yield: 75%. mp 246.2–247.9 °C.</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 3-(4-Nitrophenyl)acrylic Acid (<b>2</b>-<b>13</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 4-nitrobenzaldehyde. White solid. Yield: 83%. mp 287.5–290.6 °C.</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 3-(4-Cyanophenyl)acrylic Acid (<b>2</b>-<b>14</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 4-cyanobenzaldehyde. White solid. Yield: 87%. mp 253.3–255.8 °C.</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 3-([1,1′-Biphenyl]-4-yl)acrylic Acid (<b>2</b>-<b>15</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from [1,1′-biphenyl]-4-carbaldehyde. White solid. Yield: 75%. mp 224.6–227.8 °C.</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 3-(4-Morpholinophenyl)acrylic Acid (<b>2</b>-<b>16</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 4-morpholinobenzaldehyde. White solid. Yield: 75%. mp 244.7–246.3 °C.</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> General Procedure for the Synthesis of 2,3-Dihydro-2-substituted-1,5-benzothiazepin-4(5<i>H</i>)-one</h4><div class="NLM_p last">A mixture of 2-aminothiophenol (4 mmol), unsaturated acid <b>2</b> (2 mmoL), and TBAF (0.2 mmol, 10 mol %) was heated to 80 °C under stirring for 24 h. After cooling, 30 mL of dichloromethane was added. The mixture was washed with aq HCl (2 N), aq Na<sub>2</sub>CO<sub>3</sub> (saturated), and brine. Then, the organic layer was dried over MgSO<sub>4</sub> and concentrated. The crude product residue was purified by chromatography on silica gel to afford pure product <b>3</b>.</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 2,3-Dihydro-2-(2-thienyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>1</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 3-(2-thienyl)acrylic acid (<b>2</b>-<b>1</b>). Yield: 70%. Off-white solid. mp 172.6–173.4 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.18 (s, 1H), 7.65 (d, <i>J</i> = 8.0 Hz, 1H), 7.45–7.41 (m, 1H), 7.25–7.19 (m, 4H), 6.95–6.91 (m, 2H), 5.16 (dd, <i>J</i> = 8.0 Hz, 4.0 Hz, 1H), 2.94–2.82 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 171.1, 146.5, 135.8, 129.9, 126.2, 126.1, 125.1, 124.1, 123.4, 122.5, 76.6, 76.4, 76.2, 47.9, 41.6, 29.1. ESI-MS (positive), 262.0 (M + 1)<sup>+</sup>. HRMS (EI) <i>m</i>/<i>z</i>: calcd for C<sub>13</sub>H<sub>11</sub>NOS<sub>2</sub> (M<sup>+</sup>), 262.0355; found, 262.0367.</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 2,3-Dihydro-2-phenyl-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>2</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 3-phenylacrylic acid (<b>2</b>-<b>2</b>). Yield: 82%. White solid. mp 177.6–179.9 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.30 (s, 1H), 7.42–7.17 (m, 9H), 4.87–4.91 (m, 1H), 2.94–2.79 (m, 2H). ESI-MS (positive), 256.1 (M + 1).</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 2,3-Dihydro-2-(4-fluorophenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>3</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 3-(4-fluorophenyl)acrylic acid (<b>2</b>-<b>3</b>). Yield: 55%. White solid. mp 182.9–184.0 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 9.99 (s, 1H), 7.54 (d, <i>J</i> = 8.0 Hz, 1H), 7.47–7.43 (m, 1H), 7.39–7.35 (m, 2H), 7.21–7.11 (m, 4H), 5.01 (dd, <i>J</i> = 8.0, 4.0 Hz, 1H), 2.69–2.48 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 171.5, 162.4, 160.8, 140.7, 138.5, 135.2, 129.7, 127.6, 127.5, 126.2, 125.8, 122.7, 115.1, 114.9, 51.8, 40.9, 29.1. ESI-MS (positive), 273.9 (M + 1)<sup>+</sup>. HRMS (EI) <i>m</i>/<i>z</i>: calcd for C<sub>15</sub>H<sub>12</sub>FNOS (M<sup>+</sup>), 274.0696; found, 274.0696.</div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 2,3-Dihydro-2-(4-chlorophenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>4</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 3-(4-chlorophenyl)acrylic acid (<b>2</b>-<b>4</b>). Yield: 71%. White solid. mp 205.4–207.9 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 10.00 (s, 1H), 7.55–7.14 (m, 8H), 5.01 (dd, <i>J</i> = 8.0 Hz, 4.0 Hz, 1H), 2.70–2.48 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 171.5, 141.1, 140.7, 135.2, 133.0, 129.8, 128.3, 127.2, 126.2, 125.6, 122.7, 51.9, 40.7, 29.1. ESI-MS (positive), 289.9 (M + 1)<sup>+</sup>. HRMS (EI) <i>m</i>/<i>z</i>: calcd for C<sub>15</sub>H<sub>12</sub>ClNOS (M<sup>+</sup>), 290.0401; found, 290.0403.</div></div><div id="sec5_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 2,3-Dihydro-2-(3-chlorophenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>5</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 3-(3-chlorophenyl)acrylic acid (<b>2</b>-<b>5</b>). Yield: 64%. White solid. mp 200.9–202.2 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.62 (s, 1H), 7.66 (d, <i>J</i> = 7.6 Hz, 1H), 7.44 (t, <i>J</i> = 7.6 Hz, 1H), 7.30–7.19 (m, 6H), 4.84 (dd, <i>J</i> = 10.9, 5.8 Hz, 1H), 2.91–2.75 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 171.4, 144.6, 140.7, 135.3, 133.9, 129.8, 129.5, 127.4, 126.2, 126.1, 125.4, 124.0, 122.7, 51.9, 40.7. ESI-MS (positive), 289.9 (M + 1)<sup>+</sup>. HRMS (EI) <i>m</i>/<i>z</i>: calcd for C<sub>15</sub>H<sub>12</sub>ClNOS (M<sup>+</sup>), 290.0401; found, 290.0398.</div></div><div id="sec5_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 2,3-Dihydro-2-(2-chlorophenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>6</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 3-(2-chlorophenyl)acrylic acid (<b>2</b>-<b>6</b>). Yield: 74%. White solid. mp 188.7–189.6 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 9.07 (s, 1H), 7.61 (dd, <i>J</i> = 13.1, 7.8 Hz, 3H), 7.54–7.43 (m, 2H), 7.36 (t, <i>J</i> = 7.6 Hz, 1H), 7.26 (d, <i>J</i> = 7.4 Hz, 2H), 5.32 (dd, <i>J</i> = 10.9, 5.5 Hz, 1H), 2.96–2.86 (m, 1H), 2.81 (dd, <i>J</i> = 12.5, 5.5 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 171.4, 141.7, 141.0, 135.2, 131.9, 129.9, 127.6, 127.1, 126.2, 125.5, 125.1, 124.4, 122.9, 46.9, 40.7. ESI-MS (positive), 289.9 (M + 1)<sup>+</sup>. HRMS (EI) <i>m</i>/<i>z</i>: calcd for C<sub>15</sub>H<sub>12</sub>ClNOS (M<sup>+</sup>), 290.0401; found, 290.0411.</div></div><div id="sec5_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 2,3-Dihydro-2-(4-bromophenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>7</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 3-(4-bromophenyl)acrylic acid (<b>2</b>-<b>7</b>). Yield: 68%. White solid. mp 169.2–170.8 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 10.00 (s, 1H), 7.48–7.14 (m, 8H), 5.01 (dd, <i>J</i> = 8.0 Hz, 4.0 Hz, 1H), 2.69–2.48 (m,2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 171.1, 141.6, 140.6, 135.3, 131.3, 129.8, 127.6, 126.2, 125.7, 122.7, 121.1, 51.8, 40.6. ESI-MS (positive), 334.0, 336.0 (M + 1, M + 3)<sup>+</sup>. HRMS (EI) <i>m</i>/<i>z</i>: calcd for C<sub>15</sub>H<sub>12</sub>BrNOS (M<sup>+</sup>), 333.9896; found, 333.9900.</div></div><div id="sec5_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 2,3-Dihydro-2-(4-methylphenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>8</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 3-(4-methylphenyl)acrylic acid (<b>2</b>-<b>8</b>). Yield: 65%. Off-white solid. mp 175.6–179.1 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.06 (s, 1H), 7.65 (d, <i>J</i> = 7.7 Hz, 1H), 7.42 (t, <i>J</i> = 7.7 Hz, 1H), 7.26–7.20 (m, 3H), 7.17 (d, <i>J</i> = 7.9 Hz, 1H), 6.84 (d, <i>J</i> = 8.7 Hz, 2H), 4.86 (dd, <i>J</i> = 10.6, 5.8 Hz, 1H), 3.79 (s, 3H), 2.90–2.75 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 171.5, 158.5, 140.6, 135.3, 134.9, 129.5, 126.9, 126.2, 122.6, 113.5, 54.7, 52.1, 41.0, 29.1. ESI-MS (positive), 270.1 (M + 1)<sup>+</sup>. HRMS (EI) <i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>15</sub>NOS (M<sup>+</sup>), 270.0947; found, 270.0949.</div></div><div id="sec5_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 2,3-Dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>9</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 3-(4-methoxlphenyl)acrylic acid (<b>2</b>-<b>9</b>). Yield: 70%. Off-white solid. mp 162.7–163.9 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.35 (s, 1H), 7.65 (d, <i>J</i> = 7.7 Hz, 1H), 7.42 (t, <i>J</i> = 7.1 Hz, 1H), 7.25–7.11 (m, 6H), 4.86 (dd, <i>J</i> = 11.1, 5.6 Hz, 1H), 2.94–2.84 (m, 1H), 2.79 (dd, <i>J</i> = 12.5, 5.6 Hz, 1H), 2.32 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 171.7, 140.7, 139.9, 137.0, 135.3, 129.5, 128.9, 126.1, 126.0, 125.6, 122.6, 52.4, 40.9, 20.5. ESI-MS (positive), 286.1 (M + 1)<sup>+</sup>. HRMS (EI) <i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>15</sub>NO<sub>2</sub>S (M<sup>+</sup>), 308.0716; found, 308.0725.</div></div><div id="sec5_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 2,3-Dihydro-2-(4-trifluoromethylphenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>10</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 3-(4-trifluoromethylphenyl)acrylic acid (<b>2</b>-<b>10</b>). Yield: 30%. Off-white solid. mp 137.9–139.7 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.35 (s, 1H), 7.66 (d, <i>J</i> = 7.5 Hz, 1H), 7.58 (d, <i>J</i> = 8.2 Hz, 2H), 7.45 (dd, <i>J</i> = 14.4, 7.7 Hz, 3H), 7.30–7.16 (m, 2H), 4.92 (dd, <i>J</i> = 10.7, 5.9 Hz, 1H), 2.96–2.75 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 171.2, 146.4, 140.7, 135.3, 129.9, 126.3, 126.2, 125.4, 125.2, 122.8, 51.9, 40.5. ESI-MS (positive), 323.9 (M + 1)<sup>+</sup>. HRMS (EI) <i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>12</sub>F<sub>3</sub>NOS (M<sup>+</sup>), 324.0664; found, 324.0661.</div></div><div id="sec5_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 2,3-Dihydro-2-(2-trifluoromethylphenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>11</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 3-(2-trifluoromethylphenyl)acrylic acid (<b>2</b>-<b>11</b>). Yield: 80%. Off-white solid. mp 131.2–134.2 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.43 (s, 1H), 7.63 (d, <i>J</i> = 7.5 Hz, 1H), 7.45–7.42 (m, 2H), 7.37 (dd, <i>J</i> = 7.1, 2.0 Hz, 1H), 7.25–7.18 (m, 4H), 5.45 (dd, <i>J</i> = 10.5, 6.3 Hz, 1H), 2.90–2.78 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 171.4, 140.9, 139.6, 135.4, 131.6, 129.7, 129.2, 128.2, 126.9, 126.7, 126.1, 125.6, 122.7, 48.1, 38.9. ESI-MS (positive), 323.9 (M + 1)<sup>+</sup>. HRMS (EI) <i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>12</sub>F<sub>3</sub>NOS (M<sup>+</sup>), 324.0664; found, 324.0664.</div></div><div id="sec5_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 2,3-Dihydro-2-(4-methoxycarbonylphenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>12</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 3-(4-methoxycarbonylphenyl)acrylic acid (<b>2</b>-<b>12</b>). Yield: 57%. White solid. mp 184.2–186.7 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.83 (br s, 1H), 7.98 (d, <i>J</i> = 8.0 Hz, 2H), 7.63 (d, <i>J</i> = 8.0 Hz, 1H), 7.44–7.21 (m, 5H), 4.92 (dd, <i>J</i> = 8.0 Hz, 4.0 Hz, 1H), 3.90 (s, 3H), 2.90–2.78 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 171.9, 166.0, 147.6, 140.9, 135.2, 129.8, 129.6, 129.0, 126.1, 125.8, 125.3, 122.8, 76.7, 76.4, 76.2, 52.3, 51.5, 40.5. ESI-MS (positive), 314.0 (M + 1)<sup>+</sup>. HRMS (EI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>15</sub>NO<sub>3</sub>S (M<sup>+</sup>), 314.0845; found, 314.0847.</div></div><div id="sec5_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 2,3-Dihydro-2-(4-nitrophenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>13</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 3-(4-nitrophenyl)acrylic acid (<b>2</b>-<b>13</b>). Yield: 21%. White solid. mp 188.2–190.3 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.03–7.59 (m, 4H), 7.46–7.17 (m, 9H), 7.42–7.17 (m, 9H), 5.62–5.47 (m, 2H), 4.91–4.87 (m, 1H), 3.01–2.85 (m, 2H). ESI-MS (positive), 390.9 (M + 1)<sup>+</sup>.</div></div><div id="sec5_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 2,3-Dihydro-2-(4-cyanophenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>14</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 3-(4-cyanophenyl)acrylic acid (<b>2</b>-<b>14</b>). Yield: 25%. White solid. mp 195.5–197.1 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 10.03 (s, 1H), 8.13 (d, <i>J</i> = 8.0 Hz, 1H), 8.05–8.02 (m, 3H), 7.53–7.45 (m, 6H), 7.24–7.17 (m, 2H), 5.09 (dd, <i>J</i> = 8.0 Hz, 4.0 Hz, 1H), 2.79–2.48 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 170.1, 165.9, 152.5, 146.4, 141.4, 135.0, 134.2, 131.8, 129.7, 127.2, 126.4, 125.7, 125.3, 124.5, 123.0, 122.6, 122.2, 51.7, 40.6. ESI-MS (positive), 280.1 (M + 1)<sup>+</sup>. HRMS (EI) <i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>12</sub>N<sub>2</sub>OS (M<sup>+</sup>), 281.0743; found, 281.0746.</div></div><div id="sec5_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 2,3-Dihydro-2-([1,1′-biphenyl]-4-yl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>15</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 3-([1,1′-biphenyl]-4-yl)acrylic acid (<b>2</b>-<b>15</b>). Yield: 57%. White solid. mp 189.6–191.0 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.95 (d, <i>J</i> = 8.3 Hz, 2H),7.59 (d, <i>J</i> = 7.5 Hz, 1H), 7.55–7.47 (m, 1H), 7.41–7.31 (m, 2H), 7.26 (s, 2H), 7.17 (s, 1H), 4.73 (dt, <i>J</i> = 15.0, 7.5 Hz, 1H), 3.90 (s, 3H), 2.80 (dd, <i>J</i> = 10.3, 8.5 Hz, 2H). ESI-MS (positive), 332.1 (M + 1)<sup>+</sup>.</div></div><div id="sec5_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 2,3-Dihydro-2-(4-morpholinophenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>16</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 3-(4-morpholinophenyl)acrylic acid (<b>2</b>-<b>16</b>). Yield: 38%. White solid. mp 213.8–215.8 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.15 (s, 1H), 7.65 (d, <i>J</i> = 7.7 Hz, 1H), 7.42 (t, <i>J</i> = 7.6 Hz, 1H), 7.30–7.11 (m, 4H), 6.84 (d, <i>J</i> = 8.6 Hz, 2H), 4.85 (dd, <i>J</i> = 10.7, 5.7 Hz, 1H), 3.84 (t, <i>J</i> = 7.6 Hz, 4H), 3.14 (t, <i>J</i> = 7.6 Hz, 4H), 2.91–2.82 (m, 1H), 2.79 (dd, <i>J</i> = 12.4, 5.8 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 171.6, 150.1, 140.6, 135.3, 133.9, 129.4, 126.7, 126.3, 126.0, 122.6, 115.0, 66.2, 52.2, 48.5, 40.9. ESI-MS (positive), 341.0 (M + 1)<sup>+</sup>. HRMS (EI) <i>m</i>/<i>z</i>: calcd for C<sub>19</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub>S (M<sup>+</sup>), 341.1318; found, 341.1319.</div></div><div id="sec5_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 2,3-Dihydro-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>17</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from acrylic acid (<b>2</b>-<b>17</b>). White solid. Yield: 31%. mp 214.3–216.8 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.83 (s, 1H), 7.62–7.58 (d, <i>J</i> = 1.4 Hz, 1H), 7.38–7.34 (m, 1H), 7.19–7.15 (m, 1H), 7.11–7.08 (d, <i>J</i> = 7.9 Hz, 1H), 3.47–3.43 (m, 2H), 2.65–2.61 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 173.1, 140.8, 134.9, 129.2, 126.3, 125.9, 122.7, 76.6, 76.4, 76.2, 33.7, 32.9. ESI-MS (positive), 180.1 (M + 1)<sup>+</sup>.</div></div><div id="sec5_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 2,3-Dihydro-2-methyl-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>18</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 3-methylacrylic acid (<b>2</b>-<b>18</b>). White solid. Yield: 51%. mp 209.1–212.5 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.83 (s, 1H), 7.65–7.52 (m, 1H), 7.42–7.30 (m, 1H), 7.21–7.15 (m, 1H), 7.14–7.04 (m, 1H), 3.92–3.81 (m, 1H), 2.72–2.58 (m, 1H), 2.40–2.26 (m,1H), 1.48–1.39 (d, <i>J</i> = 6.6 Hz, 3H). ESI-MS (positive), 194.1 (M + 1)<sup>+</sup>.</div></div><div id="sec5_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> General Procedure for the Synthesis of 5-Acryloyl-2,3-dihydro-2-substituted-1,5-benzothiazepin-4(5<i>H</i>)-one 4</h4><div class="NLM_p last">To a solution of <b>3</b> (1 mmol) in dichloromethane (4 mL) was added DIEA (3 mmol), and the reaction mixture was cooled to 0 °C and acryloyl chloride (2 mmol) was added dropwise. After addition, the reaction mixture was allowed to warm to room temperature and stirred overnight. The reaction mixture was diluted with dichloromethane and washed with brine, and the organic layer was dried over anhydrous MgSO<sub>4</sub> and concentrated. The crude product was purified by chromatography on silica to afford pure product <b>4</b>.</div></div><div id="sec5_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 5-Acryloyl-2,3-dihydro-2-(2-thienyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>4</b>-<b>1</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 2,3-dihydro-2-(2-thienyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>1</b>). Yield: 60%. White solid. mp 118.2–121.5 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.46–6.64 (m, 8H), 6.49 (dd, <i>J</i> = 16.9, 1.5 Hz, 1H), 5.87 (dd, <i>J</i> = 10.3, 1.5 Hz, 1H), 4.98 (dd, <i>J</i> = 12.0, 5.6 Hz, 1H), 2.90 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 170.9, 168.5, 146.3, 142.2, 137.5, 131.5, 130.6, 130.2, 129.1, 128.1, 126.8, 126.6, 124.9, 123.9, 77.3, 77.0, 76.7, 50.9, 46.3, 44.1. ESI-MS (positive), 316.0 (M + 1)<sup>+</sup>.</div></div><div id="sec5_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 5-Acryloyl-2,3-dihydro-2-phenyl-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>4</b>-<b>2</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 2,3-dihydro-2-phenyl-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>2</b>). Yield: 65%. White solid. mp 131.2–133.3 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.73–7.26 (m, 7H), 7.06 (dd, <i>J</i> = 16.8, 10.4 Hz, 3H), 6.49 (dd, <i>J</i> = 16.9, 1.6 Hz, 1H), 5.88 (dd, <i>J</i> = 10.3, 1.5 Hz, 1H), 4.69 (t, <i>J</i> = 8.8 Hz, 1H), 2.88 (d, <i>J</i> = 8.7 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 171.5, 168.6, 131.6, 130.3, 130.1, 129.2, 128.9, 128.2, 126.1, 77.3, 77.0, 76.7, 50.9, 50.6, 43.0. ESI-MS (positive), 310.1 (M + 1)<sup>+</sup>.</div></div><div id="sec5_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 5-Acryloyl-2,3-dihydro-2-(4-fluorophenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>4</b>-<b>3</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 2,3-dihydro-2-(4-fluorophenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>3</b>). Yield: 55%. White solid. mp 119.3–122.2 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.73–7.31 (m, 4H), 7.03 (s, 5H), 6.53 (d, <i>J</i> = 1.4 Hz, 1H), 5.90 (dd, <i>J</i> = 10.3, 1.5 Hz, 1H), 4.71 (d, <i>J</i> = 7.6 Hz, 1H), 3.04–2.69 (m, 2H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 171.08, 168.56, 142.05, 136.21, 132.07, 130.56, 129.07, 129.01, 128.51, 128.10, 115.33, 115.19, 48.79, 41.98. ESI-MS (positive), 328.0 (M + 1)<sup>+</sup>.</div></div><div id="sec5_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 5-Acryloyl-2,3-dihydro-2-(4-chlorophenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>4</b>-<b>4</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 2,3-dihydro-2-(4-chlorophenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>4</b>). Yield: 68%. White solid. mp 96.8–100.7 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.71–7.29 (m, 5H), 7.28–6.87 (m, 4H), 6.52 (dd, <i>J</i> = 16.9, 1.5 Hz, 1H), 5.91 (dd, <i>J</i> = 10.3, 1.5 Hz, 1H), 4.85–4.49 (m, 1H), 3.10–2.59 (m, 2H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 171.04, 168.55, 142.05, 132.06, 130.61, 129.27, 129.09, 129.03, 128.52, 128.09, 127.97, 127.07, 48.73, 47.67, 41.59. ESI-MS (positive), 344.0 (M + 1)<sup>+</sup>.</div></div><div id="sec5_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 5-Acryloyl-2,3-dihydro-2-(3-chlorophenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>4</b>-<b>5</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 2,3-dihydro-2-(3-chlorophenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>5</b>). Yield: 51%. White solid. mp 92.3–95.0 °C. <sup>1</sup>H NMR (CDCl3): δ 7.81–6.78 (m, 9H), 6.50 (dd, <i>J</i> = 16.9, 1.1 Hz, 1H), 5.89 (dd, <i>J</i> = 10.3, 1.2 Hz, 1H), 4.81–4.48 (m, 1H), 3.03–2.64 (m, 2H). ESI-MS (positive), 344.0 (M + 1)<sup>+</sup>.</div></div><div id="sec5_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 5-Acryloyl-2,3-dihydro-2-(2-chlorophenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>4</b>-<b>6</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 2,3-dihydro-2-(2-chlorophenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>6</b>). Yield: 56%. White solid. mp 90.1–92.4 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.77–7.28 (m, 7H), 7.19–6.79 (m, 2H), 6.50 (d, <i>J</i> = 17.0 Hz, 1H), 5.89 (d, <i>J</i> = 10.3 Hz, 1H), 5.20–4.92 (m, 1H), 2.91 (m, 2H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 171.16, 168.45, 142.13, 138.41, 136.26, 131.96, 131.48, 130.72, 129.57, 129.17, 128.98, 128.53, 127.43, 126.44, 125.38, 46.20. ESI-MS (positive), 344.0 (M + 1)<sup>+</sup>.</div></div><div id="sec5_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 5-Acryloyl-2,3-dihydro-2-(4-bromophenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>4</b>-<b>7</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 2,3-dihydro-2-(4-bromophenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>7</b>). Yield: 46%. White solid. mp 117.0–118.8 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.68–7.51 (m, 2H), 7.41 (m, 4H), 7.07 (dd, <i>J</i> = 16.9, 10.3 Hz, 1H), 6.93 (t, <i>J</i> = 8.6 Hz, 2H), 6.52 (dd, <i>J</i> = 16.9, 1.5 Hz, 1H), 5.90 (dd, <i>J</i> = 10.3, 1.5 Hz, 1H), 4.86–4.50 (m, 1H), 3.06–2.60 (m, 2H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 171.02, 168.55, 142.05, 136.22, 132.06, 131.37, 130.61, 129.09, 129.03, 128.52, 128.30, 48.79, 41.51. ESI-MS (positive), 387.8, 389.8 (M, M + 2)<sup>+</sup>.</div></div><div id="sec5_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 5-Acryloyl-2,3-dihydro-2-(4-methylphenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>4</b>-<b>8</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 2,3-dihydro-2-(4-methylphenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>8</b>). Yield: 51%. White solid. mp 152.3–154.5 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.69–7.06 (m, 9H), 6.51 (dd, <i>J</i> = 16.9, 1.5 Hz, 1H), 5.89 (dd, <i>J</i> = 10.3, 1.5 Hz, 1H), 4.70 (d, <i>J</i> = 7.7 Hz, 1H), 2.88 (d, <i>J</i> = 7.1 Hz, 2H), 2.34 (s, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 171.15, 168.51, 141.98, 136.78, 132.03, 130.40, 128.96, 128.89, 128.38, 125.86, 49.42, 41.91, 20.46. ESI-MS (positive), 324.0 (M + 1)<sup>+</sup>.</div></div><div id="sec5_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 5-Acryloyl-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>4</b>-<b>9</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>9</b>). Yield: 66%. White solid. mp 121.6–124.0 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.83–7.32 (m, 4H), 7.19–6.66 (m, 5H), 6.51 (dd, <i>J</i> = 16.9, 1.5 Hz, 1H), 5.89 (dd, <i>J</i> = 10.3, 1.5 Hz, 1H), 4.70 (d, <i>J</i> = 8.0 Hz, 1H), 3.79 (d, <i>J</i> = 12.6 Hz, 3H), 3.75 (q, <i>J</i> = 7.0 Hz, 2H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 171.20, 168.57, 158.55, 142.01, 132.08, 130.41, 129.01, 128.93, 128.55, 128.42, 127.21, 113.80, 113.54, 54.99, 54.90, 49.31, 47.92, 42.20. ESI-MS (positive), 340.0 (M + 1)<sup>+</sup>.</div></div><div id="sec5_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 5-Acryloyl-2,3-dihydro-2-(4-trifluoromethylphenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>4</b>-<b>10</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 2,3-dihydro-2-(4-trifluoromethylphenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>10</b>). Yield: 62%. White solid. mp 114.6–115.1 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.83–7.08 (m, 9H), 6.51 (d, <i>J</i> = 16.7 Hz, 1H), 5.89 (d, <i>J</i> = 10.2 Hz, 1H), 4.72 (m, 1H), 2.86 (m, 2H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 171.17, 168.57, 142.07, 141.76, 139.42, 136.27, 132.09, 130.53, 129.07, 129.02, 128.82, 128.51, 127.41, 126.76, 126.66, 126.50, 49.33, 41.86. ESI-MS (positive), 378.0 (M + 1)<sup>+</sup>.</div></div><div id="sec5_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 5-Acryloyl-2,3-dihydro-2-(2-trifluoromethylphenyl)-1,5-Benzothiazepin-4(5<i>H</i>)-one (<b>4</b>-<b>11</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 2,3-dihydro-2-(2-trifluoromethylphenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>11</b>). Yield: 57%. White solid. mp 107.9–109.6 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.73–6.96 (m, 8H), 6.86 (d, <i>J</i> = 6.0 Hz, 1H), 6.52 (dd, <i>J</i> = 16.9, 1.5 Hz, 1H), 5.90 (dd, <i>J</i> = 10.3, 1.4 Hz, 1H), 5.40–5.13 (m, 1H), 2.86 (d, <i>J</i> = 7.6 Hz, 2H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.73, 168.44, 141.95, 136.32, 133.12, 131.91, 130.98, 129.28, 129.25, 128.72, 128.23, 127.11, 125.82, 44.92, 41.63. ESI-MS (positive), 378.0 (M + 1)<sup>+</sup>.</div></div><div id="sec5_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 5-Acryloyl-2,3-dihydro-2-(4-methoxycarbonylphenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>4</b>-<b>12</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 2,3-dihydro-2-(4-methoxycarbonylphenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>12</b>). Yield: 72%. White solid. mp 105.8–107.9 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.96 (d, <i>J</i> = 7.4 Hz, 2H), 7.73–7.49 (m, 2H), 7.47–7.29 (m, 2H), 7.22–6.97 (m, 3H), 6.50 (dd, <i>J</i> = 16.9, 1.5 Hz, 1H), 5.89 (dd, <i>J</i> = 10.3, 1.5 Hz, 1H), 4.73 (d, <i>J</i> = 9.2 Hz, 1H), 3.91 (s, 3H), 2.88 (d, <i>J</i> = 9.2 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 171.2, 168.5, 166.5, 147.4, 142.3, 136.9, 131.5, 130.6, 130.2, 129.3, 128.5, 126.2, 77.3, 77.2, 77.0, 76.7, 58.5, 52.2, 50.1, 42.6. ESI-MS (positive), 368.0 (M + 1)<sup>+</sup>.</div></div><div id="sec5_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 5-Acryloyl-2,3-dihydro-2-(4-nitrophenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>4</b>-<b>13</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 2,3-dihydro-2-(4-nitrophenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>13</b>). Yield: 59%. White solid. mp 137.2–144.3 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.33–7.97 (m, 2H), 7.87–7.31 (m, 5H), 7.23 (dd, <i>J</i> = 15.4, 8.5 Hz, 2H), 6.53 (dd, <i>J</i> = 15.6, 1.5 Hz, 1H), 5.93 (dd, <i>J</i> = 10.3, 1.5 Hz, 1H), 4.96–4.60 (m, 1H), 3.09–2.68 (m, 2H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.84, 168.52, 146.54, 142.03, 136.18, 131.97, 130.78, 129.15, 129.11, 128.56, 127.43, 123.65, 48.47, 40.94. ESI-MS (positive), 355.0 (M + 1)<sup>+</sup>.</div></div><div id="sec5_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> 5-Acryloyl-2,3-dihydro-2-(4-cynophenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>4</b>-<b>14</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 2,3-dihydro-2-(4-cynophenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>14</b>). Yield: 66%. White solid. mp 143.5–146.8 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.24–6.97 (m, 9H), 6.51 (d, <i>J</i> = 16.8 Hz, 1H), 5.90 (d, <i>J</i> = 10.4 Hz, 1H), 4.75 (s, 1H), 2.92 (d, <i>J</i> = 9.0 Hz, 2H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 173.61, 167.20, 153.29, 142.81, 142.51, 136.85, 130.55, 130.17, 128.96, 128.78, 127.43, 126.65, 126.52, 126.40, 125.62, 125.23, 122.85, 122.54, 122.27, 122.08, 120.78, 44.44, 42.32. ESI-MS (positive), 335.0 (M + 1)<sup>+</sup>.</div></div><div id="sec5_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> 5-Acryloyl-2,3-dihydro-2-([1,1′-biphenyl]-4-yl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>4</b>-<b>15</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 2,3-dihydro-2-([1,1′-biphenyl]-4-yl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>15</b>). Yield: 51%. White solid. mp 152.8–154.8 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.82–7.32 (m, 11H), 7.23–6.99 (m, 3H), 6.53 (dd, <i>J</i> = 16.9, 1.5 Hz, 1H), 5.91 (dd, <i>J</i> = 10.3, 1.5 Hz, 1H), 4.76 (t, <i>J</i> = 8.8 Hz, 1H), 2.94 (d, <i>J</i> = 8.4 Hz, 2H). ESI-MS (positive), 386.0 (M + 1)<sup>+</sup>.</div></div><div id="sec5_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> 5-Acryloyl-2,3-dihydro-2-(4-morpholinophenyl)-1,5-Benzothiazepin-4(5<i>H</i>)-one (<b>4</b>-<b>16</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 2,3-dihydro-2-(4-morpholinophenyl)-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>16</b>). Yield: 48%. White solid. mp 167.4–169.2 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.23–6.80 (m, 9H), 6.48 (d, <i>J</i> = 16.9 Hz, 1H), 5.85 (d, <i>J</i> = 10.3 Hz, 1H), 4.65 (s, 1H), 3.78 (m, 5H), 2.99 (m, 6H). ESI-MS (positive), 395.2 (M + 1)<sup>+</sup>.</div></div><div id="sec5_1_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> 5-Acryloyl-2,3-dihydro-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>4</b>-<b>17</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 2,3-dihydro-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>17</b>). Yield: 85%. White solid. mp 95.9 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 7.65 (dd, <i>J</i> = 7.6, 1.6 Hz, 1H), 7.54–7.47 (m, 1H), 7.44–7.37 (m, 1H), 7.30 (dd, <i>J</i> = 8.0, 1.4 Hz, 1H), 6.99–6.89 (m, 1H), 6.26–6.19 (m, 1H), 5.88–5.82 (m, 1H), 3.22 (d, <i>J</i> = 7.6 Hz, 2H), 2.58–2.48 (m, 2H). ESI-MS (positive), 234.1 (M + 1)<sup>+</sup>.</div></div><div id="sec5_1_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 5-Acryloyl-2,3-dihydro-2-methyl-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>4</b>-<b>18</b>)</h4><div class="NLM_p last">Prepared using the general procedure starting from 2,3-dihydro-2-methyl-1,5-benzothiazepin-4(5<i>H</i>)-one (<b>3</b>-<b>18</b>). Yield: 91%. White solid. mp 179.9 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 7.63 (d, <i>J</i> = 7.7 Hz, 1H), 7.51 (t, <i>J</i> = 8.0 Hz, 1H), 7.40 (t, <i>J</i> = 7.6 Hz, 1H), 7.34–7.26 (m, 1H), 6.97–6.87 (m, 1H), 6.28–6.17 (m, 1H), 5.87–5.82 (m, 1H), 3.69 (s, 1H), 2.64 (dd, <i>J</i> = 12.8, 6.4 Hz, 1H), 2.06 (s, 1H), 1.32–1.18 (m, 3H). ESI-MS (positive), 248.0 (M + 1)<sup>+</sup>.</div></div><div id="sec5_1_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> <i>N</i>-(2-(4-Oxo-2-phenyl-2,3-dihydro-1,5-benzothiazepin-5(2<i>H</i>)-yl)ethyl)acrylamide (<b>7</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 9.56 (s, 1H), 8.37 (s, 1H), 7.77 (s, 1H), 7.66 (s, 2H), 7.60 (d, <i>J</i> = 15.4 Hz, 2H), 7.45 (d, <i>J</i> = 9.5 Hz, 3H), 7.30 (s, 1H), 7.26–7.16 (m, 1H), 7.09 (d, <i>J</i> = 15.8 Hz, 1H), 6.19 (d, <i>J</i> = 11.3 Hz, 1H), 6.10 (d, <i>J</i> = 17.0 Hz, 1H), 5.60 (d, <i>J</i> = 9.8 Hz, 1H), 3.33 (s, 2H), 3.00 (d, <i>J</i> = 7.3 Hz, 2H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 164.71, 163.77, 140.36, 137.35, 134.59, 131.37, 130.77, 129.65, 128.81, 127.65, 127.00, 125.54, 125.27, 124.56, 121.92, 38.05, 32.77.</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> MS for the Covalent Binding and Label Site of 4-3 to GSK-3β</h3><div class="NLM_p last">The measurements were performed by National Center for Protein Science Shanghai (NCPSS), China. Human recombinant GSK-3β was purchased from Millipore (Millipore, Billerica, USA).</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Preparation of Protein Sample</h3><div class="NLM_p last">A stock solution of 10 μg of the enzyme in a buffer (50 mM HEPES, 1 mM EDTA, 2 mM EGTA, and 15 mM Mg(OAc)<sub>2</sub>·4 H<sub>2</sub>O) was prepared. Compound <b>4</b>-<b>3</b> (500 μM) was dissolved in dimethyl sulfoxide (DMSO), then 1.6 μL of the compound solution was added to 14.4 μL of the enzyme stock solution (10 μM) after incubating at 30 °C under constant shaking (500 rpm) for 30 min.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> LC–MS Analyses for the Covalent Mode</h3><div class="NLM_p last">The measurements were performed using liquid chromatography–MS (LC–MS) in the positive-ion mode with an Agilent 6550 quadrupole-time-of-flight mass spectrometer (Santa Clara, CA) coupled with an Agilent 1260 HPLC (Santa Clara, CA). The incubated protein sample was eluted from a Phenomenex Jupiter C4 300 Å LC Column (2 × 150 mm, 5 μm) over a 20 min gradient from 5 to 100% acetonitrile containing 0.1% formic acid at a flow rate of 0.5 mL/min. The acquisition method in the positive-ion mode with Dual Agilent Jet Stream electrospray voltage used a capillary temperature of 250 °C, a fragmentor of 175 V, a capillary voltage of 3000 V, and a <i>m</i>/<i>z</i> 600–3200 mass window. Mass deconvolution was later performed using Agilent MassHunter Qualitative Analysis B.06.00 software.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> Identification of Protein Modification Site to 4-3</h3><div id="sec5_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> Protein Precipitation and Digestion</h4><div class="NLM_p last">The incubated protein was precipitated with acetone. The protein pellet was dried by using a Speedvac for 1–2 min and subsequently dissolved in 8 M urea and 100 mM Tris–HCl (pH 8.5). TCEP (Thermo Scientific, final concentration is 5 mM) and iodoacetamide (Sigma, final concentration is 10 mM) were added to the solution for reduction and alkylation and incubated at room temperature for 20 and 15 min, respectively. The protein mixture was diluted four times and digested overnight with trypsin at 1:50 (w/w) (Promega, <a href="http://www.promega.com/" class="extLink">http://www.promega.com/</a>).</div></div><div id="sec5_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> LC/Tandem MS (MS/MS) Analysis of Peptide</h4><div class="NLM_p last">The peptide mixture was analyzed on an ACQUITY UPLC M-Class system (Waters Corporation, Milford, MA, USA) equipped with a Waters BEH C18 analytical column (75 μm*250 mm, 1.7 μm) at the temperature of 60 °C during the experiments. The mobile phase and elution gradient used for peptide separation were as follows: 0.1% formic acid in water as buffer A and 0.1% formic acid in acetonitrile as buffer B, 0–1 min, 2–5% B; 1–200 min, 5–35% B; 200–210 min, 35–100% B; 210–220 min, 100% B; 220–230 min, 100–2% B; and 230–240 min, 2% B. The flow rate was set as 300 ml/min.</div></div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> Mass Spectrometry</h3><div class="NLM_p last">Data-dependent tandem MS (MS/MS) analysis was performed with a Q Exactive Orbitrap mass spectrometer (Thermo Scientific, San Jose, CA) equipped with a nanoelectrospray ionization source using a distal 2 kV spray voltage. A cycle of one full-scan MS spectrum (<i>m</i>/<i>z</i> 300–1800) was acquired followed by top 20 MS/MS events, sequentially generated on the first to the twentieth most intense ions selected from the full MS spectrum at a 30% normalized collision energy. The number of microscans was one for both MS and MS/MS scans and the maximum ion injection time was 50 and 100 ms, respectively. The dynamic exclusion settings used were as follows: charge exclusion, 1 and >8; exclude isotopes, on; and exclusion duration, 30 s. MS scan functions and LC solvent gradients were controlled by the Xcalibur data system (Thermo Scientific).</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> Data Analysis</h3><div class="NLM_p last">The acquired MS/MS data were analyzed against a <i>Spodoptera frugiperda</i> database (including all target peptides and proteins) using Peaks8.5. Mass tolerances for precursor ions were set at 20 ppm and for MS/MS were set at 0.02 Da. Trypsin was defined as a cleavage enzyme. Cysteine alkylation by iodoacetamide was specified as a fixed modification with mass shift 57.02146 and methionine oxidation, protein C<sub>18</sub>H<sub>14</sub>FNO<sub>2</sub>S modification as a variable with mass shift 327.0729. A decoy database containing the reversed sequences of all the proteins was appended to the target database to accurately estimate peptide probabilities and false discovery rate (FDR), and FDR was set at 0.01.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> Biology</h3><div id="sec5_8_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> In Vitro Biological Evaluation Conditions</h4><div class="NLM_p">Human recombinant GSK-3β (catalog number 14–306) was purchased from Millipore Corporation (Dundee, UK). The prephosphorylated polypeptide substrate GS-2 was synthesized by GL Biochem Ltd. (Shanghai, China). The Kinase-Glo Luminescent Kinase Assay (catalog number V6713) was obtained from Promega Corporation (Madison, WI). ATP·2Na was purchased from Roche. TDZD-8 (catalog number 098K4602V) was supplied by Sigma-Aldrich (St. Louis, MO). Assay buffer contained 50 mM HEPES (pH 7.5), 1 mM EDTA, 1 mM EGTA, and 15 mM magnesium acetate. Glow-type luminescence was recorded by Fluoroskan Ascent Fl (Thermo Electron, US).</div><div class="NLM_p last">LiCl was of molecular biology grade and purchased by Sangon Biotech Co., Ltd. (Shanghai, China), which was dissolved in sterile phosphate-buffered saline (PBS) and stock solution (10 mM) was stored at −20 °C. For experimental use, the drugs were freshly prepared from the stock solution. Benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone (Z-VAD-FMK) was acquired from Enzo Life Sciences, Inc (Lausen, Switzerland). Corn oil, Cat no.1148806, Merck, Darmstadt, Germany. NB4 is an ATRA (all-trans retinoic acid)-sensitive human APL cell line and NB4-R1 is an ATRA-resistant human APL cell line, both of which were kindly supplied from the Institute of Hematology, the Affiliated Hospital of Ruijin, Jiaotong University (Shanghai, China). HL-60 (human APL) cells and Raji (Burkitt lymphoma) cell lines were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). HUVEC and LO<sub>2</sub> (human normal liver cells) cell lines were kindly provided by the Liver Cancer Research Institute of Zhongshan Hospital, Fudan University (Shanghai, China), and maintained according to the ATCC guidelines at our center. All cells were cultured in RPMI-1640 or Dulbecco’s modified Eagle’s medium (high-glucose medium) (Thermo Scientific HyClone, Logan, Utah, USA) containing 10% fetal bovine serum (Gibco, Carlsbad, CA, USA) and 1% (v/v) penicillin–streptomycin (Gibco Invitrogen, Grand Island, NY, USA) at 37 °C. in a humidified atmosphere with 5% CO<sub>2</sub>.</div></div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> Inhibition of GSK-3β</h3><div class="NLM_p last">The measurement of GSK-3β inhibition was performed in assay buffer using blank 96-well plates according to the Kinase-Glo assay method of Baki.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> In a typical assay, 4 μL of interest compound with different concentrations (dissolved in DMSO) was diluted by 14 μL of assay buffer, and 2 μL (20 ng) of enzyme solution was added to each well, followed by 20 μL of assay buffer containing 12.5 μM substrate and 4 μM ATP. After 30 min of incubation at 30 °C, the enzymatic reaction was stopped with 40 μL of Kinase-Glo reagent. Glow-type luminescence was recorded after 10 min. The activity is proportional to the difference of the total and consumed ATP. The inhibitory activities were calculated on the basis of maximal activities measured in the absence of inhibitor. The IC<sub>50</sub> value was defined as the concentration of each compound that reduces 50% of the enzymatic activity to that without inhibitors.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> Kinetic Analysis on GSK-3β</h3><div class="NLM_p last">The protocol of kinetic experiments was much similar to the GSK-3β inhibition tests. The activities of compound <b>4</b>-<b>2</b> were measured separately at 2 and 4 μM. In the experiments for testing the relationship between <b>4</b>-<b>2</b> and ATP, the concentration of substrate GS-2 was kept unchanged at 6.25 μM, while the concentration of ATP was set at 0.5, 1, 2, 4, and 8 μM separately. Then, in the following experiments for testing the relationship between <b>4</b>-<b>2</b> and GS-2, the concentration of ATP was kept unchanged at 2 μM, while GS-2 concentration was set at 0.78, 1.56, 3.13, 6.25, and 12.5 μM separately. The irreversibility of <b>4</b>-<b>2</b> was determined by evaluating its activity to the enzyme at different incubation times. The incubation time was set at 0, 5, and 10 min, while the concentration of <b>4</b>-<b>2</b> was kept at 6.25 and 12.5 μM separately.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> Selectivity Studies of Tyrosine Kinase Inhibition</h3><div class="NLM_p last">The experimental procedures for the inhibition of tyrosine kinases were conducted using the ELISA method reported by Geng et al.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Briefly, 20 μg/mL of poly (Glu, Tyr) 4:1 (Sigma) was pre-coated as a substrate in 96-well plates. About 50 μL of 10 μM ATP solution diluted with kinase reaction buffer (50 mM HEPES pH 7.4, 50 mM MgCl<sub>2</sub>, 0.5 mM MnCl<sub>2</sub>, 0.2 mM Na<sub>3</sub>VO<sub>4</sub>, and 1 mM DTT) was added to each well. Various concentrations of compounds diluted in 10 μL of 1% DMSO (v/v) were added to each reaction well, with 1% DMSO (v/v) used as the negative control. The kinase reaction was initiated by the addition of purified tyrosine kinase proteins diluted with 40 μL of kinase reaction buffer solution. After incubation for 60 min at 37 °C, the plate was washed three times with PBS containing 0.1% Tween 20 (T-PBS). Next, 100 μL of anti-phospho-tyrosine (PY99) antibody (1:500 diluted in 5 mg/mL BSA T-PBS) was added. After 30 min of incubation at 37 °C, the plate was washed three times. A solution of 100 μL of horseradish peroxidase-conjugated goat anti-mouse IgG (1:2000 diluted in 5 mg/mL BSA T-PBS) was added. The plate was reincubated at 37 °C for 30 min and washed as mentioned before. Finally, 100 μL of a solution containing 0.03% H<sub>2</sub>O<sub>2</sub> and 2 mg/mL <i>o</i>-phenylenediamine in 0.1 mM citrate buffer, pH 5.5, was added, and samples were incubated at room temperature until color emerged. The reaction was terminated by the addition of 50 μL of 2 M H<sub>2</sub>SO<sub>4</sub>, and the plate was read using a multi-well spectrophotometer (VERSA max, Molecular Devices, Sunnyvale, CA, USA) at 490 nm. The inhibition rate (%) was calculated using the following equation: [1-(A490/A490 control)]× 100%.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> Cell Proliferation Assay</h3><div class="NLM_p last">Cell proliferation of target compounds and LiCl was performed using the Cell Counting Kit-8 (CCK-8) assay (Dojindo Laboratories, Kumamoto, Japan) as per the instruction of the manufacturer. Briefly, cells were seeded in 96-well plates at 3 × 10<sup>4</sup> cells/well and treated either with these different inhibitors at serial concentrations or for various times (0, 24, or 48 h). After treatment, CCK-8 solution (10 μL) was added to each well, followed by 3 h of incubation at 37 °C. The absorbance wavelength at 450 nm was recorded for each well in a FlexStation 3 microplate reader (Molecular Devices, Sunnyvale, California, USA), and cell viability was then calculated according to the manufacturer’s instruction.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> Detection of Apoptosis with Annexin V-FITC/PI Staining</h3><div class="NLM_p last">Cell apoptosis was determined by the Annexin V-fluorescein isothiocyanate (FITC)/PI Apoptosis Detection Kit (BD Pharmingen, California, USA). Cells were cultured in a 24-well plate at a density of 6 × 10<sup>4</sup> cells/mL and treated with GSK-3β inhibitors for 24 h. The cells were harvested and resuspended in binding buffer, then stained with 5 μL Annexin V-FITC and 5 μL PI, and incubated for 20 min at room temperature in the dark. At last, the stained cells were detected within 30 min with the BD FACS Aria II flow cytometer (BD Biosciences, San Jose, California, USA).</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> Western Blotting</h3><div class="NLM_p last">Cells were harvested and washed twice with ice-cold PBS. Total protein was extracted using the RIPA kit (Beyotime Biotechnology Inc., Shanghai, China), and equal amounts of protein were separated on polyacrylamide gels and transferred to PVDF membranes. The membranes were blocked and incubated with anti-Phospho-Glycogen Synthase (Ser641) (Cell Signaling Technology, #47043, MA, USA), Glycogen Synthase (15B1) (Cell Signaling Technology, #3886, MA, USA), and anti-β-actin, AF0003 (Beyotime Biotechnology Inc., Shanghai, China) at 4 °C overnight and were then incubated with horseradish peroxidase-conjugated goat anti-rabbit or anti-mouse IgG secondary antibodies at room temperature for 1 h. The proteins were visualized using an enhanced chemiluminescence kit (Amersham Pharmacia Biotech, Buckinghamshire, UK) and analyzed by the Bio-Rad ChemiDoc MP Imaging System (California, USA).</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> PK Studies</h3><div class="NLM_p last">The PK analysis was performed in male ICR mice (30 g body weight) by i.p. bolus dose (15 mg/kg) of compound <b>4</b>-<b>3</b> dissolved in corn oil. Blood samples (∼0.2 mL) were obtained by orbital blood collection into tri-potassium ethylenediaminetetraacetic acid (K3EDTA)-containing tubes at 0.08, 0.17, 0.5, 1, 2, 4, and 8 h after administration. Within each group, blood samples of three animals were collected, resulting in a composite PK profile. The blood samples were centrifuged at 8000 rpm for 5 min to obtain plasma, and 40 μL of plasma was pipetted into a clean tube, 160 μL of ACN was added and thoroughly vortexed by a vortex mixer for 1 min. The mixture was centrifuged at 14000 rpm for 10 min, and then 100 μL of supernatant was for the analysis by AB 4000 QTRAP LC–MS/MS. The PK parameters were calculated using the non-compartmental analysis tool of WinNonlin Pro (version 6.3).</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> Efficacy of GSK-3β Inhibition on the Leukemia Xenograft Model In Vivo</h3><div class="NLM_p last">Balb/c female nude mice were obtained from Shanghai SLAC Laboratory Animal Ltd. Co. The animals were fed a sterile diet and water and kept in individually ventilated cages to avoid infection under a 12 h light/dark cycle at constant temperature and humidity. 2 × 10<sup>6</sup> leukemia cells were injected subcutaneously into the right flanks of 4 week-old nude mice. Tumor-bearing mice about 0.5 cm in diameter were randomly divided into vehicle control (corn oil) and <b>4</b>-<b>3</b> (dissolved in corn oil) treatment group (<i>n</i> = 5). Intraperitoneal administration of these animals with <b>4</b>-<b>3</b> (15 mg/kg/d) and vehicle control was carried out once a day for 2 weeks. Tumors were measured by caliper, and volumes were calculated by (length × width<sup>2</sup>)/2 once every other day. The animal experimental protocols were performed and approved by the Animal Ethics Committee of Zhongshan Hospital, Fudan University.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i94"><a href="/doi/suppl/10.1021/acs.jmedchem.0c02254" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12443" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12443" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c02254?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02254</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">HPLC traces for key target compounds and figures for the candidate of <b>4</b>-<b>3</b> including hERG inhibition and exposition curve in mouse plasma (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02254/suppl_file/jm0c02254_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and biological data (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02254/suppl_file/jm0c02254_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02254/suppl_file/jm0c02254_si_001.pdf">jm0c02254_si_001.pdf (275.98 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02254/suppl_file/jm0c02254_si_002.csv">jm0c02254_si_002.csv (1.04 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c02254" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35860" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35860" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yunfeng Cheng</span> - <span class="hlFld-Affiliation affiliation">Institute
of Clinical Science, Zhongshan Hospital,
Fudan University, Shanghai 200032, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#8ff6e9ece7eae1e8cfe9faebeee1a1eaebfaa1ece1"><span class="__cf_email__" data-cfemail="28514e4b404d464f684e5d4c4946064d4c5d064b46">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yong Chu</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#33504a02020373554657525d1d5657461d505d"><span class="__cf_email__" data-cfemail="2a49531b1b1a6a4c5f4e4b44044f4e5f044944">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peng Zhang</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">State
Key Lab of New Drug & Pharmaceutical Process, Shanghai Key Lab
of Anti-Infectives, Shanghai Institute of
Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 201203, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-2703-6009" title="Orcid link">https://orcid.org/0000-0002-2703-6009</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhihui Min</span> - <span class="hlFld-Affiliation affiliation">Institute
of Clinical Science, Zhongshan Hospital,
Fudan University, Shanghai 200032, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yang Gao</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-9131-3541" title="Orcid link">https://orcid.org/0000-0002-9131-3541</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiang Bian</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xin Lin</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jie He</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Deyong Ye</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-0498-3019" title="Orcid link">https://orcid.org/0000-0003-0498-3019</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yilin Li</span> - <span class="hlFld-Affiliation affiliation">National
Facility for Protein Science in Shanghai, Zhangjiang Lab, Shanghai
Advanced Research Institute, Chinese Academy
of Science, Shanghai 201210, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chao Peng</span> - <span class="hlFld-Affiliation affiliation">National
Facility for Protein Science in Shanghai, Zhangjiang Lab, Shanghai
Advanced Research Institute, Chinese Academy
of Science, Shanghai 201210, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>P.Z. and Z.M. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i96">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66366" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66366" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We gratefully acknowledge the financial support by the Shanghai Municipal Committee of Science and Technology, China (grant no. 19431900600 to Y.C.), and by the National Natural Science Foundation of China (grant no. 81373275 to Y.C. and grant nos. 81470282 and 81870098 to Y.F. Cheng). Thanks are due to Professor Jianzhong Lu (Department of Pharmaceutical Analysis, School of Pharmacy, Fudan University) and Professor Meiyu Geng (Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica) for assistance with the biological evaluation.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small cell lung carcinoma</p></td></tr><tr><td class="NLM_term">CK2</td><td class="NLM_def"><p class="first last">casein kinase 2</p></td></tr><tr><td class="NLM_term">PKA</td><td class="NLM_def"><p class="first last">protein kinase A</p></td></tr><tr><td class="NLM_term">Flt-1</td><td class="NLM_def"><p class="first last">Fms-related tyrosine kinase 1</p></td></tr><tr><td class="NLM_term">KDR</td><td class="NLM_def"><p class="first last">kinase insert domain receptor</p></td></tr><tr><td class="NLM_term">FGFR</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor</p></td></tr><tr><td class="NLM_term">EPH</td><td class="NLM_def"><p class="first last">ephrin</p></td></tr><tr><td class="NLM_term">RET</td><td class="NLM_def"><p class="first last">rearranged during transfection</p></td></tr><tr><td class="NLM_term">Src</td><td class="NLM_def"><p class="first last">sarcoma</p></td></tr><tr><td class="NLM_term">ABL</td><td class="NLM_def"><p class="first last">Abelson murine leukemia viral oncogene homolog</p></td></tr><tr><td class="NLM_term">HUVEC</td><td class="NLM_def"><p class="first last">human umbilical vein endothelial cells</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i98">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80461" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80461" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 46 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houk, K. N.</span></span> <span> </span><span class="NLM_article-title">Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1021/jm800498e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800498e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BD1MXis1OltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=225-233&author=A.+J.+T.+Smithauthor=X.+Zhangauthor=A.+G.+Leachauthor=K.+N.+Houk&title=Beyond+picomolar+affinities%3A+quantitative+aspects+of+noncovalent+and+covalent+binding+of+drugs+to+proteins&doi=10.1021%2Fjm800498e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins</span></div><div class="casAuthors">Smith, Adam J. T.; Zhang, Xiyun; Leach, Andrew G.; Houk, K. N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">225-233</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review of 104 refs. summarized quant. aspects of noncovalent and covalent binding of drugs to proteins with subtopics including (1) introduction; (2) factors involved in ligand-recepto binding; (3) distribution of exptl. binding consts.; (3) covalent interactions with transition states as the origins of enzyme proficiency; (4) potential quant. advantages of covalent enzyme inhibitors and colent drugs; (5) selected examples of covalent inhibitors and drugs; (6) prospects for the design of covalent drugs; (7) conclusions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAhUbRxt1fu7Vg90H21EOLACvtfcHk0lirad24Dcja_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXis1OltLw%253D&md5=529d4181046100b5e3c37a8fef571218</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Fjm800498e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800498e%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DA.%2BJ.%2BT.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLeach%26aufirst%3DA.%2BG.%26aulast%3DHouk%26aufirst%3DK.%2BN.%26atitle%3DBeyond%2520picomolar%2520affinities%253A%2520quantitative%2520aspects%2520of%2520noncovalent%2520and%2520covalent%2520binding%2520of%2520drugs%2520to%2520proteins%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D225%26epage%3D233%26doi%3D10.1021%2Fjm800498e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span> <span> </span><span class="NLM_article-title">Targeted covalent inhibitors for drug design</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">13408</span>– <span class="NLM_lpage">13421</span>, <span class="refDoi"> DOI: 10.1002/anie.201601091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1002%2Fanie.201601091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOrtb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=13408-13421&author=T.+A.+Baillie&title=Targeted+covalent+inhibitors+for+drug+design&doi=10.1002%2Fanie.201601091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Covalent Inhibitors for Drug Design</span></div><div class="casAuthors">Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">13408-13421</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">In contrast to the traditional mechanism of drug action that relies on the reversible, noncovalent interaction of a ligand with its biol. target, a targeted covalent inhibitor (TCI) is designed such that the initial, reversible assocn. is followed by the formation of a covalent bond between an electrophile on the ligand and a nucleophilic center in the protein.  Although this approach offers a variety of potential benefits (high potency and extended duration of action), concerns over the possible toxicol. consequences of protein haptenization have hindered the development of the TCI concept.  Recently, approaches to mitigate the risk of serious adverse reactions to this new class of agent have emerged, thus stimulating interest in the field and leading to authorization of the first cadre of TCIs to be marketed.  The covalent inhibitor approach is rapidly gaining acceptance as a valuable tool in drug discovery, and is poised to make a major impact on the design of enzyme inhibitors and receptor modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEbjdFrctvNrVg90H21EOLACvtfcHk0lirad24Dcja_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOrtb%252FN&md5=18bed2ae08dcb4245a42b3070abc6354</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fanie.201601091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201601091%26sid%3Dliteratum%253Aachs%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DTargeted%2520covalent%2520inhibitors%2520for%2520drug%2520design%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D13408%26epage%3D13421%26doi%3D10.1002%2Fanie.201601091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryabtsova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joossens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Der
Veken, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanden Berghe, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustyns, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Winter, H.</span></span> <span> </span><span class="NLM_article-title">Novel selective glucocorticoid receptor agonists (SEGRAs) with a covalent warhead for long-lasting inhibition</span>. <i>Bioorg. Med. Chem. Lett</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5032</span>– <span class="NLM_lpage">5038</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.08.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1016%2Fj.bmcl.2016.08.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=27612544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsV2jsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=5032-5038&author=O.+Ryabtsovaauthor=J.+Joossensauthor=P.+Van+Der%0AVekenauthor=W.+Vanden+Bergheauthor=K.+Augustynsauthor=H.+De+Winter&title=Novel+selective+glucocorticoid+receptor+agonists+%28SEGRAs%29+with+a+covalent+warhead+for+long-lasting+inhibition&doi=10.1016%2Fj.bmcl.2016.08.091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Novel selective glucocorticoid receptor agonists (SEGRAs) with a covalent warhead for long-lasting inhibition</span></div><div class="casAuthors">Ryabtsova, Oksana; Joossens, Jurgen; Van Der Veken, Pieter; Vanden Berghe, Wim; Augustyns, Koen; De Winter, Hans</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5032-5038</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The synthesis and in vitro properties of six analogs of the selective glucocorticoid receptor (GR) agonist GSK866 (I), bearing a warhead for covalent linkage to the glucocorticoid receptor, is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp6KtRHDt_X7Vg90H21EOLACvtfcHk0lirad24Dcja_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsV2jsL3I&md5=b02430eefd26167bf45e46541f765754</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.08.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.08.091%26sid%3Dliteratum%253Aachs%26aulast%3DRyabtsova%26aufirst%3DO.%26aulast%3DJoossens%26aufirst%3DJ.%26aulast%3DVan%2BDer%2BVeken%26aufirst%3DP.%26aulast%3DVanden%2BBerghe%26aufirst%3DW.%26aulast%3DAugustyns%26aufirst%3DK.%26aulast%3DDe%2BWinter%26aufirst%3DH.%26atitle%3DNovel%2520selective%2520glucocorticoid%2520receptor%2520agonists%2520%2528SEGRAs%2529%2520with%2520a%2520covalent%2520warhead%2520for%2520long-lasting%2520inhibition%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett%26date%3D2016%26volume%3D26%26spage%3D5032%26epage%3D5038%26doi%3D10.1016%2Fj.bmcl.2016.08.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Cesco, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufresne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittermaier, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moitessier, N.</span></span> <span> </span><span class="NLM_article-title">Covalent inhibitors design and discovery</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.06.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1016%2Fj.ejmech.2017.06.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=28651155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVKhsLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2017&pages=96-114&author=S.+De%0ACescoauthor=J.+Kurianauthor=C.+Dufresneauthor=A.+K.+Mittermaierauthor=N.+Moitessier&title=Covalent+inhibitors+design+and+discovery&doi=10.1016%2Fj.ejmech.2017.06.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent inhibitors design and discovery</span></div><div class="casAuthors">De Cesco, Stephane; Kurian, Jerry; Dufresne, Caroline; Mittermaier, Anthony K.; Moitessier, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">96-114</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In the history of therapeutics, covalent drugs occupy a very distinct category.  While representing a significant fraction of the drugs on the market, very few have been deliberately designed to interact covalently with their biol. target.  In this review, the prevalence of covalent drugs will first be briefly covered, followed by an introduction to their mechanisms of action and more detailed discussions of their discovery and the development of safe and efficient covalent enzyme inhibitors.  All stages of a drug discovery program will be covered, from target considerations to lead optimization, strategies to tune reactivity and computational methods.  The goal of this article is to provide an overview of the field and to outline good practices that are needed for the proper assessment and development of covalent inhibitors as well as a good understanding of the potential and limitations of current computational methods for the design of covalent drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeLNDmLtBdB7Vg90H21EOLACvtfcHk0lhlKs_UNu2rcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVKhsLrI&md5=551c9a9c4bd69d4ad4d9156c315d5a94</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.06.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.06.019%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BCesco%26aufirst%3DS.%26aulast%3DKurian%26aufirst%3DJ.%26aulast%3DDufresne%26aufirst%3DC.%26aulast%3DMittermaier%26aufirst%3DA.%2BK.%26aulast%3DMoitessier%26aufirst%3DN.%26atitle%3DCovalent%2520inhibitors%2520design%2520and%2520discovery%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D138%26spage%3D96%26epage%3D114%26doi%3D10.1016%2Fj.ejmech.2017.06.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bliven, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourne, P. E.</span></span> <span> </span><span class="NLM_article-title">Determining cysteines available for covalent inhibition across the human kinome</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2879</span>– <span class="NLM_lpage">2889</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01815</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01815" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvVGjsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2879-2889&author=Z.+Zhaoauthor=Q.+Liuauthor=S.+Blivenauthor=L.+Xieauthor=P.+E.+Bourne&title=Determining+cysteines+available+for+covalent+inhibition+across+the+human+kinome&doi=10.1021%2Facs.jmedchem.6b01815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Determining Cysteines Available for Covalent Inhibition Across the Human Kinome</span></div><div class="casAuthors">Zhao, Zheng; Liu, Qingsong; Bliven, Spencer; Xie, Lei; Bourne, Philip E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2879-2889</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Covalently bound protein kinase inhibitors have been frequently designed to target non-catalytic Cys residues at the ATP binding site.  Thus, it is important to know if a given Cys residue can form a covalent bond.  Here, we combined a function-site interaction fingerprint method and DFT calcns. to det. the potential of Cys residues to form a covalent interaction with an inhibitor.  By harnessing the human structural kinome, a comprehensive structure-based binding site Cys dataset was assembled.  The orientation of the Cys SH group indicated which Cys residues could potentially form covalent bonds.  These covalent inhibitor accessible Cys residues were located within 5 kinase regions (P-loop, roof of pocket, front pocket, catalytic-2 of the catalytic loop and DFG-3 close to the DFG peptide).  In an independent test set, these Cys residues covered 95% of covalent kinase inhibitors.  Thus, this study provides new insights into Cys reactivity and preference which is important for the prospective development of covalent kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKJnGGcKhC5rVg90H21EOLACvtfcHk0lhlKs_UNu2rcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvVGjsLg%253D&md5=22ea95ce38eb0836d32c1332dba54fad</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01815%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBliven%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DBourne%26aufirst%3DP.%2BE.%26atitle%3DDetermining%2520cysteines%2520available%2520for%2520covalent%2520inhibition%2520across%2520the%2520human%2520kinome%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2879%26epage%3D2889%26doi%3D10.1021%2Facs.jmedchem.6b01815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keeley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ábrányi-Balogh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keserű, G. M.</span></span> <span> </span><span class="NLM_article-title">Design and characterization of a heterocyclic electrophilic fragment library for the discovery of cysteine-targeted covalent inhibitors</span>. <i>Medchemcomm</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.1039/c8md00327k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1039%2FC8MD00327K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=30881613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVKqsL3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=263-267&author=A.+Keeleyauthor=P.+%C3%81br%C3%A1nyi-Baloghauthor=G.+M.+Keser%C5%B1&title=Design+and+characterization+of+a+heterocyclic+electrophilic+fragment+library+for+the+discovery+of+cysteine-targeted+covalent+inhibitors&doi=10.1039%2Fc8md00327k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Design and characterization of a heterocyclic electrophilic fragment library for the discovery of cysteine-targeted covalent inhibitors</span></div><div class="casAuthors">Keeley, A.; Abranyi-Balogh, P.; Keseru, G. M.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-267</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A fragment library of electrophilic small heterocycles was characterized through cysteine-reactivity and aq. stability tests that suggested their potential as covalent warheads.  The anal. of theor. and exptl. descriptors revealed correlations between the electronic properties of the heterocyclic cores and their reactivity against GSH that are helpful in identifying suitable fragments for cysteines with specific nucleophilicity.  The most important advantage of these fragments is that they show only minimal structural differences from non-electrophilic counterparts.  Therefore, they could be used effectively in the design of targeted covalent inhibitors with minimal influence on key non-covalent interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_kfO0y4dKtrVg90H21EOLACvtfcHk0lhlKs_UNu2rcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVKqsL3M&md5=3f1fbf3849026598029e9b8154815a3c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1039%2FC8MD00327K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8MD00327K%26sid%3Dliteratum%253Aachs%26aulast%3DKeeley%26aufirst%3DA.%26aulast%3D%25C3%2581br%25C3%25A1nyi-Balogh%26aufirst%3DP.%26aulast%3DKeser%25C5%25B1%26aufirst%3DG.%2BM.%26atitle%3DDesign%2520and%2520characterization%2520of%2520a%2520heterocyclic%2520electrophilic%2520fragment%2520library%2520for%2520the%2520discovery%2520of%2520cysteine-targeted%2520covalent%2520inhibitors%26jtitle%3DMedchemcomm%26date%3D2019%26volume%3D10%26spage%3D263%26epage%3D267%26doi%3D10.1039%2Fc8md00327k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of a series of pyrazolo[3,4-d]pyridazinone compounds as the novel covalent fibroblast growth factor receptor inhibitors by the rational drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7473</span>– <span class="NLM_lpage">7488</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00510</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00510" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVemu77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7473-7488&author=Y.+Wangauthor=Y.+Daiauthor=X.+Wuauthor=F.+Liauthor=B.+Liuauthor=C.+Liauthor=Q.+Liuauthor=Y.+Zhouauthor=B.+Wangauthor=M.+Zhuauthor=R.+Cuiauthor=X.+Tanauthor=Z.+Xiongauthor=J.+Liuauthor=M.+Tanauthor=Y.+Xuauthor=M.+Gengauthor=H.+Jiangauthor=H.+Liuauthor=J.+Aiauthor=M.+Zheng&title=Discovery+and+development+of+a+series+of+pyrazolo%5B3%2C4-d%5Dpyridazinone+compounds+as+the+novel+covalent+fibroblast+growth+factor+receptor+inhibitors+by+the+rational+drug+design&doi=10.1021%2Facs.jmedchem.9b00510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of a Series of Pyrazolo[3,4-d]pyridazinone Compounds as the Novel Covalent Fibroblast Growth Factor Receptor Inhibitors by the Rational Drug Design</span></div><div class="casAuthors">Wang, Yulan; Dai, Yang; Wu, Xiaowei; Li, Fei; Liu, Bo; Li, Chunpu; Liu, Qiufeng; Zhou, Yuanyang; Wang, Bao; Zhu, Mingrui; Cui, Rongrong; Tan, Xiaoqin; Xiong, Zhaoping; Liu, Jia; Tan, Minjia; Xu, Yechun; Geng, Meiyu; Jiang, Hualiang; Liu, Hong; Ai, Jing; Zheng, Mingyue</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7473-7488</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Alterations of fibroblast growth factor receptors (FGFRs) play key roles in numerous cancer progression and development, which makes FGFRs attractive targets in the cancer therapy.  In the present study, based on a newly devised FGFR target-specific scoring function, a novel FGFR inhibitor hit was identified through virtual screening.  Hit-to-lead optimization was then performed by integrating mol. docking and site-of-metab. predictions with an array of in vitro evaluations and X-ray cocrystal structure detn., leading to a covalent FGFR inhibitor 15, which showed a highly selective and potent FGFR inhibition profile.  Pharmacokinetic assessment, protein kinase profiling, and hERG inhibition evaluation were also conducted, and they confirmed the value of 15 as a lead for further investigation.  Overall, this study exemplifies the importance of the integrative use of computational methods and exptl. techniques in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKNbodkitt5rVg90H21EOLACvtfcHk0liVTW9Tw9ptBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVemu77L&md5=80943e14d5d126f05f7d66a88208f109</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00510%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DCui%26aufirst%3DR.%26aulast%3DTan%26aufirst%3DX.%26aulast%3DXiong%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DM.%26atitle%3DDiscovery%2520and%2520development%2520of%2520a%2520series%2520of%2520pyrazolo%255B3%252C4-d%255Dpyridazinone%2520compounds%2520as%2520the%2520novel%2520covalent%2520fibroblast%2520growth%2520factor%2520receptor%2520inhibitors%2520by%2520the%2520rational%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7473%26epage%3D7488%26doi%3D10.1021%2Facs.jmedchem.9b00510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCubrey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steelman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokolosky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montalto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Assoro, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Libra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicoletti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maestro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basecke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gizak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demidenko, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocco, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martelli, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervello, M.</span></span> <span> </span><span class="NLM_article-title">GSK-3 as potential target for therapeutic intervention in cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">2881</span>– <span class="NLM_lpage">2911</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.2037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.18632%2Foncotarget.2037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=24931005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A280%3ADC%252BC2cfislOntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=2881-2911&author=J.+A.+McCubreyauthor=L.+S.+Steelmanauthor=F.+E.+Bertrandauthor=N.+M.+Davisauthor=M.+Sokoloskyauthor=S.+L.+Abramsauthor=G.+Montaltoauthor=A.+B.+D%E2%80%99Assoroauthor=M.+Libraauthor=F.+Nicolettiauthor=R.+Maestroauthor=J.+Baseckeauthor=D.+Rakusauthor=A.+Gizakauthor=Z.+Demidenkoauthor=L.+Coccoauthor=A.+M.+Martelliauthor=M.+Cervello&title=GSK-3+as+potential+target+for+therapeutic+intervention+in+cancer&doi=10.18632%2Foncotarget.2037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">GSK-3 as potential target for therapeutic intervention in cancer</span></div><div class="casAuthors">McCubrey James A; Steelman Linda S; Bertrand Fred E; Davis Nicole M; Sokolosky Melissa; Abrams Steve L; Montalto Giuseppe; D'Assoro Antonino B; Libra Massimo; Nicoletti Ferdinando; Maestro Roberta; Basecke Jorg; Rakus Dariusz; Gizak Agnieszka; Demidenko Zoya N; Cocco Lucio; Martelli Alberto M; Cervello Melchiorre</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2881-911</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The serine/threonine kinase glycogen synthase kinase-3 (GSK-3) was initially identified and studied in the regulation of glycogen synthesis.  GSK-3 functions in a wide range of cellular processes.  Aberrant activity of GSK-3 has been implicated in many human pathologies including: bipolar depression, Alzheimer's disease, Parkinson's disease, cancer, non-insulin-dependent diabetes mellitus (NIDDM) and others.  In some cases, suppression of GSK-3 activity by phosphorylation by Akt and other kinases has been associated with cancer progression.  In these cases, GSK-3 has tumor suppressor functions.  In other cases, GSK-3 has been associated with tumor progression by stabilizing components of the beta-catenin complex.  In these situations, GSK-3 has oncogenic properties.  While many inhibitors to GSK-3 have been developed, their use remains controversial because of the ambiguous role of GSK-3 in cancer development.  In this review, we will focus on the diverse roles that GSK-3 plays in various human cancers, in particular in solid tumors.  Recently, GSK-3 has also been implicated in the generation of cancer stem cells in various cell types.  We will also discuss how this pivotal kinase interacts with multiple signaling pathways such as: PI3K/PTEN/Akt/mTORC1, Ras/Raf/MEK/ERK, Wnt/beta-catenin, Hedgehog, Notch and others.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSSfjCBotAOrCnGiHuhFGv8fW6udTcc2ebkWWCymTl277ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfislOntA%253D%253D&md5=2e76037d7b51a604ebbf686fda4473e1</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2037%26sid%3Dliteratum%253Aachs%26aulast%3DMcCubrey%26aufirst%3DJ.%2BA.%26aulast%3DSteelman%26aufirst%3DL.%2BS.%26aulast%3DBertrand%26aufirst%3DF.%2BE.%26aulast%3DDavis%26aufirst%3DN.%2BM.%26aulast%3DSokolosky%26aufirst%3DM.%26aulast%3DAbrams%26aufirst%3DS.%2BL.%26aulast%3DMontalto%26aufirst%3DG.%26aulast%3DD%25E2%2580%2599Assoro%26aufirst%3DA.%2BB.%26aulast%3DLibra%26aufirst%3DM.%26aulast%3DNicoletti%26aufirst%3DF.%26aulast%3DMaestro%26aufirst%3DR.%26aulast%3DBasecke%26aufirst%3DJ.%26aulast%3DRakus%26aufirst%3DD.%26aulast%3DGizak%26aufirst%3DA.%26aulast%3DDemidenko%26aufirst%3DZ.%26aulast%3DCocco%26aufirst%3DL.%26aulast%3DMartelli%26aufirst%3DA.%2BM.%26aulast%3DCervello%26aufirst%3DM.%26atitle%3DGSK-3%2520as%2520potential%2520target%2520for%2520therapeutic%2520intervention%2520in%2520cancer%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D2881%26epage%3D2911%26doi%3D10.18632%2Foncotarget.2037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snider, W. D.</span></span> <span> </span><span class="NLM_article-title">Functions of GSK-3 Signaling in development of the nervous system</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">44</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2011.00044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.3389%2Ffnmol.2011.00044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=22125510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC38XovVyk" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=44&author=W.+Y.+Kimauthor=W.+D.+Snider&title=Functions+of+GSK-3+Signaling+in+development+of+the+nervous+system&doi=10.3389%2Ffnmol.2011.00044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Functions of GSK-3 signaling in development of the nervous system</span></div><div class="casAuthors">Kim, Woo-Yang; Snider, William D.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">Nov.</span>),
    <span class="NLM_cas:pages">44</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Glycogen synthase kinase-3 (GSK-3) is central to multiple intracellular pathways including those activated by Wnt/β-catenin, Sonic Hedgehog, Notch, growth factor/RTK, and G protein-coupled receptor signals.  All of these signals importantly contribute to neural development.  Early attention on GSK-3 signaling in neural development centered on the regulation of neuronal polarity using in vitro paradigms.  However, recent creation of appropriate genetic models has demonstrated the importance of GSK-3 to multiple aspects of neural development including neural progenitor self-renewal, neurogenesis, neuronal migration, neural differentiation, and synaptic development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSTo0OCsFLg7Vg90H21EOLACvtfcHk0liVTW9Tw9ptBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovVyk&md5=eb422d247103891be2e9a4a4e2ad4f9f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2011.00044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2011.00044%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DW.%2BY.%26aulast%3DSnider%26aufirst%3DW.%2BD.%26atitle%3DFunctions%2520of%2520GSK-3%2520Signaling%2520in%2520development%2520of%2520the%2520nervous%2520system%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2011%26volume%3D4%26spage%3D44%26doi%3D10.3389%2Ffnmol.2011.00044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficara, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matheny, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S. H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleary, M. L.</span></span> <span> </span><span class="NLM_article-title">GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis</span>. <i>Canc. Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">597</span>– <span class="NLM_lpage">608</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2010.04.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1016%2Fj.ccr.2010.04.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=20541704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC3cXot1Cgsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=597-608&author=Z.+Wangauthor=M.+Iwasakiauthor=F.+Ficaraauthor=C.+Linauthor=C.+Mathenyauthor=S.+H.+K.+Wongauthor=K.+S.+Smithauthor=M.+L.+Cleary&title=GSK-3+promotes+conditional+association+of+CREB+and+its+coactivators+with+MEIS1+to+facilitate+HOX-mediated+transcription+and+oncogenesis&doi=10.1016%2Fj.ccr.2010.04.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis</span></div><div class="casAuthors">Wang, Zhong; Iwasaki, Masayuki; Ficara, Francesca; Lin, Chenwei; Matheny, Christina; Wong, Stephen H. K.; Smith, Kevin S.; Cleary, Michael L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">597-608</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Acute leukemias induced by MLL chimeric oncoproteins are among the subset of cancers distinguished by a paradoxical dependence on GSK-3 kinase activity for sustained proliferation.  We demonstrate here that GSK-3 maintains the MLL leukemia stem cell transcriptional program by promoting the conditional assocn. of CREB and its coactivators TORC and CBP with homedomain protein MEIS1, a crit. component of the MLL-subordinate program, which in turn facilitates HOX-mediated transcription and transformation.  This mechanism also applies to hematopoietic cells transformed by other HOX genes, including CDX2, which is highly expressed in a majority of acute myeloid leukemias, thus providing a mol. approach based on GSK-3 inhibitory strategies to target HOX-assocd. transcription in a broad spectrum of leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZlG8S2736Z7Vg90H21EOLACvtfcHk0ljLVg4T8Nadiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXot1Cgsbg%253D&md5=6243be5ff831cb1afe592f0e8b7ff5ba</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2010.04.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2010.04.024%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DIwasaki%26aufirst%3DM.%26aulast%3DFicara%26aufirst%3DF.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DMatheny%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DS.%2BH.%2BK.%26aulast%3DSmith%26aufirst%3DK.%2BS.%26aulast%3DCleary%26aufirst%3DM.%2BL.%26atitle%3DGSK-3%2520promotes%2520conditional%2520association%2520of%2520CREB%2520and%2520its%2520coactivators%2520with%2520MEIS1%2520to%2520facilitate%2520HOX-mediated%2520transcription%2520and%2520oncogenesis%26jtitle%3DCanc.%2520Cell%26date%3D2010%26volume%3D17%26spage%3D597%26epage%3D608%26doi%3D10.1016%2Fj.ccr.2010.04.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tullai, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, G. M.</span></span> <span> </span><span class="NLM_article-title">A GSK-3-mediated transcriptional network maintains repression of immediate early genes in quiescent cells</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">3072</span>– <span class="NLM_lpage">3077</span>, <span class="refDoi"> DOI: 10.4161/cc.10.18.17321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.4161%2Fcc.10.18.17321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=21900749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A280%3ADC%252BC3Mfosl2jtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=3072-3077&author=J.+W.+Tullaiauthor=J.+R.+Grahamauthor=G.+M.+Cooper&title=A+GSK-3-mediated+transcriptional+network+maintains+repression+of+immediate+early+genes+in+quiescent+cells&doi=10.4161%2Fcc.10.18.17321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A GSK-3-mediated transcriptional network maintains repression of immediate early genes in quiescent cells</span></div><div class="casAuthors">Tullai John W; Graham Julie R; Cooper Geoffrey M</div><div class="citationInfo"><span class="NLM_cas:title">Cell cycle (Georgetown, Tex.)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3072-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Glycogen synthase kinase-3 (GSK-3) plays a central role in cell survival and proliferation, in part by the regulation of transcription.  Unlike most protein kinases, GSK-3 is active in quiescent cells in the absence of growth factor signaling.  In a recent series of studies, we employed a systems-level approach to understanding the transcription network regulated by GSK-3 in a quiescent cell model.  We identified a group of immediate early genes that were upregulated in quiescent cells solely by the inhibition of GSK-3 in the absence of growth factor stimulation.  Computational analysis of the upstream sequences of these genes identified statistically over-represented binding sites for the transcription factors CREB, NFκB and AP-1, and the roles of these factors in regulating expression of GSK-3 target genes were verified by chromatin immunoprecipitation and RNA interference.  In quiescent cells, GSK-3 inhibits CREB, NFκB and AP-1, thereby maintaining repression of their target genes and contributing to maintenance of cell cycle arrest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTkNpHR0NjEf252AMpI4GK2fW6udTcc2eYqdBN5tnPqlLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mfosl2jtQ%253D%253D&md5=b4a96b4b037463eb7eb4928e7dbf3228</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.4161%2Fcc.10.18.17321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.10.18.17321%26sid%3Dliteratum%253Aachs%26aulast%3DTullai%26aufirst%3DJ.%2BW.%26aulast%3DGraham%26aufirst%3DJ.%2BR.%26aulast%3DCooper%26aufirst%3DG.%2BM.%26atitle%3DA%2520GSK-3-mediated%2520transcriptional%2520network%2520maintains%2520repression%2520of%2520immediate%2520early%2520genes%2520in%2520quiescent%2520cells%26jtitle%3DCell%2520Cycle%26date%3D2011%26volume%3D10%26spage%3D3072%26epage%3D3077%26doi%3D10.4161%2Fcc.10.18.17321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugolkov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Zapico, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couch, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billadeau, D. D.</span></span> <span> </span><span class="NLM_article-title">Mutant K-Ras increases GSK-3beta gene expression via an ETS-p300 transcriptional complex in pancreatic cancer</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">3705</span>– <span class="NLM_lpage">3715</span>, <span class="refDoi"> DOI: 10.1038/onc.2011.90</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1038%2Fonc.2011.90" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=21441955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvVOisb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2011&pages=3705-3715&author=J.-S.+Zhangauthor=A.+Koenigauthor=A.+Harrisonauthor=A.+V.+Ugolkovauthor=M.+E.+Fernandez-Zapicoauthor=F.+J.+Couchauthor=D.+D.+Billadeau&title=Mutant+K-Ras+increases+GSK-3beta+gene+expression+via+an+ETS-p300+transcriptional+complex+in+pancreatic+cancer&doi=10.1038%2Fonc.2011.90"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Mutant K-Ras increases GSK-3β gene expression via an ETS-p300 transcriptional complex in pancreatic cancer</span></div><div class="casAuthors">Zhang, J.-S.; Koenig, A.; Harrison, A.; Ugolkov, A. V.; Fernandez-Zapico, M. E.; Couch, F. J.; Billadeau, D. D.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">3705-3715</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Glycogen synthase kinase-3 beta (GSK-3β) is overexpressed in a no. of human malignancies and has been shown to contribute to tumor cell proliferation and survival.  Although regulation of GSK-3β activity has been extensively studied, the mechanisms governing GSK-3β gene expression are still unknown.  Using pancreatic cancer as a model, we find that constitutively active Ras signaling increases GSK-3β gene expression via the canonical mitogen-activated protein kinase signaling pathway.  Anal. of the mechanism revealed that K-Ras regulates the expression of this kinase through two highly conserved E-twenty six (ETS) binding elements within the proximal region.  Furthermore, we demonstrate that mutant K-Ras enhances ETS2 loading onto the promoter, and ETS requires its transcriptional activity to increase GSK-3β gene transcription in pancreatic cancer cells.  Lastly, we show that ETS2 cooperates with p300 histone acetyltransferase to remodel chromatin and promote GSK-3β expression.  Taken together, these results provide a general mechanism for increased expression of GSK-3β in pancreatic cancer and perhaps other cancers, where Ras signaling is deregulated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZqggAKHEZRbVg90H21EOLACvtfcHk0ljLVg4T8Nadiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvVOisb0%253D&md5=54915bdecb6740689361f7f61627c044</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fonc.2011.90&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2011.90%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.-S.%26aulast%3DKoenig%26aufirst%3DA.%26aulast%3DHarrison%26aufirst%3DA.%26aulast%3DUgolkov%26aufirst%3DA.%2BV.%26aulast%3DFernandez-Zapico%26aufirst%3DM.%2BE.%26aulast%3DCouch%26aufirst%3DF.%2BJ.%26aulast%3DBilladeau%26aufirst%3DD.%2BD.%26atitle%3DMutant%2520K-Ras%2520increases%2520GSK-3beta%2520gene%2520expression%2520via%2520an%2520ETS-p300%2520transcriptional%2520complex%2520in%2520pancreatic%2520cancer%26jtitle%3DOncogene%26date%3D2011%26volume%3D30%26spage%3D3705%26epage%3D3715%26doi%3D10.1038%2Fonc.2011.90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arioka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi-Yanaga, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomooka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaguri, T.</span></span> <span> </span><span class="NLM_article-title">Anti-tumor effects of differentiation-inducing factor-1 in malignant melanoma: GSK-3-mediated inhibition of cell proliferation and GSK-3-independent suppression of cell migration and invasion</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2017.05.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1016%2Fj.bcp.2017.05.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=28501501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsl2rtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2017&pages=31-48&author=M.+Ariokaauthor=F.+Takahashi-Yanagaauthor=M.+Kuboauthor=K.+Igawaauthor=K.+Tomookaauthor=T.+Sasaguri&title=Anti-tumor+effects+of+differentiation-inducing+factor-1+in+malignant+melanoma%3A+GSK-3-mediated+inhibition+of+cell+proliferation+and+GSK-3-independent+suppression+of+cell+migration+and+invasion&doi=10.1016%2Fj.bcp.2017.05.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-tumor effects of differentiation-inducing factor-1 in malignant melanoma: GSK-3-mediated inhibition of cell proliferation and GSK-3-independent suppression of cell migration and invasion</span></div><div class="casAuthors">Arioka, Masaki; Takahashi-Yanaga, Fumi; Kubo, Momoko; Igawa, Kazunobu; Tomooka, Katsuhiko; Sasaguri, Toshiyuki</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">31-48</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Differentiation-inducing factor-1 (DIF-1) isolated from Dictyostelium discoideum strongly inhibits the proliferation of various mammalian cells through the activation of glycogen synthase kinase-3 (GSK-3).  To evaluate DIF-1 as a novel anti-cancer agent for malignant melanoma, we examd. whether DIF-1 has anti-proliferative, anti-migratory, and anti-invasive effects on melanoma cells using in vitro and in vivo systems.  DIF-1 reduced the expression levels of cyclin D1 and c-Myc by facilitating their degrdn. via GSK-3 in mouse (B16BL6) and human (A2058) malignant melanoma cells, and thereby strongly inhibited their proliferation.  DIF-1 suppressed the canonical Wnt signaling pathway by lowering the expression levels of transcription factor 7-like 2 and β-catenin, key transcription factors in this pathway.  DIF-1 also inhibited cell migration and invasion, reducing the expression of matrix metalloproteinase-2; however, this effect was not dependent on GSK-3 activity.  In a mouse lung tumor formation model, repeated oral administrations of DIF-1 markedly reduced melanoma colony formation in the lung.  These results suggest that DIF-1 inhibits cell proliferation by a GSK-3-dependent mechanism and suppresses cell migration and invasion by a GSK-3-independent mechanism.  Therefore, DIF-1 may have a potential as a novel anti-cancer agent for the treatment of malignant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCpDuiIQ-vWLVg90H21EOLACvtfcHk0ljRChO-CztfhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsl2rtbw%253D&md5=c8c56bfe0fe9b621e0ab8ce361462cdd</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2017.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2017.05.004%26sid%3Dliteratum%253Aachs%26aulast%3DArioka%26aufirst%3DM.%26aulast%3DTakahashi-Yanaga%26aufirst%3DF.%26aulast%3DKubo%26aufirst%3DM.%26aulast%3DIgawa%26aufirst%3DK.%26aulast%3DTomooka%26aufirst%3DK.%26aulast%3DSasaguri%26aufirst%3DT.%26atitle%3DAnti-tumor%2520effects%2520of%2520differentiation-inducing%2520factor-1%2520in%2520malignant%2520melanoma%253A%2520GSK-3-mediated%2520inhibition%2520of%2520cell%2520proliferation%2520and%2520GSK-3-independent%2520suppression%2520of%2520cell%2520migration%2520and%2520invasion%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2017%26volume%3D138%26spage%3D31%26epage%3D48%26doi%3D10.1016%2Fj.bcp.2017.05.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, J.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shieh, D.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.-J.</span></span> <span> </span><span class="NLM_article-title">GSK-3 inhibitors enhance TRAIL-mediated apoptosis in human gastric adenocarcinoma cells</span>. <i>PloS One</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">e0208094</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0208094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1371%2Fjournal.pone.0208094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=30557366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtlGhs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&author=Y.-Y.+Wuauthor=C.-T.+Hsiehauthor=Y.-M.+Chiuauthor=S.-C.+Chouauthor=J.-T.+Kaoauthor=D.-C.+Shiehauthor=Y.-J.+Lee&title=GSK-3+inhibitors+enhance+TRAIL-mediated+apoptosis+in+human+gastric+adenocarcinoma+cells&doi=10.1371%2Fjournal.pone.0208094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">GSK-3 inhibitors enhance TRAIL-mediated apoptosis in human gastric adenocarcinoma cells</span></div><div class="casAuthors">Wu, Yi-Ying; Hsieh, Chin-Tung; Chiu, Ying-Ming; Chou, Shen-Chieh; Kao, Jung-Ta; Shieh, Dong-Chen; Lee, Yi-Ju</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e0208094</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis has been reported in some cancer cells, including AGS human gastric adenocarcinoma cells.  Reducing this resistance might shed light on the treatment of human gastric adenocarcinoma.  In this study, we examd. whether glycogen synthase kinase-3 (GSK-3) inhibitors can restore TRAIL responsiveness in gastric adenocarcinoma cells.  The effect of two GSK-3 inhibitors, SB-415286, and LiCl, on apoptosis signaling of TRAIL in human gastric adenocarcinoma cell lines and primary gastric epithelial cells was analyzed.  Both inhibitors can sensitize gastric adenocarcinoma cells, but not primary gastric epithelial cells, to TRAIL-induced apoptosis by increasing caspase-8 activity and its downstream signal transmission.  Adding p53 siRNA can downregulate GSK-3 inhibitor-related sensitization to TRAIL-induced apoptosis and caspase-3 activity.  GSK-3 inhibitors strongly activate the phosphorylation of JNK.  Inhibition of JNK leads to earlier and more intense apoptosis, showing that the activation of JNK may provide anti-apoptotic equil. of pro-apoptotic cells.  Our observations indicate that GSK-3 inhibitors can sentize AGS gastric adenocarcinoma cells to TRAIL-induced apoptosis.  Therefore, in certain types of gastric adenocarcinoma, GSK-3 inhibitor might enhance the antitumor activity of TRAIL and mightbe a promising candidate for the treatment of certain types of gastric adenocarcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovD_QbXs_X2LVg90H21EOLACvtfcHk0ljRChO-CztfhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtlGhs7Y%253D&md5=f8f0f0720c678fd05a964752083dc44e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0208094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0208094%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.-Y.%26aulast%3DHsieh%26aufirst%3DC.-T.%26aulast%3DChiu%26aufirst%3DY.-M.%26aulast%3DChou%26aufirst%3DS.-C.%26aulast%3DKao%26aufirst%3DJ.-T.%26aulast%3DShieh%26aufirst%3DD.-C.%26aulast%3DLee%26aufirst%3DY.-J.%26atitle%3DGSK-3%2520inhibitors%2520enhance%2520TRAIL-mediated%2520apoptosis%2520in%2520human%2520gastric%2520adenocarcinoma%2520cells%26jtitle%3DPloS%2520One%26date%3D2018%26volume%3D13%26doi%3D10.1371%2Fjournal.pone.0208094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hur, E.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.-Q.</span></span> <span> </span><span class="NLM_article-title">GSK3 signaling in neural development</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">539</span>– <span class="NLM_lpage">551</span>, <span class="refDoi"> DOI: 10.1038/nrn2870</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1038%2Fnrn2870" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=20648061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptVGisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=539-551&author=E.-M.+Hurauthor=F.-Q.+Zhou&title=GSK3+signaling+in+neural+development&doi=10.1038%2Fnrn2870"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">GSK3 signaling in neural development</span></div><div class="casAuthors">Hur, Eun-Mi; Zhou, Feng-Quan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">539-551</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Recent evidence suggests that glycogen synthase kinase-3 (GSK3) proteins and their upstream and downstream regulators have key roles in many fundamental processes during neurodevelopment.  Disruption of GSK3 signaling adversely affects brain development and is assocd. with several neurodevelopmental disorders.  Here, the authors discuss the mechanisms by which GSK3 activity is regulated in the nervous system and provide an overview of the recent advances in the understanding of how GSK3 signaling controls neurogenesis, neuronal polarization, and axon growth during brain development.  These recent advances suggest that GSK3 is a crucial node that mediates various cellular processes that are controlled by multiple signaling mols., e.g., disrupted in schizophrenia 1 (DISC1), partitioning defective homolog 3 (PAR3), PAR6, and Wnt proteins, that regulate neurodevelopment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiOzmiQawg1rVg90H21EOLACvtfcHk0ljRChO-CztfhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptVGisro%253D&md5=7ad4651b8fd5a97028df1a57be2c4b38</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnrn2870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn2870%26sid%3Dliteratum%253Aachs%26aulast%3DHur%26aufirst%3DE.-M.%26aulast%3DZhou%26aufirst%3DF.-Q.%26atitle%3DGSK3%2520signaling%2520in%2520neural%2520development%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2010%26volume%3D11%26spage%3D539%26epage%3D551%26doi%3D10.1038%2Fnrn2870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Medina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avila, J.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer’s disease</span>. <i>Curr. Pharmaceut. Des.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2790</span>– <span class="NLM_lpage">2798</span>, <span class="refDoi"> DOI: 10.2174/138161210793176581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.2174%2F138161210793176581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=20698823" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=2790-2798&author=M.+Medinaauthor=J.+Avila&title=Glycogen+synthase+kinase-3+%28GSK-3%29+inhibitors+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.2174%2F138161210793176581"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2174%2F138161210793176581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161210793176581%26sid%3Dliteratum%253Aachs%26aulast%3DMedina%26aufirst%3DM.%26aulast%3DAvila%26aufirst%3DJ.%26atitle%3DGlycogen%2520synthase%2520kinase-3%2520%2528GSK-3%2529%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DCurr.%2520Pharmaceut.%2520Des.%26date%3D2010%26volume%3D16%26spage%3D2790%26epage%3D2798%26doi%3D10.2174%2F138161210793176581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo Monte, F.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibitors of GSK-3: structural insights and their application to Alzheimer’s disease models</span>. <i>Int. J. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2012</i></span>,  <span class="NLM_fpage">381029</span>, <span class="refDoi"> DOI: 10.1155/2012/381029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1155%2F2012%2F381029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=22888461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A280%3ADC%252BC38fpvVKmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2012&publication_year=2012&pages=381029&author=T.+Kramerauthor=B.+Schmidtauthor=F.+Lo+Monte&title=Small-molecule+inhibitors+of+GSK-3%3A+structural+insights+and+their+application+to+Alzheimer%E2%80%99s+disease+models&doi=10.1155%2F2012%2F381029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease Models</span></div><div class="casAuthors">Kramer Thomas; Schmidt Boris; Lo Monte Fabio</div><div class="citationInfo"><span class="NLM_cas:title">International journal of Alzheimer's disease</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2012</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">381029</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The world health organization (WHO) estimated that 18 million people are struck by Alzheimer's disease (AD).  The USA, France, Germany, and other countries launched major programmes targeting the identification of risk factors, the improvement of caretaking, and fundamental research aiming to postpone the onset of AD.  The glycogen synthase kinase 3 (GSK-3) is implicated in multiple cellular processes and has been linked to the pathogenesis of several diseases including diabetes mellitus, cancer, and AD.  Inhibition of GSK-3 leads to neuroprotective effects, decreased β-amyloid production, and a reduction in tau hyperphosphorylation, which are all associated with AD.  Various classes of small molecule GSK-3 inhibitors have been published in patents and original publications.  Herein, we present a comprehensive summary of small molecules reported to interact with GSK-3.  We illustrate the interactions of the inhibitors with the active site.  Furthermore, we refer to the biological characterisation in terms of activity and selectivity for GSK-3, elucidate in vivo studies and pre-/clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRgN9KQeV4e1yA3UY9EwTNrfW6udTcc2eZxlUWtM2hxmLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38fpvVKmug%253D%253D&md5=100844ec1c85bbf465eeecb27559066d</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1155%2F2012%2F381029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2012%252F381029%26sid%3Dliteratum%253Aachs%26aulast%3DKramer%26aufirst%3DT.%26aulast%3DSchmidt%26aufirst%3DB.%26aulast%3DLo%2BMonte%26aufirst%3DF.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520GSK-3%253A%2520structural%2520insights%2520and%2520their%2520application%2520to%2520Alzheimer%25E2%2580%2599s%2520disease%2520models%26jtitle%3DInt.%2520J.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2012%26volume%3D2012%26spage%3D381029%26doi%3D10.1155%2F2012%2F381029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Llorens-Martín, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurado, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avila, J.</span></span> <span> </span><span class="NLM_article-title">GSK-3beta, a pivotal kinase in Alzheimer disease</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">46</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2014.00046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.3389%2Ffnmol.2014.00046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=24904272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVaqs7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=46&author=M.+Llorens-Mart%C3%ADnauthor=J.+Juradoauthor=F.+Hern%C3%A1ndezauthor=J.+Avila&title=GSK-3beta%2C+a+pivotal+kinase+in+Alzheimer+disease&doi=10.3389%2Ffnmol.2014.00046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">GSK-3β, a pivotal kinase in Alzheimer disease</span></div><div class="casAuthors">Llorens-Martin, Maria; Jurado, Jeronimo; Hernandez, Felix; Avila, Jesus</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">00046</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Alzheimer disease (AD) is the most common form of age-related dementia.  The etiol. of AD is considered to be multifactorial as only a negligible percentage of cases have a familial or genetic origin.  Glycogen synthase kinase-3 (GSK-3) is regarded as a crit. mol. link between the two histopathol. hallmarks of the disease, namely senile plaques and neurofibrillary tangles.  In this review, we summarize current data regarding the involvement of this kinase in several aspects of AD development and progression, as well as key observations highlighting GSK-3 as one of the most relevant targets for AD treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-u6YWBRA8XLVg90H21EOLACvtfcHk0lh8Fw6xQqV2fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVaqs7fM&md5=7ea2969c4a89644aebb73701cf7b7d60</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2014.00046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2014.00046%26sid%3Dliteratum%253Aachs%26aulast%3DLlorens-Mart%25C3%25ADn%26aufirst%3DM.%26aulast%3DJurado%26aufirst%3DJ.%26aulast%3DHern%25C3%25A1ndez%26aufirst%3DF.%26aulast%3DAvila%26aufirst%3DJ.%26atitle%3DGSK-3beta%252C%2520a%2520pivotal%2520kinase%2520in%2520Alzheimer%2520disease%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2014%26volume%3D7%26spage%3D46%26doi%3D10.3389%2Ffnmol.2014.00046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MacAulay, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doble, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansotia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinclair, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drucker, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodgett, J. R.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism</span>. <i>Cell Metabol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2007.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1016%2Fj.cmet.2007.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=17908561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1Sjsr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=329-337&author=K.+MacAulayauthor=B.+W.+Dobleauthor=S.+Patelauthor=T.+Hansotiaauthor=E.+M.+Sinclairauthor=D.+J.+Druckerauthor=A.+Nagyauthor=J.+R.+Woodgett&title=Glycogen+synthase+kinase+3alpha-specific+regulation+of+murine+hepatic+glycogen+metabolism&doi=10.1016%2Fj.cmet.2007.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase 3α-specific regulation of murine hepatic glycogen metabolism</span></div><div class="casAuthors">MacAulay, Katrina; Doble, Bradley W.; Patel, Satish; Hansotia, Tanya; Sinclair, Elaine M.; Drucker, Daniel J.; Nagy, Andras; Woodgett, James R.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">329-337</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Glycogen synthase kinase 3 comprises two isoforms (GSK-3α and GSK-3β) that are implicated in type II diabetes, neurodegeneration, and cancer.  GSK-3 activity is elevated in human and rodent models of diabetes, and various GSK-3 inhibitors improve glucose tolerance and insulin sensitivity in rodent models of obesity and diabetes.  Here, we report the generation of mice lacking GSK-3α.  Unlike GSK-3β mutants, which die before birth, GSK-3α knockout (GSK-3α KO) animals are viable but display enhanced glucose and insulin sensitivity accompanied by reduced fat mass.  Fasted and glucose-stimulated hepatic glycogen content was enhanced in GSK-3α KO mice, whereas muscle glycogen was unaltered.  Insulin-stimulated protein kinase B (PKB/Akt) and GSK-3β phosphorylation was higher in GSK-3α KO livers compared to wild-type littermates, and IRS-1 expression was markedly increased.  We conclude that GSK-3 isoforms exhibit tissue-specific physiol. functions and that GSK-3α KO mice are insulin sensitive, reinforcing the potential of GSK-3 as a therapeutic target for type II diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAu8sNwPv527Vg90H21EOLACvtfcHk0liu08mYrRfbtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1Sjsr3F&md5=43b2a915a2e2ca90cca6954ab7f5e2f4</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2007.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2007.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DMacAulay%26aufirst%3DK.%26aulast%3DDoble%26aufirst%3DB.%2BW.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DHansotia%26aufirst%3DT.%26aulast%3DSinclair%26aufirst%3DE.%2BM.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DNagy%26aufirst%3DA.%26aulast%3DWoodgett%26aufirst%3DJ.%2BR.%26atitle%3DGlycogen%2520synthase%2520kinase%25203alpha-specific%2520regulation%2520of%2520murine%2520hepatic%2520glycogen%2520metabolism%26jtitle%3DCell%2520Metabol.%26date%3D2007%26volume%3D6%26spage%3D329%26epage%3D337%26doi%3D10.1016%2Fj.cmet.2007.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hölscher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span> <span> </span><span class="NLM_article-title">GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease</span>. <i>Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1515/rns.2011.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1515%2Frns.2011.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC2cXms1Chtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=1-11&author=C.+Gaoauthor=C.+H%C3%B6lscherauthor=Y.+Liuauthor=L.+Li&title=GSK3%3A+a+key+target+for+the+development+of+novel+treatments+for+type+2+diabetes+mellitus+and+Alzheimer+disease&doi=10.1515%2Frns.2011.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease</span></div><div class="casAuthors">Gao, Chong; Hoelscher, Christian; Liu, Yueze; Li, Lin</div><div class="citationInfo"><span class="NLM_cas:title">Reviews in the Neurosciences (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-11</span>CODEN:
                <span class="NLM_cas:coden">RNEUEO</span>;
        ISSN:<span class="NLM_cas:issn">0334-1763</span>.
    
            (<span class="NLM_cas:orgname">Walter de Gruyter GmbH</span>)
        </div><div class="casAbstract">As a constitutively active kinase, glycogen synthase kinase 3 (GSK3) is a kinase which regulates body metab. by phosphorylation of glycogen synthase (GS) and other substrates.  Considerable evidence suggests that GSK3 is involved in the common pathol. underlying Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM).  The overexpression or overactivation of GSK3 could induce a series of pathol. changes, most of which are hallmarks of AD and T2DM.  Therefore, GSK3 could be a novel target to treat these two age-dependent diseases.  The inhibition of this kinase can prevent the aggregation of β-amyloid (Aβ) and hyperphosphorylation of tau protein.  GSK3 inhibition can also be a promising strategy to ameliorate neurodegenerative developments.  Its potential assocn. with memory formation has been shown in electrophysiol. and behavioral expts.  The neuroprotective effects of novel drugs developed to treat T2DM, glucagon-like peptide 1 (GLP-1) and its long-lasting analogs, have a possible link to GSK3 modification.  Recent investigations of the interaction between the phosphatidylinositol 3 kinase (PI3K) signaling pathway and the protective effect of novel GPL-1 receptor agonist geniposide on PC12 cells support this theory.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj-xIygR59CrVg90H21EOLACvtfcHk0lhW8aXbv8zZpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXms1Chtrs%253D&md5=7cc38766de07ecbe784755569c712bd5</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1515%2Frns.2011.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252Frns.2011.061%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DC.%26aulast%3DH%25C3%25B6lscher%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%26atitle%3DGSK3%253A%2520a%2520key%2520target%2520for%2520the%2520development%2520of%2520novel%2520treatments%2520for%2520type%25202%2520diabetes%2520mellitus%2520and%2520Alzheimer%2520disease%26jtitle%3DRev.%2520Neurosci.%26date%3D2012%26volume%3D23%26spage%3D1%26epage%3D11%26doi%3D10.1515%2Frns.2011.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jope, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuskaitis, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beurel, E.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics</span>. <i>Neurochem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">595</span>, <span class="refDoi"> DOI: 10.1007/s11064-006-9128-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1007%2Fs11064-006-9128-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=16944320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtlynu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2007&pages=577-595&author=R.+S.+Jopeauthor=C.+J.+Yuskaitisauthor=E.+Beurel&title=Glycogen+synthase+kinase-3+%28GSK3%29%3A+inflammation%2C+diseases%2C+and+therapeutics&doi=10.1007%2Fs11064-006-9128-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen Synthase Kinase-3 (GSK3): Inflammation, Diseases, and Therapeutics</span></div><div class="casAuthors">Jope, Richard S.; Yuskaitis, Christopher J.; Beurel, Eleonore</div><div class="citationInfo"><span class="NLM_cas:title">Neurochemical Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4-5</span>),
    <span class="NLM_cas:pages">577-595</span>CODEN:
                <span class="NLM_cas:coden">NEREDZ</span>;
        ISSN:<span class="NLM_cas:issn">0364-3190</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Deciphering what governs inflammation and its effects on tissues is vital for understanding many pathologies.  The recent discovery that glycogen synthase kinase-3 (GSK3) promotes inflammation reveals a new component of its well-documented actions in several prevalent diseases which involve inflammation, including mood disorders, Alzheimer's disease, diabetes, and cancer.  Involvement in such disparate conditions stems from the widespread influences of GSK3 on many cellular functions, with this review focusing on its regulation of inflammatory processes.  GSK3 promotes the prodn. of inflammatory mols. and cell migration, which together make GSK3 a powerful regulator of inflammation, while GSK3 inhibition provides protection from inflammatory conditions in animal models.  The involvement of GSK3 and inflammation in these diseases are highlighted.  Thus, GSK3 may contribute not only to primary pathologies in these diseases, but also to the assocd. inflammation, suggesting that GSK3 inhibitors may have multiple effects influencing these conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_YzT_EaqXUbVg90H21EOLACvtfcHk0lhW8aXbv8zZpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtlynu7w%253D&md5=c417ca3168b0b216eb1be89beffc3cef</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1007%2Fs11064-006-9128-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11064-006-9128-5%26sid%3Dliteratum%253Aachs%26aulast%3DJope%26aufirst%3DR.%2BS.%26aulast%3DYuskaitis%26aufirst%3DC.%2BJ.%26aulast%3DBeurel%26aufirst%3DE.%26atitle%3DGlycogen%2520synthase%2520kinase-3%2520%2528GSK3%2529%253A%2520inflammation%252C%2520diseases%252C%2520and%2520therapeutics%26jtitle%3DNeurochem.%2520Res.%26date%3D2007%26volume%3D32%26spage%3D577%26epage%3D595%26doi%3D10.1007%2Fs11064-006-9128-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osolodkin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palyulin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zefirov, N.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase 3 as an anticancer drug target: novel experimental findings and trends in the design of inhibitors</span>. <i>Curr. Pharmaceut. Des.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">665</span>, <span class="refDoi"> DOI: 10.2174/13816128130407</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.2174%2F1381612811306040665" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=665&author=D.+Osolodkinauthor=V.+Palyulinauthor=N.+Zefirov&title=Glycogen+synthase+kinase+3+as+an+anticancer+drug+target%3A+novel+experimental+findings+and+trends+in+the+design+of+inhibitors&doi=10.2174%2F13816128130407"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.2174%2F1381612811306040665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612811306040665%26sid%3Dliteratum%253Aachs%26aulast%3DOsolodkin%26aufirst%3DD.%26aulast%3DPalyulin%26aufirst%3DV.%26aulast%3DZefirov%26aufirst%3DN.%26atitle%3DGlycogen%2520synthase%2520kinase%25203%2520as%2520an%2520anticancer%2520drug%2520target%253A%2520novel%2520experimental%2520findings%2520and%2520trends%2520in%2520the%2520design%2520of%2520inhibitors%26jtitle%3DCurr.%2520Pharmaceut.%2520Des.%26date%3D2012%26volume%3D19%26spage%3D665%26doi%3D10.2174%2F13816128130407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Momcilovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishbein, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graeber, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parlati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walser, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gricowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibarra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phelps, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. John, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernthal, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubinett, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadeghi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christofk, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackelford, D. B.</span></span> <span> </span><span class="NLM_article-title">The GSK3 signaling axis regulates adaptive glutamine metabolism in lung squamous cell carcinoma</span>. <i>Canc. Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">905</span>– <span class="NLM_lpage">921</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2018.04.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1016%2Fj.ccell.2018.04.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=29763624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsFCnsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2018&pages=905-921&author=M.+Momcilovicauthor=S.+T.+Baileyauthor=J.+T.+Leeauthor=M.+C.+Fishbeinauthor=D.+Braasauthor=J.+Goauthor=T.+G.+Graeberauthor=F.+Parlatiauthor=S.+Demoauthor=R.+Liauthor=T.+C.+Walserauthor=M.+Gricowskiauthor=R.+Shumanauthor=J.+Ibarraauthor=D.+Fridmanauthor=M.+E.+Phelpsauthor=K.+Badranauthor=M.+St.+Johnauthor=N.+M.+Bernthalauthor=N.+Federmanauthor=J.+Yanagawaauthor=S.+M.+Dubinettauthor=S.+Sadeghiauthor=H.+R.+Christofkauthor=D.+B.+Shackelford&title=The+GSK3+signaling+axis+regulates+adaptive+glutamine+metabolism+in+lung+squamous+cell+carcinoma&doi=10.1016%2Fj.ccell.2018.04.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma</span></div><div class="casAuthors">Momcilovic, Milica; Bailey, Sean T.; Lee, Jason T.; Fishbein, Michael C.; Braas, Daniel; Go, James; Graeber, Thomas G.; Parlati, Francesco; Demo, Susan; Li, Rui; Walser, Tonya C.; Gricowski, Michael; Shuman, Robert; Ibarra, Julio; Fridman, Deborah; Phelps, Michael E.; Badran, Karam; St. John, Maie; Bernthal, Nicholas M.; Federman, Noah; Yanagawa, Jane; Dubinett, Steven M.; Sadeghi, Saman; Christofk, Heather R.; Shackelford, David B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">905-921.e5</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Altered metab. is a hallmark of cancer growth, forming the conceptual basis for development of metabolic therapies as cancer treatments.  We performed in vivo metabolic profiling and mol. anal. of lung squamous cell carcinoma (SCC) to identify metabolic nodes for therapeutic targeting.  Lung SCCs adapt to chronic mTOR inhibition and suppression of glycolysis through the GSK3α/β signaling pathway, which upregulates glutaminolysis.  Phospho-GSK3α/β protein levels are predictive of response to single-therapy mTOR inhibition while combinatorial treatment with the glutaminase inhibitor CB-839 effectively overcomes therapy resistance.  In addn., we identified a conserved metabolic signature in a broad spectrum of hypermetabolic human tumors that may be predictive of patient outcome and response to combined metabolic therapies targeting mTOR and glutaminase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX7uLIrnPF27Vg90H21EOLACvtfcHk0ljaXKGIGNgTFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsFCnsLY%253D&md5=4539f1b8727ec7d4d34332756c1ffca7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2018.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2018.04.002%26sid%3Dliteratum%253Aachs%26aulast%3DMomcilovic%26aufirst%3DM.%26aulast%3DBailey%26aufirst%3DS.%2BT.%26aulast%3DLee%26aufirst%3DJ.%2BT.%26aulast%3DFishbein%26aufirst%3DM.%2BC.%26aulast%3DBraas%26aufirst%3DD.%26aulast%3DGo%26aufirst%3DJ.%26aulast%3DGraeber%26aufirst%3DT.%2BG.%26aulast%3DParlati%26aufirst%3DF.%26aulast%3DDemo%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DWalser%26aufirst%3DT.%2BC.%26aulast%3DGricowski%26aufirst%3DM.%26aulast%3DShuman%26aufirst%3DR.%26aulast%3DIbarra%26aufirst%3DJ.%26aulast%3DFridman%26aufirst%3DD.%26aulast%3DPhelps%26aufirst%3DM.%2BE.%26aulast%3DBadran%26aufirst%3DK.%26aulast%3DSt.%2BJohn%26aufirst%3DM.%26aulast%3DBernthal%26aufirst%3DN.%2BM.%26aulast%3DFederman%26aufirst%3DN.%26aulast%3DYanagawa%26aufirst%3DJ.%26aulast%3DDubinett%26aufirst%3DS.%2BM.%26aulast%3DSadeghi%26aufirst%3DS.%26aulast%3DChristofk%26aufirst%3DH.%2BR.%26aulast%3DShackelford%26aufirst%3DD.%2BB.%26atitle%3DThe%2520GSK3%2520signaling%2520axis%2520regulates%2520adaptive%2520glutamine%2520metabolism%2520in%2520lung%2520squamous%2520cell%2520carcinoma%26jtitle%3DCanc.%2520Cell%26date%3D2018%26volume%3D33%26spage%3D905%26epage%3D921%26doi%3D10.1016%2Fj.ccell.2018.04.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sahin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eturi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Souza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pamarthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavora, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giles, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carneiro, B. A.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses</span>. <i>Canc. Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1047</span>– <span class="NLM_lpage">1056</span>, <span class="refDoi"> DOI: 10.1080/15384047.2019.1595283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1080%2F15384047.2019.1595283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=30975030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnt1Cls74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1047-1056&author=I.+Sahinauthor=A.+Eturiauthor=A.+De+Souzaauthor=S.+Pamarthyauthor=F.+Tavoraauthor=F.+J.+Gilesauthor=B.+A.+Carneiro&title=Glycogen+synthase+kinase-3+beta+inhibitors+as+novel+cancer+treatments+and+modulators+of+antitumor+immune+responses&doi=10.1080%2F15384047.2019.1595283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses</span></div><div class="casAuthors">Sahin, Ilyas; Eturi, Aditya; De Souza, Andre; Pamarthy, Sahithi; Tavora, Fabio; Giles, Francis J.; Carneiro, Benedito A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1047-1056</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1555-8576</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  As a kinase at the crossroads of numerous metabolic and cell growth signaling pathways, glycogen synthase kinase-3 beta (GSK-3β) is a highly desirable therapeutic target in cancer.  Despite its involvement in pathways assocd. with the pathogenesis of several malignancies, no selective GSK-3β inhibitor has been approved for the treatment of cancer.  The regulatory role of GSK-3β in apoptosis, cell cycle, DNA repair, tumor growth, invasion, and metastasis reflects the therapeutic relevance of this target and provides the rationale for drug combinations.  Emerging data on GSK-3β as a mediator of anticancer immune response also highlight the potential clin. applications of novel selective GSK-3β inhibitors that are entering clin. studies.  This manuscript reviews the preclin. and early clin. results with GSK-3β inhibitors and delineates the developmental therapeutics landscape for this potentially important target in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrksdIiVuC4KLVg90H21EOLACvtfcHk0ljaXKGIGNgTFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnt1Cls74%253D&md5=e23cc7a6b913c192bcbc6afebcdc1314</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1080%2F15384047.2019.1595283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384047.2019.1595283%26sid%3Dliteratum%253Aachs%26aulast%3DSahin%26aufirst%3DI.%26aulast%3DEturi%26aufirst%3DA.%26aulast%3DDe%2BSouza%26aufirst%3DA.%26aulast%3DPamarthy%26aufirst%3DS.%26aulast%3DTavora%26aufirst%3DF.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DCarneiro%26aufirst%3DB.%2BA.%26atitle%3DGlycogen%2520synthase%2520kinase-3%2520beta%2520inhibitors%2520as%2520novel%2520cancer%2520treatments%2520and%2520modulators%2520of%2520antitumor%2520immune%2520responses%26jtitle%3DCanc.%2520Biol.%2520Ther.%26date%3D2019%26volume%3D20%26spage%3D1047%26epage%3D1056%26doi%3D10.1080%2F15384047.2019.1595283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudd, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and its therapeutic implications</span>. <i>Semin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">101295</span>, <span class="refDoi"> DOI: 10.1016/j.smim.2019.101295</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1016%2Fj.smim.2019.101295" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=31604533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFCms7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2019&pages=101295&author=J.+Kruegerauthor=C.+E.+Ruddauthor=A.+Taylor&title=Glycogen+synthase+3+%28GSK-3%29+regulation+of+PD-1+expression+and+its+therapeutic+implications&doi=10.1016%2Fj.smim.2019.101295"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications</span></div><div class="casAuthors">Krueger, Janna; Rudd, Christopher E.; Taylor, Alison</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">101295</span>CODEN:
                <span class="NLM_cas:coden">SEIME2</span>;
        ISSN:<span class="NLM_cas:issn">1044-5323</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The past few years have witnessed exciting progress in the application of immune check-point blockade (ICB) for the treatment of various human cancers.  ICB was first used against cytotoxic T-lymphocyte-assocd. protein 4 (CTLA-4) to demonstrate durable anti-tumor responses followed by ICB against programmed cell death-1 (PD-1) or its ligand, PD-L1.  Present approaches involve the use of combinations of blocking antibodies against CTLA-4, PD-1 and other inhibitory receptors (IRs) such as TIM3, TIGIT and LAG3.  Despite this success, most patients are not cured by ICB therapy and there are limitations to the use of antibodies including cost, tumor penetration, the accessibility of receptors, and clearance from the cell surface as well as inflammatory and autoimmune complications.  Recently, we demonstrated that the down-regulation or inhibition of glycogen synthase kinase 3 (GSK-3) down-regulates PD-1 expression in infectious diseases and cancer (Taylor et al., 2016 Immunity 44, 274-86; 2018 Cancer Research 78, 706-717; Krueger and Rudd 2018 Immunity 46, 529-531).  In this Review, we outline the use of small mol. inhibitors (SMIs) that target intracellular pathways for co-receptor blockade in cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMPDRi02HZSLVg90H21EOLACvtfcHk0ljaXKGIGNgTFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFCms7bI&md5=cdf8db1fc481008c5a50f00fbf2e7578</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.smim.2019.101295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.smim.2019.101295%26sid%3Dliteratum%253Aachs%26aulast%3DKrueger%26aufirst%3DJ.%26aulast%3DRudd%26aufirst%3DC.%2BE.%26aulast%3DTaylor%26aufirst%3DA.%26atitle%3DGlycogen%2520synthase%25203%2520%2528GSK-3%2529%2520regulation%2520of%2520PD-1%2520expression%2520and%2520its%2520therapeutic%2520implications%26jtitle%3DSemin.%2520Immunol.%26date%3D2019%26volume%3D42%26spage%3D101295%26doi%3D10.1016%2Fj.smim.2019.101295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudd, C. E.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase 3 inactivation compensates for the lack of CD28 in the priming of CD8(+) cytotoxic T-Cells: implications for anti-PD-1 immunotherapy</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1653</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2017.01653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.3389%2Ffimmu.2017.01653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=29312284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFOgsrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1653&author=A.+Taylorauthor=C.+E.+Rudd&title=Glycogen+synthase+kinase+3+inactivation+compensates+for+the+lack+of+CD28+in+the+priming+of+CD8%28%2B%29+cytotoxic+T-Cells%3A+implications+for+anti-PD-1+immunotherapy&doi=10.3389%2Ffimmu.2017.01653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase 3 inactivation compensates for the lack of CD28 in the priming of CD8+ cytotoxic T-cells: implications for anti-PD-1 immunotherapy</span></div><div class="casAuthors">Taylor, Alison; Rudd, Christopher E.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1653/1-1653/9</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The rescue of exhausted CD8+ cytolytic T-cells (CTLs) by anti-Programmed Cell Death-1 (anti-PD-1) blockade has been found to require CD28 expression.  At the same time, we have shown that the inactivation of the serine/threonine kinase glycogen synthase kinase (GSK)-3α/β with small-interfering RNAs (siRNAs) and small mol. inhibitors (SMIs) specifically down-regulates PD-1 expression for enhanced CD8+ CTL function and clearance of tumors and viral infections.  Despite this, it has been unclear whether the GSK-3α/β pathway accounts for CD28 costimulation of CD8+ CTL function.  In this article, we show that inactivation of GSK-3α/β through siRNA or by SMIs during priming can substitute CD28 co-stimulation in the potentiation of cytotoxic CD8+ CTL function against the EL-4 lymphoma cells expressing OVA peptide.  The effect was seen using several structurally distinct GSK-3 SMIs and was accompanied by an increase in Lamp-1 and GZMB expression.  Conversely, CD28 crosslinking obviated the need for GSK-3α/β inhibition in its enhancement of CTL function.  Our findings support a model where GSK-3 is the central cosignal for CD28 priming of CD8+ CTLs in anti-PD-1 immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL4BaOmVL5gbVg90H21EOLACvtfcHk0lhRGHXNxieIpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFOgsrrM&md5=d9f9ec8f4dd3ba2d11f170068d77f09b</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2017.01653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2017.01653%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DRudd%26aufirst%3DC.%2BE.%26atitle%3DGlycogen%2520synthase%2520kinase%25203%2520inactivation%2520compensates%2520for%2520the%2520lack%2520of%2520CD28%2520in%2520the%2520priming%2520of%2520CD8%2528%252B%2529%2520cytotoxic%2520T-Cells%253A%2520implications%2520for%2520anti-PD-1%2520immunotherapy%26jtitle%3DFront.%2520Immunol.%26date%3D2017%26volume%3D8%26spage%3D1653%26doi%3D10.3389%2Ffimmu.2017.01653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jellusova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cato, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apgar, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramezani-Rad, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conner, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benschop, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodgett, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rickert, R. C.</span></span> <span> </span><span class="NLM_article-title">GSK3 is a metabolic checkpoint regulator in B cells</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">303</span>, <span class="refDoi"> DOI: 10.1038/ni.3664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1038%2Fni.3664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=28114292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFeiur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=303&author=J.+Jellusovaauthor=M.+H.+Catoauthor=J.+R.+Apgarauthor=P.+Ramezani-Radauthor=C.+R.+Leungauthor=C.+Chenauthor=A.+D.+Richardsonauthor=E.+M.+Connerauthor=R.+J.+Benschopauthor=J.+R.+Woodgettauthor=R.+C.+Rickert&title=GSK3+is+a+metabolic+checkpoint+regulator+in+B+cells&doi=10.1038%2Fni.3664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Gsk3 is a metabolic checkpoint regulator in B cells</span></div><div class="casAuthors">Jellusova, Julia; Cato, Matthew H.; Apgar, John R.; Ramezani-Rad, Parham; Leung, Charlotte R.; Chen, Cindi; Richardson, Adam D.; Conner, Elaine M.; Benschop, Robert J.; Woodgett, James R.; Rickert, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">303-312</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">B cells predominate in a quiescent state until an antigen is encountered, which results in rapid growth, proliferation and differentiation of the B cells.  These distinct cell states are probably accompanied by differing metabolic needs, yet little is known about the metabolic control of B cell fate.  Here we show that glycogen synthase kinase 3 (Gsk3) is a metabolic sensor that promotes the survival of naive recirculating B cells by restricting cell mass accumulation.  In antigen-driven responses, Gsk3 was selectively required for regulation of B cell size, mitochondrial biogenesis, glycolysis and prodn. of reactive oxygen species (ROS), in a manner mediated by the co-stimulatory receptor CD40.  Gsk3 was required to prevent metabolic collapse and ROS-induced apoptosis after glucose became limiting, functioning in part by repressing growth dependent on the myelocytomatosis oncoprotein c-Myc.  Notably, we found that Gsk3 was required for the generation and maintenance of germinal center B cells, which require high glycolytic activity to support growth and proliferation in a hypoxic microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQVB5dTbAtxbVg90H21EOLACvtfcHk0lhRGHXNxieIpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFeiur8%253D&md5=aee3859537ff7c5f59a78cc90ea29318</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fni.3664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.3664%26sid%3Dliteratum%253Aachs%26aulast%3DJellusova%26aufirst%3DJ.%26aulast%3DCato%26aufirst%3DM.%2BH.%26aulast%3DApgar%26aufirst%3DJ.%2BR.%26aulast%3DRamezani-Rad%26aufirst%3DP.%26aulast%3DLeung%26aufirst%3DC.%2BR.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DRichardson%26aufirst%3DA.%2BD.%26aulast%3DConner%26aufirst%3DE.%2BM.%26aulast%3DBenschop%26aufirst%3DR.%2BJ.%26aulast%3DWoodgett%26aufirst%3DJ.%2BR.%26aulast%3DRickert%26aufirst%3DR.%2BC.%26atitle%3DGSK3%2520is%2520a%2520metabolic%2520checkpoint%2520regulator%2520in%2520B%2520cells%26jtitle%3DNat.%2520Immunol.%26date%3D2017%26volume%3D18%26spage%3D303%26doi%3D10.1038%2Fni.3664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakesh, K. P.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3beta inhibitors: A critical review</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">448</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.12.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1016%2Fj.ejmech.2018.12.073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=30616053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvVGgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2019&pages=448-470&author=M.+Xuauthor=S.+L.+Wangauthor=L.+Zhuauthor=P.+Y.+Wuauthor=W.+B.+Daiauthor=K.+P.+Rakesh&title=Structure-activity+relationship+%28SAR%29+studies+of+synthetic+glycogen+synthase+kinase-3beta+inhibitors%3A+A+critical+review&doi=10.1016%2Fj.ejmech.2018.12.073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3β inhibitors: A critical review</span></div><div class="casAuthors">Xu, M.; Wang, S. L.; Zhu, L.; Wu, P. Y.; Dai, W. B.; Rakesh, K. P.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">448-470</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Glycogen Synthase Kinase-3 (GSK-3) is a constitutively dynamic, omnipresent serine/threonine protein kinase regularly called as a "multi-tasking kinase" due to its pliable function in diverse signaling pathways.  It exists in two isoforms i.e., GSK-3α and GSK-3β.  Inhibition of GSK-3 may be useful in curing various diseases such as Alzheimer's disease, type II diabetes, mood disorders, cancers, chronic inflammatory agents, stroke, bipolar disorders and so on, but the approach poses significant challenges.  Lithium was the first GSK-3β inhibitor to be used for therapeutic outcome and has been effectively used for many years.  In recent years, a large no. of structurally diverse potent GSK-3β inhibitors are reported.  The present review focuses on the recent developments in the area of medicinal chem. to explore the diverse chem. structures of potent GSK-3β inhibitors and also describes its structure-activity relationships (SAR) and mol. binding interactions of favorable applicability in various diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp72bJHjANYA7Vg90H21EOLACvtfcHk0lgJBadq7yl-Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvVGgug%253D%253D&md5=3ee6633bf8aea71b4eec73979f2f39c9</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.12.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.12.073%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DS.%2BL.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DP.%2BY.%26aulast%3DDai%26aufirst%3DW.%2BB.%26aulast%3DRakesh%26aufirst%3DK.%2BP.%26atitle%3DStructure-activity%2520relationship%2520%2528SAR%2529%2520studies%2520of%2520synthetic%2520glycogen%2520synthase%2520kinase-3beta%2520inhibitors%253A%2520A%2520critical%2520review%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D164%26spage%3D448%26epage%3D470%26doi%3D10.1016%2Fj.ejmech.2018.12.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, F. J.</span></span> <span> </span><span class="NLM_article-title">First non-ATP competitive glycogen synthase kinase 3β (GSK-3β) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of alzheimer’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1292</span>– <span class="NLM_lpage">1299</span>, <span class="refDoi"> DOI: 10.1021/jm011020u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm011020u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtFCgu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=1292-1299&author=A.+Martinezauthor=M.+Alonsoauthor=A.+Castroauthor=C.+P%C3%A9rezauthor=F.+J.+Moreno&title=First+non-ATP+competitive+glycogen+synthase+kinase+3%CE%B2+%28GSK-3%CE%B2%29+inhibitors%3A+thiadiazolidinones+%28TDZD%29+as+potential+drugs+for+the+treatment+of+alzheimer%E2%80%99s+disease&doi=10.1021%2Fjm011020u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">First Non-ATP Competitive Glycogen Synthase Kinase 3β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease</span></div><div class="casAuthors">Martinez, Ana; Alonso, Mercedes; Castro, Ana; Perez, Concepcion; Moreno, Francisco J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1292-1299</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glycogen synthase kinase 3β (GSK-3β) has a central role in Alzheimer's disease (AD).  Selective inhibitors which avoid τ hyperphosphorylation may represent an effective therapeutic approach to the pharmacotherapy of AD and other neurodegenerative disorders.  The synthesis, biol. evaluation, and SAR of some thiadiazolidinones (TDZD) as the first non-ATP competitive inhibitor of GSK-3β.  Their synthesis is based on the reactivity of sulfenyl chlorides.  In GSK-3β assays, TDZD derivs. showed IC50 values in the micromolar range, whereas in other protein kinase assays they were devoid of any inhibitory activity.  SAR studies allowed the identification of the key structural features.  Finally, a possible enzymic binding mode is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofQZkRe2BHh7Vg90H21EOLACvtfcHk0ljNxU6UvRDByg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtFCgu70%253D&md5=a364133d1035bee183c58ad30ac140f8</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm011020u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm011020u%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DAlonso%26aufirst%3DM.%26aulast%3DCastro%26aufirst%3DA.%26aulast%3DP%25C3%25A9rez%26aufirst%3DC.%26aulast%3DMoreno%26aufirst%3DF.%2BJ.%26atitle%3DFirst%2520non-ATP%2520competitive%2520glycogen%2520synthase%2520kinase%25203%25CE%25B2%2520%2528GSK-3%25CE%25B2%2529%2520inhibitors%253A%2520thiadiazolidinones%2520%2528TDZD%2529%2520as%2520potential%2520drugs%2520for%2520the%2520treatment%2520of%2520alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D1292%26epage%3D1299%26doi%3D10.1021%2Fjm011020u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conde, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, F. J.</span></span> <span> </span><span class="NLM_article-title">Thienyl and phenyl α-halomethyl ketones: new inhibitors of glycogen synthase kinase (GSK-3β) from a library of compounds searching</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">4631</span>– <span class="NLM_lpage">4633</span>, <span class="refDoi"> DOI: 10.1021/jm034108b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm034108b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BD3sXntlyqtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=4631-4633&author=S.+Condeauthor=D.+I.+P%C3%A9rezauthor=A.+Mart%C3%ADnezauthor=C.+Perezauthor=F.+J.+Moreno&title=Thienyl+and+phenyl+%CE%B1-halomethyl+ketones%3A+new+inhibitors+of+glycogen+synthase+kinase+%28GSK-3%CE%B2%29+from+a+library+of+compounds+searching&doi=10.1021%2Fjm034108b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Thienyl and Phenyl α-Halomethyl Ketones: New Inhibitors of Glycogen Synthase Kinase (GSK-3β) from a Library of Compound Searching</span></div><div class="casAuthors">Conde, Santiago; Perez, Daniel I.; Martinez, Ana; Perez, Concepcion; Moreno, Francisco J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4631-4633</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glycogen synthase kinase (GSK-3β) plays a crucial role in Alzheimer's disease (AD).  Its inhibition is a valid approach to the treatment of AD.  In this initial letter, some thienyl and Ph α-halomethyl ketones are described as new non-ATP competitive inhibitors of GSK-3β.  They are considered as lead compds. for designing and synthesizing new series, to carry out SAR studies, clear up the mechanism of action, and, in general, evaluate their therapeutical usefulness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiiPuuJrm3WbVg90H21EOLACvtfcHk0ljNxU6UvRDByg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXntlyqtbc%253D&md5=0e54107efbdf7e644679ad55beba574c</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm034108b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm034108b%26sid%3Dliteratum%253Aachs%26aulast%3DConde%26aufirst%3DS.%26aulast%3DP%25C3%25A9rez%26aufirst%3DD.%2BI.%26aulast%3DMart%25C3%25ADnez%26aufirst%3DA.%26aulast%3DPerez%26aufirst%3DC.%26aulast%3DMoreno%26aufirst%3DF.%2BJ.%26atitle%3DThienyl%2520and%2520phenyl%2520%25CE%25B1-halomethyl%2520ketones%253A%2520new%2520inhibitors%2520of%2520glycogen%2520synthase%2520kinase%2520%2528GSK-3%25CE%25B2%2529%2520from%2520a%2520library%2520of%2520compounds%2520searching%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D4631%26epage%3D4633%26doi%3D10.1021%2Fjm034108b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perez, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conde, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wandosell, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelpí, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luque, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez, A.</span></span> <span> </span><span class="NLM_article-title">irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">6914</span>– <span class="NLM_lpage">6925</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2009.08.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1016%2Fj.bmc.2009.08.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=19747834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFamsbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=6914-6925&author=D.+I.+Perezauthor=S.+Condeauthor=C.+P%C3%A9rezauthor=C.+Gilauthor=D.+Simonauthor=F.+Wandosellauthor=F.+J.+Morenoauthor=J.+L.+Gelp%C3%ADauthor=F.+J.+Luqueauthor=A.+Mart%C3%ADnez&title=irreversible+glycogen+synthase+kinase+3+inhibitors+as+useful+pharmacological+tools&doi=10.1016%2Fj.bmc.2009.08.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools</span></div><div class="casAuthors">Perez, Daniel I.; Conde, Santiago; Perez, Concepcion; Gil, Carmen; Simon, Diana; Wandosell, Francisco; Moreno, Francisco J.; Gelpi, Jose L.; Luque, Francisco J.; Martinez, Ana</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6914-6925</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Thienylhalomethylketones, whose chem., biol., and pharmaceutical data are here reported, are the first irreversible inhibitors of GSK-3β described to date.  Their inhibitory activity is likely related to the cysteine residue present in the ATP-binding site, which is proposed as a relevant residue for modulation of GSK-3 activity.  The good cell permeability of the compds. allows them to be used in different cell models.  Overall, the results presented here support the potential use of halomethylketones as pharmacol. tools for the study of GSK-3β functions and suggest a new mechanism for GSK-3β inhibition that may be considered for further drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVCmgufk4pSrVg90H21EOLACvtfcHk0lhfkDFVeiKevg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFamsbvF&md5=bc84d34e0bec0bd9f0c87376ab2b4b3c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2009.08.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2009.08.042%26sid%3Dliteratum%253Aachs%26aulast%3DPerez%26aufirst%3DD.%2BI.%26aulast%3DConde%26aufirst%3DS.%26aulast%3DP%25C3%25A9rez%26aufirst%3DC.%26aulast%3DGil%26aufirst%3DC.%26aulast%3DSimon%26aufirst%3DD.%26aulast%3DWandosell%26aufirst%3DF.%26aulast%3DMoreno%26aufirst%3DF.%2BJ.%26aulast%3DGelp%25C3%25AD%26aufirst%3DJ.%2BL.%26aulast%3DLuque%26aufirst%3DF.%2BJ.%26aulast%3DMart%25C3%25ADnez%26aufirst%3DA.%26atitle%3Dirreversible%2520glycogen%2520synthase%2520kinase%25203%2520inhibitors%2520as%2520useful%2520pharmacological%2520tools%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D6914%26epage%3D6925%26doi%3D10.1016%2Fj.bmc.2009.08.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">del
Ser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinwachs, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gertz, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andres, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Carrillo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vericat, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redondo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leon, T.</span></span> <span> </span><span class="NLM_article-title">Treatment of Alzheimer’s disease with the GSK-3 inhibitor tideglusib: a pilot study</span>. <i>J. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">215</span>, <span class="refDoi"> DOI: 10.3233/JAD-2012-120805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.3233%2FJAD-2012-120805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=22936007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslGrurjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=205-215&author=T.+del%0ASerauthor=K.+C.+Steinwachsauthor=H.+J.+Gertzauthor=M.+V.+Andresauthor=B.+Gomez-Carrilloauthor=M.+Medinaauthor=J.+A.+Vericatauthor=P.+Redondoauthor=D.+Fleetauthor=T.+Leon&title=Treatment+of+Alzheimer%E2%80%99s+disease+with+the+GSK-3+inhibitor+tideglusib%3A+a+pilot+study&doi=10.3233%2FJAD-2012-120805"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of Alzheimer's Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study</span></div><div class="casAuthors">del Ser, Teodoro; Steinwachs, Klaus C.; Gertz, Hermann J.; Andres, Maria V.; Gomez-Carrillo, Belen; Medina, Miguel; Vericat, Joan A.; Redondo, Pilar; Fleet, David; Leon, Teresa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">205-215</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">This pilot, double-blind, placebo-controlled, randomized, escalating dose trial explored the safety and efficacy of tideglusib, an inhibitor of glycogen synthase kinase-3, in Alzheimer's disease (AD) patients.  Thirty mild-moderate AD patients on cholinesterase inhibitor treatment were administered escalating doses (400, 600, 800, 1,000 mg) of tideglusib or placebo (ratio 2 : 1) for 4, 4, 6, and 6 wk, resp.  The primary objective was to evaluate the safety and tolerability of tideglusib with strict criteria for drug escalation or withdrawal.  Mini-Mental Status Examn. (MMSE), Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog+), word fluency, Geriatric Depression Scale (GDS), and a final Global Clin. Assessment (GCA) were assessed as secondary objectives.  Treatment was well tolerated.  Adverse events were as frequent in active and placebo groups, except for some moderate, asymptomatic, and fully reversible increases (>2.5 × ULN) of serum transaminases in 6 active cases (p = 0.001).  Tideglusib produced pos. trends in MMSE, ADAS-cog, GDS, and GCA without statistical significance in this small sample.  Responders in MMSE were significantly higher in the active group (p = 0.05).  Patients escalated up to 1000 mg/day had a benefit of 1.68 points in the MMSE and 4.72 points in the ADAS-cog+ when compared to placebo.  This small pilot study provides valuable safety and efficacy ests. for the treatment of AD patients with tideglusib, currently being confirmed in a larger clin. trial.  Due to escalating doses and the small sample size, this trial provides insufficient evidence to support or reject a benefit of tideglusib in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrETLaPrOao1rVg90H21EOLACvtfcHk0lhfkDFVeiKevg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslGrurjE&md5=7a75de640f08ff234d4e3f50838c4967</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.3233%2FJAD-2012-120805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-2012-120805%26sid%3Dliteratum%253Aachs%26aulast%3Ddel%2BSer%26aufirst%3DT.%26aulast%3DSteinwachs%26aufirst%3DK.%2BC.%26aulast%3DGertz%26aufirst%3DH.%2BJ.%26aulast%3DAndres%26aufirst%3DM.%2BV.%26aulast%3DGomez-Carrillo%26aufirst%3DB.%26aulast%3DMedina%26aufirst%3DM.%26aulast%3DVericat%26aufirst%3DJ.%2BA.%26aulast%3DRedondo%26aufirst%3DP.%26aulast%3DFleet%26aufirst%3DD.%26aulast%3DLeon%26aufirst%3DT.%26atitle%3DTreatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%2520with%2520the%2520GSK-3%2520inhibitor%2520tideglusib%253A%2520a%2520pilot%2520study%26jtitle%3DJ.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2013%26volume%3D33%26spage%3D205%26epage%3D215%26doi%3D10.3233%2FJAD-2012-120805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tolosa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litvan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Höglinger, G. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrés, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gómez-Carrillo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">León, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Ser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Investigators, T.</span></span> <span> </span><span class="NLM_article-title">A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy</span>. <i>Mov. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">470</span>– <span class="NLM_lpage">478</span>, <span class="refDoi"> DOI: 10.1002/mds.25824</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1002%2Fmds.25824" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=24532007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvFSmtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2014&pages=470-478&author=E.+Tolosaauthor=I.+Litvanauthor=G.+U.+H%C3%B6glingerauthor=D.+Burnauthor=A.+Leesauthor=M.+V.+Andr%C3%A9sauthor=B.+G%C3%B3mez-Carrilloauthor=T.+Le%C3%B3nauthor=T.+Del+Serauthor=T.+Investigators&title=A+phase+2+trial+of+the+GSK-3+inhibitor+tideglusib+in+progressive+supranuclear+palsy&doi=10.1002%2Fmds.25824"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy</span></div><div class="casAuthors">Tolosa, Eduardo; Litvan, Irene; Hoeglinger, Guenter U.; Burn, David; Lees, Andrew; Andres, Maria V.; Gomez-Carrillo, Belen; Leon, Teresa; del Ser, Teodoro</div><div class="citationInfo"><span class="NLM_cas:title">Movement Disorders</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">470-478</span>CODEN:
                <span class="NLM_cas:coden">MOVDEA</span>;
        ISSN:<span class="NLM_cas:issn">0885-3185</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">It is believed that glycogen synthase kinase-3 (GSK-3) hyperphosphorylates tau protein in progressive supranuclear palsy (PSP).  The Tau Restoration on PSP (TAUROS) study was a double-blind, placebo-controlled, randomized trial to assess the efficacy, safety, and tolerability of tideglusib, a GSK-3 inhibitor, as potential treatment for PSP.  The study enrolled 146 PSP patients with mild-to-moderate disease who were randomized to receive once-daily 600 mg tideglusib, 800 mg tideglusib, or placebo (ratio, 2:2:1) administered orally over 52 wk.  The primary endpoint was the change from baseline to week 52 on the PSP rating scale.  Secondary endpoints were safety and tolerability of tideglusib, changes in motor function (the Timed Up and Go Test), cognition (Dementia Rating Scale-2, Frontal Assessment Battery, verbal fluency), apathy (Starkstein scale), activities of daily living (Schwab and England scale; Unified Parkinson's Disease Rating Scale, part II), quality of life (EuroQol), and Global Clin. Assessment.  Brain atrophy on magnetic resonance imaging and several biomarkers in plasma and cerebrospinal fluid also were examd.  No significant differences were detected in the primary or secondary endpoints at week 52 between placebo and either dose of tideglusib.  Tideglusib was safe, with the exception of some asymptomatic, transient, and reversible transaminase elevations (mainly alanine aminotransferase) in 9% of patients, and diarrhea in 13% of patients.  Tideglusib was generally well tolerated but it did not show clin. efficacy in patients with mild-to-moderate PSP. © 2014 International Parkinson and Movement Disorder Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgJLeCmPA9ULVg90H21EOLACvtfcHk0lhnzZm8yOy8wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvFSmtL8%253D&md5=4b7899d99427a60b8edae580355a740d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fmds.25824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.25824%26sid%3Dliteratum%253Aachs%26aulast%3DTolosa%26aufirst%3DE.%26aulast%3DLitvan%26aufirst%3DI.%26aulast%3DH%25C3%25B6glinger%26aufirst%3DG.%2BU.%26aulast%3DBurn%26aufirst%3DD.%26aulast%3DLees%26aufirst%3DA.%26aulast%3DAndr%25C3%25A9s%26aufirst%3DM.%2BV.%26aulast%3DG%25C3%25B3mez-Carrillo%26aufirst%3DB.%26aulast%3DLe%25C3%25B3n%26aufirst%3DT.%26aulast%3DDel%2BSer%26aufirst%3DT.%26aulast%3DInvestigators%26aufirst%3DT.%26atitle%3DA%2520phase%25202%2520trial%2520of%2520the%2520GSK-3%2520inhibitor%2520tideglusib%2520in%2520progressive%2520supranuclear%2520palsy%26jtitle%3DMov.%2520Disord.%26date%3D2014%26volume%3D29%26spage%3D470%26epage%3D478%26doi%3D10.1002%2Fmds.25824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovestone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hüll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinne, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huppertz, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrés, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gómez-Carrillo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">León, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">del Ser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">investigators, A.</span></span> <span> </span><span class="NLM_article-title">A phase II trial of tideglusib in Alzheimer’s disease</span>. <i>J. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.3233/jad-141959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.3233%2FJAD-141959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=25537011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjslOltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2015&pages=75-88&author=S.+Lovestoneauthor=M.+Boadaauthor=B.+Duboisauthor=M.+H%C3%BCllauthor=J.+O.+Rinneauthor=H.-J.+Huppertzauthor=M.+Caleroauthor=M.+V.+Andr%C3%A9sauthor=B.+G%C3%B3mez-Carrilloauthor=T.+Le%C3%B3nauthor=T.+del+Serauthor=A.+investigators&title=A+phase+II+trial+of+tideglusib+in+Alzheimer%E2%80%99s+disease&doi=10.3233%2Fjad-141959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase II Trial of Tideglusib in Alzheimer's Disease</span></div><div class="casAuthors">Lovestone, Simon; Boada, Merce; Dubois, Bruno; Huell, Michael; Rinne, Juha O.; Huppertz, Hans-Juergen; Calero, Miguel; Andres, Maria V.; Gomez-Carrillo, Belen; Leon, Teresa; del Ser, Teodoro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-88</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">Background: The ARGO study was a phase II, double-blind, placebo controlled, four parallel arm trial of tideglusib in Alzheimer's disease (AD).  Objective: To prove the clin. efficacy of an inhibitor of glycogen synthase kinase-3 (GSK-3), in AD.  Methods: Mild to moderate (Mini-Mental State Examn. (MMSE) score, 14-26) AD patients on cholinesterase inhibitor and/or memantine treatment were administered tideglusib or placebo for 26 wk.  The ADAS-cog15 was the primary efficacy measure; function, cognition, behavior, and quality of life were assessed as secondary measures; cerebral atrophy in MRI and the levels of tau, amyloid-β, and BACE1 in cerebrospinal fluid (CSF) were exploratory endpoints.  Results: 306 AD patients were randomized to active (1000 mg QD: n = 86, 1000 mg QOD: n = 90, and 500 mg QD: n = 50) or placebo (n = 85) in 55 sites in four European countries.  There were no statistically significant differences between either active and placebo arms in the efficacy variables.  However, BACE1 in CSF significantly decreased with treatment in a small subgroup of patients.  Participants with mild AD in the 500 mg QD group showed significant responses on ADAS-cog15, MMSE, and word fluency.  Diarrhea (14-18% in active, 11% placebo) and dose-dependent, mild to moderate, and fully reversible transaminase increase (9-16% in active, 3.5% placebo) were the most frequent adverse events.  Conclusions: Short term (26 wk) tideglusib was acceptably safe but produced no clin. benefit in this trial.  However, given the non-linear dose response, esp. in mildly affected patients, further dose finding studies in early disease stages and for longer duration are warranted to examine GSK-3 inhibition in AD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGru-ZlfznWkUbVg90H21EOLACvtfcHk0lhnzZm8yOy8wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjslOltb8%253D&md5=7a342ad28ad2cfbbc3dc768849fb73ef</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.3233%2FJAD-141959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-141959%26sid%3Dliteratum%253Aachs%26aulast%3DLovestone%26aufirst%3DS.%26aulast%3DBoada%26aufirst%3DM.%26aulast%3DDubois%26aufirst%3DB.%26aulast%3DH%25C3%25BCll%26aufirst%3DM.%26aulast%3DRinne%26aufirst%3DJ.%2BO.%26aulast%3DHuppertz%26aufirst%3DH.-J.%26aulast%3DCalero%26aufirst%3DM.%26aulast%3DAndr%25C3%25A9s%26aufirst%3DM.%2BV.%26aulast%3DG%25C3%25B3mez-Carrillo%26aufirst%3DB.%26aulast%3DLe%25C3%25B3n%26aufirst%3DT.%26aulast%3Ddel%2BSer%26aufirst%3DT.%26aulast%3Dinvestigators%26aufirst%3DA.%26atitle%3DA%2520phase%2520II%2520trial%2520of%2520tideglusib%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2015%26volume%3D45%26spage%3D75%26epage%3D88%26doi%3D10.3233%2Fjad-141959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, Y.</span></span> <span> </span><span class="NLM_article-title">An efficient one-pot procedure for the synthesis of 1,5-benzothiazepinones catalyzed by tetrabutylammonium fluoride (TBAF)</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3743</span>– <span class="NLM_lpage">3745</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2016.07.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1016%2Fj.tetlet.2016.07.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Shs73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2016&pages=3743-3745&author=P.+Zhangauthor=D.+Yeauthor=Y.+Chu&title=An+efficient+one-pot+procedure+for+the+synthesis+of+1%2C5-benzothiazepinones+catalyzed+by+tetrabutylammonium+fluoride+%28TBAF%29&doi=10.1016%2Fj.tetlet.2016.07.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">An efficient one-pot procedure for the synthesis of 1,5-benzothiazepinones catalyzed by tetrabutylammonium fluoride (TBAF)</span></div><div class="casAuthors">Zhang, Peng; Ye, Deyong; Chu, Yong</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">3743-3745</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A practical and efficient method for the prepn. of 1,5-benzothiazepinones I (R = H, Me, 2-thienyl, Ph, 4-BrC6H4, etc.) in good yields has been developed from o-aminothiophenol and the corresponding α,β-unsatd. carboxylic acids RCH:CHCO2H using tetrabutylammonium fluoride (TBAF) as a catalyst.  This study not only expands the previous work on the substrate scope but also provides more understanding of the chem. of such drug scaffolds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplZl4XgkBZWrVg90H21EOLACvtfcHk0liZ21PN6Dhk5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Shs73P&md5=c9bac27bcd201e63067f2bb366090bb0</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2016.07.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2016.07.012%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DYe%26aufirst%3DD.%26aulast%3DChu%26aufirst%3DY.%26atitle%3DAn%2520efficient%2520one-pot%2520procedure%2520for%2520the%2520synthesis%2520of%25201%252C5-benzothiazepinones%2520catalyzed%2520by%2520tetrabutylammonium%2520fluoride%2520%2528TBAF%2529%26jtitle%3DTetrahedron%2520Lett.%26date%3D2016%26volume%3D57%26spage%3D3743%26epage%3D3745%26doi%3D10.1016%2Fj.tetlet.2016.07.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molnár, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szendrei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keserü, G. M.</span></span> <span> </span><span class="NLM_article-title">A high throughput luminescent assay for glycogen synthase kinase-3beta inhibitors</span>. <i>Assay Drug Dev. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1089/adt.2006.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1089%2Fadt.2006.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=17355201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BD2sXislCktbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2007&pages=75-84&author=A.+Bakiauthor=A.+Bielikauthor=L.+Moln%C3%A1rauthor=G.+Szendreiauthor=G.+M.+Keser%C3%BC&title=A+high+throughput+luminescent+assay+for+glycogen+synthase+kinase-3beta+inhibitors&doi=10.1089%2Fadt.2006.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A High Throughput Luminescent Assay for Glycogen Synthase Kinase-3β Inhibitors</span></div><div class="casAuthors">Baki, Andrea; Bielik, Attila; Molnar, Laszlo; Szendrei, Gyoergyi; Keserue, Gyoergy M.</div><div class="citationInfo"><span class="NLM_cas:title">Assay and Drug Development Technologies</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-84</span>CODEN:
                <span class="NLM_cas:coden">ADDTAR</span>;
        ISSN:<span class="NLM_cas:issn">1540-658X</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">A high throughput luminescent assay based on the Kinase-Glo system (Promega, Madison, WI) has been developed for screening against glycogen synthase kinase-3β (GSK-3β).  Careful optimization of assay parameters allowed us to develop a robust, reproducible, and sensitive assay.  Its usefulness has been demonstrated in a high throughput screening run when screening 55,000 compds.  This campaign yielded five chem. classes of hits, including several highly potent GSK-3β inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYXSuULTtzHLVg90H21EOLACvtfcHk0liZ21PN6Dhk5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXislCktbg%253D&md5=d9e594ab3d34af353b12b53eb41e43cb</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1089%2Fadt.2006.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fadt.2006.029%26sid%3Dliteratum%253Aachs%26aulast%3DBaki%26aufirst%3DA.%26aulast%3DBielik%26aufirst%3DA.%26aulast%3DMoln%25C3%25A1r%26aufirst%3DL.%26aulast%3DSzendrei%26aufirst%3DG.%26aulast%3DKeser%25C3%25BC%26aufirst%3DG.%2BM.%26atitle%3DA%2520high%2520throughput%2520luminescent%2520assay%2520for%2520glycogen%2520synthase%2520kinase-3beta%2520inhibitors%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2007%26volume%3D5%26spage%3D75%26epage%3D84%26doi%3D10.1089%2Fadt.2006.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piloto, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somervaille, T. C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleary, M. L.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase 3 in MLL leukemia maintenance and targeted therapy</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>455</i></span>,  <span class="NLM_fpage">1205</span>– <span class="NLM_lpage">1209</span>, <span class="refDoi"> DOI: 10.1038/nature07284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1038%2Fnature07284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=18806775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlSku7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=1205-1209&author=Z.+Wangauthor=K.+S.+Smithauthor=M.+Murphyauthor=O.+Pilotoauthor=T.+C.+P.+Somervailleauthor=M.+L.+Cleary&title=Glycogen+synthase+kinase+3+in+MLL+leukemia+maintenance+and+targeted+therapy&doi=10.1038%2Fnature07284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase 3 in MLL leukemia maintenance and targeted therapy</span></div><div class="casAuthors">Wang, Zhong; Smith, Kevin S.; Murphy, Mark; Piloto, Obdulio; Somervaille, Tim C. P.; Cleary, Michael L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">7217</span>),
    <span class="NLM_cas:pages">1205-1209</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Glycogen synthase kinase 3 (GSK3) is a multifunctional serine/threonine kinase that participates in numerous signalling pathways involved in diverse physiol. processes.  Several of these pathways are implicated in disease pathogenesis, which has prompted efforts to develop GSK3-specific inhibitors for therapeutic applications.  However, before now, there has been no strong rationale for targeting GSK3 in malignancies.  Here we report pharmacol., physiol. and genetic studies that demonstrate an oncogenic requirement for GSK3 in the maintenance of a specific subtype of poor prognosis human leukemia, genetically defined by mutations of the MLL proto-oncogene.  In contrast to its previously characterized roles in suppression of neoplasia-assocd. signalling pathways, GSK3 paradoxically supports MLL leukemia cell proliferation and transformation by a mechanism that ultimately involves destabilization of the cyclin-dependent kinase inhibitor p27Kip1.  Inhibition of GSK3 in a preclin. murine model of MLL leukemia provides promising evidence of efficacy and earmarks GSK3 as a candidate cancer drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-n74Rwvs6drVg90H21EOLACvtfcHk0ljK8hb4LfRN1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlSku7bK&md5=fdda58e7cb5c987be7c0a2fe52877c67</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fnature07284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07284%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSmith%26aufirst%3DK.%2BS.%26aulast%3DMurphy%26aufirst%3DM.%26aulast%3DPiloto%26aufirst%3DO.%26aulast%3DSomervaille%26aufirst%3DT.%2BC.%2BP.%26aulast%3DCleary%26aufirst%3DM.%2BL.%26atitle%3DGlycogen%2520synthase%2520kinase%25203%2520in%2520MLL%2520leukemia%2520maintenance%2520and%2520targeted%2520therapy%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D1205%26epage%3D1209%26doi%3D10.1038%2Fnature07284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindeman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symonds, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolnikov, A.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3beta inhibition preserves hematopoietic stem cell activity and inhibits leukemic cell growth</span>. <i>Stem Cell.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1288</span>– <span class="NLM_lpage">1297</span>, <span class="refDoi"> DOI: 10.1634/stemcells.2007-0600</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1634%2Fstemcells.2007-0600" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=18323411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsFCgtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=1288-1297&author=T.+Holmesauthor=T.+A.+O%E2%80%99Brienauthor=R.+Knightauthor=R.+Lindemanauthor=S.+Shenauthor=E.+Songauthor=G.+Symondsauthor=A.+Dolnikov&title=Glycogen+synthase+kinase-3beta+inhibition+preserves+hematopoietic+stem+cell+activity+and+inhibits+leukemic+cell+growth&doi=10.1634%2Fstemcells.2007-0600"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase-3β inhibition preserves hematopoietic stem cell activity and inhibits leukemic cell growth</span></div><div class="casAuthors">Holmes, Tiffany; O'Brien, Tracey A.; Knight, Robert; Lindeman, Robert; Shen, Sylvie; Song, Emma; Symonds, Geoff; Dolnikov, Alla</div><div class="citationInfo"><span class="NLM_cas:title">Stem Cells (Durham, NC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1288-1297</span>CODEN:
                <span class="NLM_cas:coden">STCEEJ</span>;
        ISSN:<span class="NLM_cas:issn">1066-5099</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">Ex vivo expansion of cord blood cells generally results in reduced stem cell activity in vivo.  Glycogen synthase kinase-3β (GSK-3β) regulates the degrdn. of β-catenin, a crit. regulator of hematopoietic stem cells (HSCs).  Here we show that GSK-3β inhibition activates β-catenin in cord blood CD34+ cells and upregulates β-catenin transcriptional targets c-myc and HoxB4, both known to regulate HSC self-renewal.  GSK-3β inhibition resulted in delayed ex vivo expansion of CD34+ cells, yet enhanced the preservation of stem cell activity as tested in long-term culture with bone marrow stroma.  Delayed cell cycling, reduced apoptosis, and increased adherence of hematopoietic progenitor cells to bone marrow stroma were obsd. in these long-term cultures treated with GSK-3β inhibitor.  This improved adherence to stroma was mediated via upregulation of CXCR4.  In addn., GSK-3β inhibition preserved severe combined immunodeficiency (SCID) repopulating cells as tested in the nonobese diabetic/SCID mouse model.  Our data suggest the involvement of GSK-3β inhibition in the preservation of HSC and their interaction with the bone marrow environment.  Methods for the inhibition of GSK-3β may be developed for clin. ex vivo expansion of HSC for transplantation.  In addn., GSK-3β inhibition suppressed leukemic cell growth via the induction of apoptosis mediated by the down-regulation of survivin.  Modulators of GSK-3β may increase the range of novel drugs that specifically kill leukemic cells while sparing normal stem cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhyjEN8EYUhLVg90H21EOLACvtfcHk0ljK8hb4LfRN1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsFCgtLk%253D&md5=1835e5518b6580e843b55cdafd494602</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1634%2Fstemcells.2007-0600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Fstemcells.2007-0600%26sid%3Dliteratum%253Aachs%26aulast%3DHolmes%26aufirst%3DT.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DT.%2BA.%26aulast%3DKnight%26aufirst%3DR.%26aulast%3DLindeman%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DE.%26aulast%3DSymonds%26aufirst%3DG.%26aulast%3DDolnikov%26aufirst%3DA.%26atitle%3DGlycogen%2520synthase%2520kinase-3beta%2520inhibition%2520preserves%2520hematopoietic%2520stem%2520cell%2520activity%2520and%2520inhibits%2520leukemic%2520cell%2520growth%26jtitle%3DStem%2520Cell.%26date%3D2008%26volume%3D26%26spage%3D1288%26epage%3D1297%26doi%3D10.1634%2Fstemcells.2007-0600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kretzschmar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roolf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langhammer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekora, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pews-Davtyan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frech, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenloffel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junghanss, C.</span></span> <span> </span><span class="NLM_article-title">The novel arylindolylmaleimide PDA-66 displays pronounced antiproliferative effects in acute lymphoblastic leukemia cells</span>. <i>BMC Canc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">71</span>, <span class="refDoi"> DOI: 10.1186/1471-2407-14-71</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1186%2F1471-2407-14-71" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=24502201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVymtLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=71&author=C.+Kretzschmarauthor=C.+Roolfauthor=T.+S.+Langhammerauthor=A.+Sekoraauthor=A.+Pews-Davtyanauthor=M.+Bellerauthor=M.+J.+Frechauthor=C.+Eisenloffelauthor=A.+Rolfsauthor=C.+Junghanss&title=The+novel+arylindolylmaleimide+PDA-66+displays+pronounced+antiproliferative+effects+in+acute+lymphoblastic+leukemia+cells&doi=10.1186%2F1471-2407-14-71"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The novel arylindolylmaleimide PDA-66 displays pronounced antiproliferative effects in acute lymphoblastic leukemia cells</span></div><div class="casAuthors">Kretzschmar, Christin; Roolf, Catrin; Langhammer, Tina-Susann; Sekora, Anett; Pews-Davtyan, Anahit; Beller, Matthias; Frech, Moritz J.; Eisenloeffel, Christian; Rolfs, Arndt; Junghanss, Christian</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">71/1-71/9</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Prognosis of adult patients suffering from acute lymphoblastic leukemia (ALL) is still unsatisfactory.  Targeted therapy via inhibition of deregulated signaling pathways appears to be a promising therapeutic option for the treatment of ALL.  Herein, we evaluated the influence of a novel arylindolylmaleimide (PDA-66), a potential GSK3β inhibitor, on several ALL cell lines.  Methods: ALL cell lines (SEM, RS4;11, Jurkat and MOLT4) were exposed to different concns. of PDA-66.  Subsequently, proliferation, metabolic activity, apoptosis and necrosis, cell cycle distribution and protein expression of Wnt and PI3K/Akt signaling pathways were analyzed at different time points.  Results: PDA-66 inhibited the proliferation of ALL cells significantly by redn. of metabolic activity.  The 72 h IC50 values ranged between 0.41 to 1.28 μM PDA-66.  Addnl., caspase activated induction of apoptosis could be detected in the analyzed cell lines.  PDA-66 influenced the cell cycle distribution of ALL cell lines differently.  While RS4;11 and MOLT4 cells were found to be arrested in G2 phase, SEM cells showed an increased cell cycle in G0/1 phase.  Conclusion: PDA-66 displays significant antileukemic activity in ALL cells and classifies as candidate for further evaluation as a potential drug in targeted therapy of ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYuSa5oVmUyLVg90H21EOLACvtfcHk0lihpxHLIsbKYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVymtLzE&md5=baf0f5cb99b4b2e8a58e3bb3851f4015</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-14-71&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-14-71%26sid%3Dliteratum%253Aachs%26aulast%3DKretzschmar%26aufirst%3DC.%26aulast%3DRoolf%26aufirst%3DC.%26aulast%3DLanghammer%26aufirst%3DT.%2BS.%26aulast%3DSekora%26aufirst%3DA.%26aulast%3DPews-Davtyan%26aufirst%3DA.%26aulast%3DBeller%26aufirst%3DM.%26aulast%3DFrech%26aufirst%3DM.%2BJ.%26aulast%3DEisenloffel%26aufirst%3DC.%26aulast%3DRolfs%26aufirst%3DA.%26aulast%3DJunghanss%26aufirst%3DC.%26atitle%3DThe%2520novel%2520arylindolylmaleimide%2520PDA-66%2520displays%2520pronounced%2520antiproliferative%2520effects%2520in%2520acute%2520lymphoblastic%2520leukemia%2520cells%26jtitle%3DBMC%2520Canc.%26date%3D2014%26volume%3D14%26spage%3D71%26doi%3D10.1186%2F1471-2407-14-71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span> <span> </span><span class="NLM_article-title">Lithium exacerbates hepatic ischemia/reperfusion injury by inhibiting GSK-3beta/NF-kappaB-mediated protective signaling in mice</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>697</i></span>,  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2012.09.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1016%2Fj.ejphar.2012.09.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=23051669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFymurbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=697&publication_year=2012&pages=117-125&author=Y.+Xiaauthor=J.+Raoauthor=A.+Yaoauthor=F.+Zhangauthor=G.+Liauthor=X.+Wangauthor=L.+Lu&title=Lithium+exacerbates+hepatic+ischemia%2Freperfusion+injury+by+inhibiting+GSK-3beta%2FNF-kappaB-mediated+protective+signaling+in+mice&doi=10.1016%2Fj.ejphar.2012.09.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Lithium exacerbates hepatic ischemia/reperfusion injury by inhibiting GSK-3β/NF-κB-mediated protective signaling in mice</span></div><div class="casAuthors">Xia, Yongxiang; Rao, Jianhua; Yao, Aihua; Zhang, Feng; Li, Guoqiang; Wang, Xuehao; Lu, Ling</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">697</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">117-125</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Lithium (an inhibitor of GSK-3β activity) has beneficial effects on ischemia/reperfusion (I/R) injury in the central nervous system, heart and kidney.  However, the role of lithium in hepatic I/R injury is unknown.  The aim of this study was to assess the effects of lithium on hepatic I/R injury in a mouse model of partial hepatic I/R.  Previous studies showed that lithium chloride (LiCl) can phosphorylate residue Ser9, inhibit GSK-3β activity, and improve I/R injury in other organs.  In the present study, mice were pretreated with either vehicle or LiCl, which had similar effects on GSK-3β activity.  Surprisingly, treatment with LiCl significantly exacerbated hepatic I/R injury, which was detd. by serol. and histol. analyses.  Acute and chronic LiCl treatment caused serious damage in hepatic I/R injury, including increased apoptosis and oxidative stress.  To gain insight into the mechanism involved in this damage, the activity of nuclear factor-κB (NF-κB) (GSK-3β can regulate the transcriptional complex of NF-κB) was analyzed, which revealed that LiCl treatment significantly down-regulated the activity of NF-κB.  The NF-κB-mediated protective genes were then further evaluated, including anti-apoptotic genes (RAF2, cIAP 2, Bfl-1 and cFLIP) and the antioxidant gene MnSOD.  The expression of these protective genes was obviously suppressed compared with the vehicle group.  Taken together, these findings show that lithium exacerbates hepatic I/R injury by suppressing the expression of GSK-3β/NF-κB-mediated protective genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_V3ZvjCOo4LVg90H21EOLACvtfcHk0lihpxHLIsbKYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFymurbM&md5=e9b581fbe71e3ea7da2ad8900adafc33</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2012.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2012.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DY.%26aulast%3DRao%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DL.%26atitle%3DLithium%2520exacerbates%2520hepatic%2520ischemia%252Freperfusion%2520injury%2520by%2520inhibiting%2520GSK-3beta%252FNF-kappaB-mediated%2520protective%2520signaling%2520in%2520mice%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D697%26spage%3D117%26epage%3D125%26doi%3D10.1016%2Fj.ejphar.2012.09.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, H.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, D.-M.</span></span> <span> </span><span class="NLM_article-title">Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model</span>. <i>Neuroscience</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">572</span>, <span class="refDoi"> DOI: 10.1016/j.neuroscience.2008.06.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1016%2Fj.neuroscience.2008.06.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=18640245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVSgtbjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2008&pages=567-572&author=H.-L.+Fengauthor=Y.+Lengauthor=C.-H.+Maauthor=J.+Zhangauthor=M.+Renauthor=D.-M.+Chuang&title=Combined+lithium+and+valproate+treatment+delays+disease+onset%2C+reduces+neurological+deficits+and+prolongs+survival+in+an+amyotrophic+lateral+sclerosis+mouse+model&doi=10.1016%2Fj.neuroscience.2008.06.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model</span></div><div class="casAuthors">Feng, H.-L.; Leng, Y.; Ma, C.-H.; Zhang, J.; Ren, M.; Chuang, D.-M.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">567-572</span>CODEN:
                <span class="NLM_cas:coden">NRSCDN</span>;
        ISSN:<span class="NLM_cas:issn">0306-4522</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Lithium and valproic acid (VPA) are two primary drugs used to treat bipolar disorder, and have been shown to have neuroprotective properties in vivo and in vitro.  A recent study demonstrated that combined treatment with lithium and VPA elicits synergistic neuroprotective effects against glutamate excitotoxicity in cultured brain neurons, and the synergy involves potentiated inhibition of glycogen synthase kinase-3 (GSK-3) activity through enhanced GSK-3 serine phosphorylation.  We therefore investigated the effects of lithium and VPA cotreatment on the disease symptom onset, survival time and neurol. deficits in cooper zinc superoxide dismutase (SOD1) G93A mutant mice, a commonly used mouse model of amyotrophic lateral sclerosis (ALS).  The G93A ALS mice received twice daily i.p. injections with LiCl (60 mg/kg), VPA (300 mg/kg) or lithium plus VPA, starting from the 30th day after birth and continuing until death.  We found that combined treatment with lithium and VPA produced a greater and more consistent effect in delaying the onset of disease symptoms, prolonging the lifespan and decreasing the neurol. deficit scores, compared with the results of monotreatment with lithium or VPA.  Moreover, lithium in conjunction with VPA was more effective than lithium or VPA alone in enhancing the immunostaining of phospho-GSK-3βSer9 in brain and lumbar spinal cord sections.  To our knowledge, this is the first demonstration of enhanced neuroprotection by a combinatorial approach using mood stabilizers in a mouse ALS model.  Our results suggest that clin. trials using lithium and VPA in combination for ALS patients are a rational strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEQ05OC3y2rrVg90H21EOLACvtfcHk0ljAvTzxvmz4iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVSgtbjL&md5=d2c2256442657088e199a5b2094f9bd7</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroscience.2008.06.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroscience.2008.06.040%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DH.-L.%26aulast%3DLeng%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DC.-H.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DM.%26aulast%3DChuang%26aufirst%3DD.-M.%26atitle%3DCombined%2520lithium%2520and%2520valproate%2520treatment%2520delays%2520disease%2520onset%252C%2520reduces%2520neurological%2520deficits%2520and%2520prolongs%2520survival%2520in%2520an%2520amyotrophic%2520lateral%2520sclerosis%2520mouse%2520model%26jtitle%3DNeuroscience%26date%3D2008%26volume%3D155%26spage%3D567%26epage%3D572%26doi%3D10.1016%2Fj.neuroscience.2008.06.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span> <span> </span><span class="NLM_article-title">In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) in the treatment of acute promyelocytic leukemia: As<sub>2</sub>O<sub>3</sub> induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">1052</span>– <span class="NLM_lpage">1061</span>, <span class="refDoi"> DOI: 10.1182/blood.v88.3.1052.bloodjournal8831052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1182%2Fblood.V88.3.1052.1052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=8704214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADyaK28Xks1Cjur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1996&pages=1052-1061&author=G.+Chenauthor=J.+Zhuauthor=X.+Shiauthor=J.+Niauthor=H.+Zhongauthor=G.+Siauthor=X.+Jinauthor=W.+Tangauthor=X.+Liauthor=S.+Xongauthor=Z.+Shenauthor=G.+Sunauthor=J.+Maauthor=P.+Zhangauthor=T.+Zhangauthor=C.+Gazinauthor=T.+Naoeauthor=S.+Chenauthor=Z.+Wangauthor=Z.+Chen&title=In+vitro+studies+on+cellular+and+molecular+mechanisms+of+arsenic+trioxide+%28As2O3%29+in+the+treatment+of+acute+promyelocytic+leukemia%3A+As2O3+induces+NB4+cell+apoptosis+with+downregulation+of+Bcl-2+expression+and+modulation+of+PML-RAR+alpha%2FPML+proteins&doi=10.1182%2Fblood.v88.3.1052.bloodjournal8831052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins</span></div><div class="casAuthors">Chen, Guo-Qiang; Zhu, Jun; Shi, Xue-Geng; Ni, Jian-Hua; Zhong, Hao-Jie; Si, Gui-Ying; Jin, Xiao-Long; Tang, Wei; Li, Xiu-Shong; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1052-1061</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">Saunders</span>)
        </div><div class="casAbstract">It has been shown recently in China that arsenic trioxide (As2O3) is a very effective treatment for acute promyelocytic leukemia (APL).  APL patients resistant to all-trans retinoic acid (ATRA) and conventional chemotherapy can still respond to As2O3.  In this study, we addressed the possible cellular and mol. mechanisms of this treatment by using NB4 cells as a model.  The results show that: (1) As2O3 triggers relatively specific NB4 cell apoptosis at micromolar concn., as proved by morphol., histogramic related nuclear DNA contents, and DNA gel electrophoresis. (2) As2O3 does not influence bax, bcl-x, c-myc, and p53 gene expression, but downregulates bcl-2 gene expression at both mRNA and protein levels.  (3)As2O3 induces a significant modulation of the PML staining pattern in NB4 cells and HL-60 cells.  The micropunctates characteristic of PML-RARα in NB4 cells disappear after treatment with As2O3, whereas a diffuse PML staining occurs in the perinuclear cytoplasmic region.  In addn., a low percentage of untreated NB4 cells exhibits an accumulation of PML> pos. particles in a compartment of cytoplasm.  The percentage of these cells can be significantly increased after As2O3 treatment.  A similar PML staining pattern is obsd. in apoptotic cells.  (4) ATRA pretreatment does not influence As2O3-induced apoptosis.  These results suggest that induction of cell apoptosis can be one of the mechanisms of the therapeutic effect of As2O3.  Moreover, this apoptosis induction occurs independently of the retinoid pathway and may be mediated, at least partly, through the modulation of bcl-2, as well as PML-RARα and/or PML proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5d7RDGm_BkrVg90H21EOLACvtfcHk0ljAvTzxvmz4iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xks1Cjur0%253D&md5=402dd3dea5e64ebd998c559f3d2dd747</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1182%2Fblood.V88.3.1052.1052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V88.3.1052.1052%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DNi%26aufirst%3DJ.%26aulast%3DZhong%26aufirst%3DH.%26aulast%3DSi%26aufirst%3DG.%26aulast%3DJin%26aufirst%3DX.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXong%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DG.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DGazin%26aufirst%3DC.%26aulast%3DNaoe%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DZ.%26atitle%3DIn%2520vitro%2520studies%2520on%2520cellular%2520and%2520molecular%2520mechanisms%2520of%2520arsenic%2520trioxide%2520%2528As2O3%2529%2520in%2520the%2520treatment%2520of%2520acute%2520promyelocytic%2520leukemia%253A%2520As2O3%2520induces%2520NB4%2520cell%2520apoptosis%2520with%2520downregulation%2520of%2520Bcl-2%2520expression%2520and%2520modulation%2520of%2520PML-RAR%2520alpha%252FPML%2520proteins%26jtitle%3DBlood%26date%3D1996%26volume%3D88%26spage%3D1052%26epage%3D1061%26doi%3D10.1182%2Fblood.v88.3.1052.bloodjournal8831052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flexor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, P.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waxman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanotte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J.-H.</span></span> <span> </span><span class="NLM_article-title">Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">1014</span>– <span class="NLM_lpage">1022</span>, <span class="refDoi"> DOI: 10.1182/blood.v99.3.1014.h80302001014_1014_1022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1182%2Fblood.V99.3.1014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=11807007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtValtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=1014-1022&author=Q.+Zhuauthor=J.-W.+Zhangauthor=H.-Q.+Zhuauthor=Y.-L.+Shenauthor=M.+Flexorauthor=P.-M.+Jiaauthor=Y.+Yuauthor=X.+Caiauthor=S.+Waxmanauthor=M.+Lanotteauthor=S.-J.+Chenauthor=Z.+Chenauthor=J.-H.+Tong&title=Synergic+effects+of+arsenic+trioxide+and+cAMP+during+acute+promyelocytic+leukemia+cell+maturation+subtends+a+novel+signaling+cross-talk&doi=10.1182%2Fblood.v99.3.1014.h80302001014_1014_1022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk</span></div><div class="casAuthors">Zhu, Qi; Zhang, Ji-Wang; Zhu, Hai-Qing; Shen, Yu-Lei; Flexor, Maria; Jia, Pei-Ming; Yu, Yun; Cai, Xun; Waxman, Samuel; Lanotte, Michel; Chen, Sai-Juan; Chen, Zhu; Tong, Jian-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1014-1022</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Acute promyelocytic leukemia (APL) is characterized by the specific chromosome translocation t(15;17) with promyelocytic leukemia-retinoic acid receptor-α (PML-RARA) fusion gene and the ability to undergo terminal differentiation as an effect of all-trans retinoic acid (ATRA).  Recently, arsenic trioxide (As2O3) was identified as an alternative therapy in patients with both ATRA-sensitive and ATRA-resistant APL.  At the cellular level, As2O3 triggers apoptosis and a partial differentiation of APL cells in a dose-dependent manner; both effects are obsd. in vivo among patients with APL and APL animal models.  To further explore the mechanism of As2O3-induced differentiation, the combined effects of arsenic and a no. of other differentiation inducers on APL cell lines (NB4 and NB4-R1) and some fresh APL cells were examd.  The data show that a strong synergy exists between a low concn. of As2O3 (0.25 μM) and the cyclic adenosine monophosphate (cAMP) analog, 8-CPT-cAMP, in fully inducing differentiation of NB4, NB4-R1, and fresh APL cells.  Furthermore, cAMP facilitated the degrdn. of As2O3-mediated fusion protein PML-RARα, a process considered to play a key role in overcoming the differentiation arrest of APL cells.  On the other hand, cAMP could significantly inhibit cell growth by modulating several major players in G1/S transition regulation.  Interestingly, H89, an antagonist of protein kinase A, could block the differentiation-inducing effect of As2O3 potentiated by cAMP.  These results thus support the existence of a novel signaling cross-talk for APL maturation, which may deepen understanding of As2O3-induced differentiation in vivo, and thus furnish insights for new therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdhZXNWJYYTbVg90H21EOLACvtfcHk0liey82fhWFOHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtValtrc%253D&md5=18d70d5b0166d768ddba9b5581775741</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1182%2Fblood.V99.3.1014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V99.3.1014%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DJ.-W.%26aulast%3DZhu%26aufirst%3DH.-Q.%26aulast%3DShen%26aufirst%3DY.-L.%26aulast%3DFlexor%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DP.-M.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DWaxman%26aufirst%3DS.%26aulast%3DLanotte%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DS.-J.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DTong%26aufirst%3DJ.-H.%26atitle%3DSynergic%2520effects%2520of%2520arsenic%2520trioxide%2520and%2520cAMP%2520during%2520acute%2520promyelocytic%2520leukemia%2520cell%2520maturation%2520subtends%2520a%2520novel%2520signaling%2520cross-talk%26jtitle%3DBlood%26date%3D2002%26volume%3D99%26spage%3D1014%26epage%3D1022%26doi%3D10.1182%2Fblood.v99.3.1014.h80302001014_1014_1022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benajiba, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiwer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacher, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gale, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puissant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Back, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pikman, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galinsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeAngelo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robers, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machleidt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermine, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakshminarasimhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemann, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scolnick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegmaier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holson, E. B.</span></span> <span> </span><span class="NLM_article-title">Exploiting an Asp-Glu “switch” in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">eaam8460</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.aam8460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1126%2Fscitranslmed.aam8460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=29515000" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&author=F.+F.+Wagnerauthor=L.+Benajibaauthor=A.+J.+Campbellauthor=M.+Weiwerauthor=J.+R.+Sacherauthor=J.+P.+Galeauthor=L.+Rossauthor=A.+Puissantauthor=G.+Alexeauthor=A.+Conwayauthor=M.+Backauthor=Y.+Pikmanauthor=I.+Galinskyauthor=D.+J.+DeAngeloauthor=R.+M.+Stoneauthor=T.+Kayaauthor=X.+Shiauthor=M.+B.+Robersauthor=T.+Machleidtauthor=J.+Wilkinsonauthor=O.+Hermineauthor=A.+Kungauthor=A.+J.+Steinauthor=D.+Lakshminarasimhanauthor=M.+T.+Hemannauthor=E.+Scolnickauthor=Y.+L.+Zhangauthor=J.+Q.+Panauthor=K.+Stegmaierauthor=E.+B.+Holson&title=Exploiting+an+Asp-Glu+%E2%80%9Cswitch%E2%80%9D+in+glycogen+synthase+kinase+3+to+design+paralog-selective+inhibitors+for+use+in+acute+myeloid+leukemia&doi=10.1126%2Fscitranslmed.aam8460"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aam8460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aam8460%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DF.%2BF.%26aulast%3DBenajiba%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DA.%2BJ.%26aulast%3DWeiwer%26aufirst%3DM.%26aulast%3DSacher%26aufirst%3DJ.%2BR.%26aulast%3DGale%26aufirst%3DJ.%2BP.%26aulast%3DRoss%26aufirst%3DL.%26aulast%3DPuissant%26aufirst%3DA.%26aulast%3DAlexe%26aufirst%3DG.%26aulast%3DConway%26aufirst%3DA.%26aulast%3DBack%26aufirst%3DM.%26aulast%3DPikman%26aufirst%3DY.%26aulast%3DGalinsky%26aufirst%3DI.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DKaya%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DRobers%26aufirst%3DM.%2BB.%26aulast%3DMachleidt%26aufirst%3DT.%26aulast%3DWilkinson%26aufirst%3DJ.%26aulast%3DHermine%26aufirst%3DO.%26aulast%3DKung%26aufirst%3DA.%26aulast%3DStein%26aufirst%3DA.%2BJ.%26aulast%3DLakshminarasimhan%26aufirst%3DD.%26aulast%3DHemann%26aufirst%3DM.%2BT.%26aulast%3DScolnick%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DY.%2BL.%26aulast%3DPan%26aufirst%3DJ.%2BQ.%26aulast%3DStegmaier%26aufirst%3DK.%26aulast%3DHolson%26aufirst%3DE.%2BB.%26atitle%3DExploiting%2520an%2520Asp-Glu%2520%25E2%2580%259Cswitch%25E2%2580%259D%2520in%2520glycogen%2520synthase%2520kinase%25203%2520to%2520design%2520paralog-selective%2520inhibitors%2520for%2520use%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2018%26volume%3D10%26doi%3D10.1126%2Fscitranslmed.aam8460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span> <span> </span><span class="NLM_article-title">Assessing lysine and cysteine reactivities for designing targeted covalent kinase inhibitors</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">6553</span>– <span class="NLM_lpage">6560</span>, <span class="refDoi"> DOI: 10.1021/jacs.8b13248</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.8b13248" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmslSgur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2019&pages=6553-6560&author=R.+Liuauthor=Z.+Yueauthor=C.-C.+Tsaiauthor=J.+Shen&title=Assessing+lysine+and+cysteine+reactivities+for+designing+targeted+covalent+kinase+inhibitors&doi=10.1021%2Fjacs.8b13248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Assessing Lysine and Cysteine Reactivities for Designing Targeted Covalent Kinase Inhibitors</span></div><div class="casAuthors">Liu, Ruibin; Yue, Zhi; Tsai, Cheng-Chieh; Shen, Jana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6553-6560</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Targeted covalent inhibitor design is gaining increasing interest and acceptance.  A typical covalent kinase inhibitor design targets a reactive cysteine; however, this strategy is limited by the low abundance of cysteine and acquired drug resistance from point mutations.  Inspired by the recent development of lysine-targeted chem. probes, we asked if nucleophilic (reactive) catalytic lysines are common on the basis of the published crystal structures of the human kinome.  Using a newly developed pKa prediction tool based on continuous const. pH mol. dynamics, the catalytic lysines of eight unique kinases from various human kinase groups were retrospectively and prospectively predicted to be nucleophilic, when kinase is in the rare DFG-out/αC-out type of conformation.  Importantly, other reactive lysines as well as cysteines at various locations were also identified.  On the basis of the findings, we proposed a new strategy in which selective type II reversible kinase inhibitors are modified to design highly selective, lysine-targeted covalent inhibitors.  Traditional covalent drugs were discovered serendipitously; the presented tool, which can assess the reactivities of any potentially targetable residues, may accelerate the rational discovery of new covalent inhibitors.  Another significant finding of the work is that lysines and cysteines in kinases may adopt neutral and charged states at physiol. pH, resp.  This finding may shift the current paradigm of computational studies of kinases, which assume fixed soln. protonation states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXUZJq48FZTLVg90H21EOLACvtfcHk0ljbN2dvmAsOzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmslSgur8%253D&md5=aab2762e5cbcedae163c38445f48bdd7</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjacs.8b13248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.8b13248%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DYue%26aufirst%3DZ.%26aulast%3DTsai%26aufirst%3DC.-C.%26aulast%3DShen%26aufirst%3DJ.%26atitle%3DAssessing%2520lysine%2520and%2520cysteine%2520reactivities%2520for%2520designing%2520targeted%2520covalent%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2019%26volume%3D141%26spage%3D6553%26epage%3D6560%26doi%3D10.1021%2Fjacs.8b13248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2127</span>– <span class="NLM_lpage">2142</span>, <span class="refDoi"> DOI: 10.1021/jm101340q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101340q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjt1yrtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2127-2142&author=Y.+Wangauthor=J.+Aiauthor=Y.+Wangauthor=Y.+Chenauthor=L.+Wangauthor=G.+Liuauthor=M.+Gengauthor=A.+Zhang&title=Synthesis+and+c-Met+kinase+inhibition+of+3%2C5-disubstituted+and+3%2C5%2C7-trisubstituted+quinolines%3A+identification+of+3-%284-acetylpiperazin-1-yl%29-5-%283-nitrobenzylamino%29-7-+%28trifluoromethyl%29quinoline+as+a+novel+anticancer+agent&doi=10.1021%2Fjm101340q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and c-Met Kinase Inhibition of 3,5-Disubstituted and 3,5,7-Trisubstituted Quinolines: Identification of 3-(4-Acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a Novel Anticancer Agent</span></div><div class="casAuthors">Wang, Yuanxiang; Ai, Jing; Wang, Ying; Chen, Yi; Wang, Lu; Liu, Gang; Geng, Meiyu; Zhang, Ao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2127-2142</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By use of an improved synthetic strategy, a series of 3,5-disubstituted and 3,5,7-trisubstituted quinolines were readily prepd.  3,5,7-Trisubstituted quinolines I (X = NMe, NCOMe, NEt, O, NSO2-cPr, NSO2Me, NCH2CO2Et) were identified as the most potent c-Met inhibitors with IC50 of less than 1.0 nM.  Compd. I (X = NCOMe)(II) showed the most promising overall PK profile and has high potency and extraordinary selectivity to c-Met against c-Met family member Ron and 12 other tyrosine kinases.  It produced constitutive inhibition of c-Met phosphorylation in c-Met dependent cell lines.  At doses of 100 mg/kg, compd. II showed statistically significant tumor growth inhibition (68-69%) in both NIH-3T3-TPR-Met and U-87 MG human gliobastoma xenograft models.  These results clearly indicated that compd. II is a potent and highly selective c-Met inhibitor.  Its favorable in vitro and in vivo profiles warrant further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaaPLbjIALwbVg90H21EOLACvtfcHk0lhvOLZbZKCTjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjt1yrtbk%253D&md5=b7e0a14f0f710b066051f01bf15397e4</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm101340q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101340q%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DSynthesis%2520and%2520c-Met%2520kinase%2520inhibition%2520of%25203%252C5-disubstituted%2520and%25203%252C5%252C7-trisubstituted%2520quinolines%253A%2520identification%2520of%25203-%25284-acetylpiperazin-1-yl%2529-5-%25283-nitrobenzylamino%2529-7-%2520%2528trifluoromethyl%2529quinoline%2520as%2520a%2520novel%2520anticancer%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2127%26epage%3D2142%26doi%3D10.1021%2Fjm101340q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/medium/jm0c02254_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02254&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/medium/jm0c02254_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative covalent kinase inhibitors approved by the FDA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02254&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/medium/jm0c02254_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Novel irreversible GSK-3β inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02254&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/medium/jm0c02254_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0014.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Reagents and Conditions: (a) Malonic Acid, Piperidine, Pyridine, Reflux, 4 h; (b) 2-Aminothiophenol, TBAF·3H<sub>2</sub>O, 80 °C, 24 h; and (c) Acrolyl Chloride, DIPEA, DCM, rt, 24 h</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02254&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/medium/jm0c02254_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compounds for identification of acryloyl attaching position and reactive mode.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02254&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/medium/jm0c02254_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. <sup>1</sup>H NMR spectra of compounds <b>4</b>-<b>2</b> and <b>8</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02254&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/medium/jm0c02254_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0015.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Reagents and Conditions: MeOH, H<sub>2</sub>O, rt, 24 h, Yield: 64%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02254&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/medium/jm0c02254_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Double-reciprocal plot of kinetic data for the GSK-3β assay at different <b>4</b>-<b>2</b> concentrations. (A) ATP concentrations varied from 0.5 to 8 μM in the final reaction mixture. The GS-2 concentration was kept at 6.25 μM constant in all of the tests. (B) GS-2 concentrations varied from 0.78 to 12.5 μM in the final reaction mixture. The ATP concentration was kept 2 μM constant in all of the tests. (C) Time-dependent inhibition to GSK-3β for <b>4</b>-<b>2</b>. Each point was the mean of two separate experiments, which were performed in triplicate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02254&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/medium/jm0c02254_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. TOF MS spectra. (A) Pure GSK-3β enzyme (MW = 48919.99) without <b>4</b>-<b>3</b> as a control showed a 48919.9907 mass peak. (B) GSK-3β with inhibitor <b>4</b>-<b>3</b> (MW = 327.37) showed a 49247.9014 mass peak corresponding to the C–S bond covalently formed between inhibitor <b>4</b>-<b>3</b> and the GSK-3β enzyme.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02254&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/medium/jm0c02254_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Higher-energy collisional dissociation MS/MS spectrum of GSK-3β peptide-modified <b>4</b>-<b>3</b>. The above listed are predicted b- and y-type ions (not including all) and below listed is the peptide sequence. C* means the cysteine labeled by <b>4</b>-<b>3.</b> (A) The data was recorded on the [M + H]<sup>2+</sup> ion at <i>m</i>/<i>z</i> 1279.5638 of the GSK-3β peptide TTSFAES(C*)KPVQQPSAFGSMK (residues 7–27) harboring a modification(C<sub>18</sub>H<sub>14</sub>FNO<sub>2</sub>S) on Cys14. The spec count value is 12. (B) The data was recorded on the [M + H]<sup>3+</sup> ion at <i>m</i>/<i>z</i> 1014.5118 of the GSK-3β peptide DIKPQNLLLDPDTAVLKL(C*)DFGSAK (residues 181–205) harboring a modification (C<sub>18</sub>H<sub>14</sub>FNO<sub>2</sub>S) on Cys199. The spec count value is 1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02254&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/medium/jm0c02254_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Proliferation inhibition of three GSK-3β inhibitors in NB4 and NB4-R1 cells and their cytotoxicity to normal cell lines by the CCK-8 assay. (A) Proliferation inhibition rate of NB4 cells after exposure to three inhibitors at various concentrations for 24 h. (B) Proliferation inhibition rate of NB4-R1 cells after exposure to three inhibitors at various concentrations for 24 h. Inhibition rate of NB4 cells (C) and NB4-R1 cells (D) after exposure to <b>4</b>-<b>3</b> at various concentrations for 24 and 48 h. Viability of two normal cell lines HUVECs (E) and LO<sub>2</sub> cells (F) after exposure to three inhibitors at various concentrations for 24 h. Data are presented as mean ± standard error of the mean (SEM) of three independent experiments and significant differences are indicated as *<i>P</i> < 0.01 vs control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02254&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/medium/jm0c02254_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Induction of cell apoptosis by three inhibitors of GSK-3β. Apoptosis of NB4 cells (A) and NB4-R1 cells (B) exposed to different concentrations of three inhibitors for 24 h. Apoptotic cells were detected by a flow cytometer using Annexin V/PI double staining. (C) Representative scatter plot for a flow cytometer. <b>4</b>-<b>3</b> induced apoptosis in NB4 cells in combination with Z-VAD-FMK (irreversible pan-caspase inhibitor) in a dose-dependent manner. (D) Percentages of apoptotic NB4 cells treated with indicated inhibitor <b>4</b>-<b>3</b> or in combination with Z-VAD-FMK for 24 h. (E,F) Representative scatter plots for flow cytometer in NB4-R1 cells. Apoptosis of NB4-R1 cells exposed to different concentrations of <b>4</b>-<b>3</b> or in combination with Z-VAD-FMK for 24 h. The data shown are representative of values from at least three independent experiments (mean ± SEM; ** <i>P</i> < 0.05; * <i>P</i> < 0.01 vs control).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02254&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/medium/jm0c02254_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Cell proliferation and viability of <b>4</b>-<b>3</b> and LiCl. (A) IC<sub>50</sub> of <b>4</b>-<b>3</b> for several tumor cells. (B) Proliferation inhibition of NB4 and NB4-R1cells exposed to different concentrations of LiCl for 24 h by the CCK-8 assay. The data shown are representative of values from at least three independent experiments (mean ± SEM; *, <i>P</i> < 0.01 vs control).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02254&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/medium/jm0c02254_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. (A) The western blot analysis of p-GS and GS expression of NB4 and NB4-R1 cells was obtained after 24 h of treatment with <b>4</b>-<b>3</b>, and the representative bands were shown. (B) Values denoted the relative protein intensity as ratios of p-GS to GS. Data were represented as means ± SEM (<i>n</i> = 3), and significant differences were indicated as **, <i>P</i> < 0.05; *, <i>P</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02254&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/medium/jm0c02254_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. <i>In vivo</i> activity of <b>4</b>-<b>3</b>. (A). <b>4</b>-<b>3</b> inhibition of localized growth in NB4 cells. NB4 cells were transplanted into the right flanks of nude mice, which were intraperitoneally injected daily with <b>4</b>-<b>3</b> (15 mg/kg/d) for 2 weeks. Tumor volumes were measured (mean ± SEM, <i>n</i> = 5; *, <i>P</i> < 0.01 vs control). (B). The body weight of mice recorded during the treatment period. Data were recorded as the mean ± SEM, <i>n</i> = 5; **, <i>P</i> < 0.05 vs control. (C). Weights of tumors dissected from mice treated with <b>4</b>-<b>3</b> or control (mean ± SEM, <i>n</i> = 5; *, <i>P</i> < 0.01 vs control). (D). The gross subcutaneous xenografts of NB4 cells were determined.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c02254/20210602/images/large/jm0c02254_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02254&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i98">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25350" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25350" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 46 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houk, K. N.</span></span> <span> </span><span class="NLM_article-title">Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1021/jm800498e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800498e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BD1MXis1OltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=225-233&author=A.+J.+T.+Smithauthor=X.+Zhangauthor=A.+G.+Leachauthor=K.+N.+Houk&title=Beyond+picomolar+affinities%3A+quantitative+aspects+of+noncovalent+and+covalent+binding+of+drugs+to+proteins&doi=10.1021%2Fjm800498e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins</span></div><div class="casAuthors">Smith, Adam J. T.; Zhang, Xiyun; Leach, Andrew G.; Houk, K. N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">225-233</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review of 104 refs. summarized quant. aspects of noncovalent and covalent binding of drugs to proteins with subtopics including (1) introduction; (2) factors involved in ligand-recepto binding; (3) distribution of exptl. binding consts.; (3) covalent interactions with transition states as the origins of enzyme proficiency; (4) potential quant. advantages of covalent enzyme inhibitors and colent drugs; (5) selected examples of covalent inhibitors and drugs; (6) prospects for the design of covalent drugs; (7) conclusions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAhUbRxt1fu7Vg90H21EOLACvtfcHk0lgglJJgmbLTsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXis1OltLw%253D&md5=529d4181046100b5e3c37a8fef571218</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Fjm800498e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800498e%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DA.%2BJ.%2BT.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLeach%26aufirst%3DA.%2BG.%26aulast%3DHouk%26aufirst%3DK.%2BN.%26atitle%3DBeyond%2520picomolar%2520affinities%253A%2520quantitative%2520aspects%2520of%2520noncovalent%2520and%2520covalent%2520binding%2520of%2520drugs%2520to%2520proteins%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D225%26epage%3D233%26doi%3D10.1021%2Fjm800498e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span> <span> </span><span class="NLM_article-title">Targeted covalent inhibitors for drug design</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">13408</span>– <span class="NLM_lpage">13421</span>, <span class="refDoi"> DOI: 10.1002/anie.201601091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1002%2Fanie.201601091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOrtb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=13408-13421&author=T.+A.+Baillie&title=Targeted+covalent+inhibitors+for+drug+design&doi=10.1002%2Fanie.201601091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Covalent Inhibitors for Drug Design</span></div><div class="casAuthors">Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">13408-13421</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">In contrast to the traditional mechanism of drug action that relies on the reversible, noncovalent interaction of a ligand with its biol. target, a targeted covalent inhibitor (TCI) is designed such that the initial, reversible assocn. is followed by the formation of a covalent bond between an electrophile on the ligand and a nucleophilic center in the protein.  Although this approach offers a variety of potential benefits (high potency and extended duration of action), concerns over the possible toxicol. consequences of protein haptenization have hindered the development of the TCI concept.  Recently, approaches to mitigate the risk of serious adverse reactions to this new class of agent have emerged, thus stimulating interest in the field and leading to authorization of the first cadre of TCIs to be marketed.  The covalent inhibitor approach is rapidly gaining acceptance as a valuable tool in drug discovery, and is poised to make a major impact on the design of enzyme inhibitors and receptor modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEbjdFrctvNrVg90H21EOLACvtfcHk0liSHceQm6e7pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOrtb%252FN&md5=18bed2ae08dcb4245a42b3070abc6354</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fanie.201601091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201601091%26sid%3Dliteratum%253Aachs%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DTargeted%2520covalent%2520inhibitors%2520for%2520drug%2520design%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D13408%26epage%3D13421%26doi%3D10.1002%2Fanie.201601091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryabtsova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joossens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Der
Veken, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanden Berghe, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustyns, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Winter, H.</span></span> <span> </span><span class="NLM_article-title">Novel selective glucocorticoid receptor agonists (SEGRAs) with a covalent warhead for long-lasting inhibition</span>. <i>Bioorg. Med. Chem. Lett</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5032</span>– <span class="NLM_lpage">5038</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.08.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1016%2Fj.bmcl.2016.08.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=27612544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsV2jsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=5032-5038&author=O.+Ryabtsovaauthor=J.+Joossensauthor=P.+Van+Der%0AVekenauthor=W.+Vanden+Bergheauthor=K.+Augustynsauthor=H.+De+Winter&title=Novel+selective+glucocorticoid+receptor+agonists+%28SEGRAs%29+with+a+covalent+warhead+for+long-lasting+inhibition&doi=10.1016%2Fj.bmcl.2016.08.091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Novel selective glucocorticoid receptor agonists (SEGRAs) with a covalent warhead for long-lasting inhibition</span></div><div class="casAuthors">Ryabtsova, Oksana; Joossens, Jurgen; Van Der Veken, Pieter; Vanden Berghe, Wim; Augustyns, Koen; De Winter, Hans</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5032-5038</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The synthesis and in vitro properties of six analogs of the selective glucocorticoid receptor (GR) agonist GSK866 (I), bearing a warhead for covalent linkage to the glucocorticoid receptor, is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp6KtRHDt_X7Vg90H21EOLACvtfcHk0liSHceQm6e7pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsV2jsL3I&md5=b02430eefd26167bf45e46541f765754</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.08.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.08.091%26sid%3Dliteratum%253Aachs%26aulast%3DRyabtsova%26aufirst%3DO.%26aulast%3DJoossens%26aufirst%3DJ.%26aulast%3DVan%2BDer%2BVeken%26aufirst%3DP.%26aulast%3DVanden%2BBerghe%26aufirst%3DW.%26aulast%3DAugustyns%26aufirst%3DK.%26aulast%3DDe%2BWinter%26aufirst%3DH.%26atitle%3DNovel%2520selective%2520glucocorticoid%2520receptor%2520agonists%2520%2528SEGRAs%2529%2520with%2520a%2520covalent%2520warhead%2520for%2520long-lasting%2520inhibition%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett%26date%3D2016%26volume%3D26%26spage%3D5032%26epage%3D5038%26doi%3D10.1016%2Fj.bmcl.2016.08.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Cesco, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufresne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittermaier, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moitessier, N.</span></span> <span> </span><span class="NLM_article-title">Covalent inhibitors design and discovery</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.06.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1016%2Fj.ejmech.2017.06.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=28651155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVKhsLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2017&pages=96-114&author=S.+De%0ACescoauthor=J.+Kurianauthor=C.+Dufresneauthor=A.+K.+Mittermaierauthor=N.+Moitessier&title=Covalent+inhibitors+design+and+discovery&doi=10.1016%2Fj.ejmech.2017.06.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent inhibitors design and discovery</span></div><div class="casAuthors">De Cesco, Stephane; Kurian, Jerry; Dufresne, Caroline; Mittermaier, Anthony K.; Moitessier, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">96-114</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In the history of therapeutics, covalent drugs occupy a very distinct category.  While representing a significant fraction of the drugs on the market, very few have been deliberately designed to interact covalently with their biol. target.  In this review, the prevalence of covalent drugs will first be briefly covered, followed by an introduction to their mechanisms of action and more detailed discussions of their discovery and the development of safe and efficient covalent enzyme inhibitors.  All stages of a drug discovery program will be covered, from target considerations to lead optimization, strategies to tune reactivity and computational methods.  The goal of this article is to provide an overview of the field and to outline good practices that are needed for the proper assessment and development of covalent inhibitors as well as a good understanding of the potential and limitations of current computational methods for the design of covalent drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeLNDmLtBdB7Vg90H21EOLACvtfcHk0liSHceQm6e7pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVKhsLrI&md5=551c9a9c4bd69d4ad4d9156c315d5a94</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.06.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.06.019%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BCesco%26aufirst%3DS.%26aulast%3DKurian%26aufirst%3DJ.%26aulast%3DDufresne%26aufirst%3DC.%26aulast%3DMittermaier%26aufirst%3DA.%2BK.%26aulast%3DMoitessier%26aufirst%3DN.%26atitle%3DCovalent%2520inhibitors%2520design%2520and%2520discovery%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D138%26spage%3D96%26epage%3D114%26doi%3D10.1016%2Fj.ejmech.2017.06.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bliven, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourne, P. E.</span></span> <span> </span><span class="NLM_article-title">Determining cysteines available for covalent inhibition across the human kinome</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2879</span>– <span class="NLM_lpage">2889</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01815</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01815" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvVGjsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2879-2889&author=Z.+Zhaoauthor=Q.+Liuauthor=S.+Blivenauthor=L.+Xieauthor=P.+E.+Bourne&title=Determining+cysteines+available+for+covalent+inhibition+across+the+human+kinome&doi=10.1021%2Facs.jmedchem.6b01815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Determining Cysteines Available for Covalent Inhibition Across the Human Kinome</span></div><div class="casAuthors">Zhao, Zheng; Liu, Qingsong; Bliven, Spencer; Xie, Lei; Bourne, Philip E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2879-2889</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Covalently bound protein kinase inhibitors have been frequently designed to target non-catalytic Cys residues at the ATP binding site.  Thus, it is important to know if a given Cys residue can form a covalent bond.  Here, we combined a function-site interaction fingerprint method and DFT calcns. to det. the potential of Cys residues to form a covalent interaction with an inhibitor.  By harnessing the human structural kinome, a comprehensive structure-based binding site Cys dataset was assembled.  The orientation of the Cys SH group indicated which Cys residues could potentially form covalent bonds.  These covalent inhibitor accessible Cys residues were located within 5 kinase regions (P-loop, roof of pocket, front pocket, catalytic-2 of the catalytic loop and DFG-3 close to the DFG peptide).  In an independent test set, these Cys residues covered 95% of covalent kinase inhibitors.  Thus, this study provides new insights into Cys reactivity and preference which is important for the prospective development of covalent kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKJnGGcKhC5rVg90H21EOLACvtfcHk0liReY766QQuDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvVGjsLg%253D&md5=22ea95ce38eb0836d32c1332dba54fad</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01815%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBliven%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DBourne%26aufirst%3DP.%2BE.%26atitle%3DDetermining%2520cysteines%2520available%2520for%2520covalent%2520inhibition%2520across%2520the%2520human%2520kinome%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2879%26epage%3D2889%26doi%3D10.1021%2Facs.jmedchem.6b01815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keeley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ábrányi-Balogh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keserű, G. M.</span></span> <span> </span><span class="NLM_article-title">Design and characterization of a heterocyclic electrophilic fragment library for the discovery of cysteine-targeted covalent inhibitors</span>. <i>Medchemcomm</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.1039/c8md00327k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1039%2FC8MD00327K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=30881613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVKqsL3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=263-267&author=A.+Keeleyauthor=P.+%C3%81br%C3%A1nyi-Baloghauthor=G.+M.+Keser%C5%B1&title=Design+and+characterization+of+a+heterocyclic+electrophilic+fragment+library+for+the+discovery+of+cysteine-targeted+covalent+inhibitors&doi=10.1039%2Fc8md00327k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Design and characterization of a heterocyclic electrophilic fragment library for the discovery of cysteine-targeted covalent inhibitors</span></div><div class="casAuthors">Keeley, A.; Abranyi-Balogh, P.; Keseru, G. M.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-267</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A fragment library of electrophilic small heterocycles was characterized through cysteine-reactivity and aq. stability tests that suggested their potential as covalent warheads.  The anal. of theor. and exptl. descriptors revealed correlations between the electronic properties of the heterocyclic cores and their reactivity against GSH that are helpful in identifying suitable fragments for cysteines with specific nucleophilicity.  The most important advantage of these fragments is that they show only minimal structural differences from non-electrophilic counterparts.  Therefore, they could be used effectively in the design of targeted covalent inhibitors with minimal influence on key non-covalent interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_kfO0y4dKtrVg90H21EOLACvtfcHk0liReY766QQuDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVKqsL3M&md5=3f1fbf3849026598029e9b8154815a3c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1039%2FC8MD00327K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8MD00327K%26sid%3Dliteratum%253Aachs%26aulast%3DKeeley%26aufirst%3DA.%26aulast%3D%25C3%2581br%25C3%25A1nyi-Balogh%26aufirst%3DP.%26aulast%3DKeser%25C5%25B1%26aufirst%3DG.%2BM.%26atitle%3DDesign%2520and%2520characterization%2520of%2520a%2520heterocyclic%2520electrophilic%2520fragment%2520library%2520for%2520the%2520discovery%2520of%2520cysteine-targeted%2520covalent%2520inhibitors%26jtitle%3DMedchemcomm%26date%3D2019%26volume%3D10%26spage%3D263%26epage%3D267%26doi%3D10.1039%2Fc8md00327k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of a series of pyrazolo[3,4-d]pyridazinone compounds as the novel covalent fibroblast growth factor receptor inhibitors by the rational drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7473</span>– <span class="NLM_lpage">7488</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00510</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00510" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVemu77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7473-7488&author=Y.+Wangauthor=Y.+Daiauthor=X.+Wuauthor=F.+Liauthor=B.+Liuauthor=C.+Liauthor=Q.+Liuauthor=Y.+Zhouauthor=B.+Wangauthor=M.+Zhuauthor=R.+Cuiauthor=X.+Tanauthor=Z.+Xiongauthor=J.+Liuauthor=M.+Tanauthor=Y.+Xuauthor=M.+Gengauthor=H.+Jiangauthor=H.+Liuauthor=J.+Aiauthor=M.+Zheng&title=Discovery+and+development+of+a+series+of+pyrazolo%5B3%2C4-d%5Dpyridazinone+compounds+as+the+novel+covalent+fibroblast+growth+factor+receptor+inhibitors+by+the+rational+drug+design&doi=10.1021%2Facs.jmedchem.9b00510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of a Series of Pyrazolo[3,4-d]pyridazinone Compounds as the Novel Covalent Fibroblast Growth Factor Receptor Inhibitors by the Rational Drug Design</span></div><div class="casAuthors">Wang, Yulan; Dai, Yang; Wu, Xiaowei; Li, Fei; Liu, Bo; Li, Chunpu; Liu, Qiufeng; Zhou, Yuanyang; Wang, Bao; Zhu, Mingrui; Cui, Rongrong; Tan, Xiaoqin; Xiong, Zhaoping; Liu, Jia; Tan, Minjia; Xu, Yechun; Geng, Meiyu; Jiang, Hualiang; Liu, Hong; Ai, Jing; Zheng, Mingyue</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7473-7488</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Alterations of fibroblast growth factor receptors (FGFRs) play key roles in numerous cancer progression and development, which makes FGFRs attractive targets in the cancer therapy.  In the present study, based on a newly devised FGFR target-specific scoring function, a novel FGFR inhibitor hit was identified through virtual screening.  Hit-to-lead optimization was then performed by integrating mol. docking and site-of-metab. predictions with an array of in vitro evaluations and X-ray cocrystal structure detn., leading to a covalent FGFR inhibitor 15, which showed a highly selective and potent FGFR inhibition profile.  Pharmacokinetic assessment, protein kinase profiling, and hERG inhibition evaluation were also conducted, and they confirmed the value of 15 as a lead for further investigation.  Overall, this study exemplifies the importance of the integrative use of computational methods and exptl. techniques in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKNbodkitt5rVg90H21EOLACvtfcHk0lhjff838k7Wdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVemu77L&md5=80943e14d5d126f05f7d66a88208f109</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00510%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DCui%26aufirst%3DR.%26aulast%3DTan%26aufirst%3DX.%26aulast%3DXiong%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DM.%26atitle%3DDiscovery%2520and%2520development%2520of%2520a%2520series%2520of%2520pyrazolo%255B3%252C4-d%255Dpyridazinone%2520compounds%2520as%2520the%2520novel%2520covalent%2520fibroblast%2520growth%2520factor%2520receptor%2520inhibitors%2520by%2520the%2520rational%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7473%26epage%3D7488%26doi%3D10.1021%2Facs.jmedchem.9b00510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCubrey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steelman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokolosky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montalto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Assoro, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Libra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicoletti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maestro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basecke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gizak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demidenko, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocco, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martelli, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervello, M.</span></span> <span> </span><span class="NLM_article-title">GSK-3 as potential target for therapeutic intervention in cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">2881</span>– <span class="NLM_lpage">2911</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.2037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.18632%2Foncotarget.2037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=24931005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A280%3ADC%252BC2cfislOntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=2881-2911&author=J.+A.+McCubreyauthor=L.+S.+Steelmanauthor=F.+E.+Bertrandauthor=N.+M.+Davisauthor=M.+Sokoloskyauthor=S.+L.+Abramsauthor=G.+Montaltoauthor=A.+B.+D%E2%80%99Assoroauthor=M.+Libraauthor=F.+Nicolettiauthor=R.+Maestroauthor=J.+Baseckeauthor=D.+Rakusauthor=A.+Gizakauthor=Z.+Demidenkoauthor=L.+Coccoauthor=A.+M.+Martelliauthor=M.+Cervello&title=GSK-3+as+potential+target+for+therapeutic+intervention+in+cancer&doi=10.18632%2Foncotarget.2037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">GSK-3 as potential target for therapeutic intervention in cancer</span></div><div class="casAuthors">McCubrey James A; Steelman Linda S; Bertrand Fred E; Davis Nicole M; Sokolosky Melissa; Abrams Steve L; Montalto Giuseppe; D'Assoro Antonino B; Libra Massimo; Nicoletti Ferdinando; Maestro Roberta; Basecke Jorg; Rakus Dariusz; Gizak Agnieszka; Demidenko Zoya N; Cocco Lucio; Martelli Alberto M; Cervello Melchiorre</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2881-911</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The serine/threonine kinase glycogen synthase kinase-3 (GSK-3) was initially identified and studied in the regulation of glycogen synthesis.  GSK-3 functions in a wide range of cellular processes.  Aberrant activity of GSK-3 has been implicated in many human pathologies including: bipolar depression, Alzheimer's disease, Parkinson's disease, cancer, non-insulin-dependent diabetes mellitus (NIDDM) and others.  In some cases, suppression of GSK-3 activity by phosphorylation by Akt and other kinases has been associated with cancer progression.  In these cases, GSK-3 has tumor suppressor functions.  In other cases, GSK-3 has been associated with tumor progression by stabilizing components of the beta-catenin complex.  In these situations, GSK-3 has oncogenic properties.  While many inhibitors to GSK-3 have been developed, their use remains controversial because of the ambiguous role of GSK-3 in cancer development.  In this review, we will focus on the diverse roles that GSK-3 plays in various human cancers, in particular in solid tumors.  Recently, GSK-3 has also been implicated in the generation of cancer stem cells in various cell types.  We will also discuss how this pivotal kinase interacts with multiple signaling pathways such as: PI3K/PTEN/Akt/mTORC1, Ras/Raf/MEK/ERK, Wnt/beta-catenin, Hedgehog, Notch and others.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSSfjCBotAOrCnGiHuhFGv8fW6udTcc2eaaWWwAZ2Xvsbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfislOntA%253D%253D&md5=2e76037d7b51a604ebbf686fda4473e1</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2037%26sid%3Dliteratum%253Aachs%26aulast%3DMcCubrey%26aufirst%3DJ.%2BA.%26aulast%3DSteelman%26aufirst%3DL.%2BS.%26aulast%3DBertrand%26aufirst%3DF.%2BE.%26aulast%3DDavis%26aufirst%3DN.%2BM.%26aulast%3DSokolosky%26aufirst%3DM.%26aulast%3DAbrams%26aufirst%3DS.%2BL.%26aulast%3DMontalto%26aufirst%3DG.%26aulast%3DD%25E2%2580%2599Assoro%26aufirst%3DA.%2BB.%26aulast%3DLibra%26aufirst%3DM.%26aulast%3DNicoletti%26aufirst%3DF.%26aulast%3DMaestro%26aufirst%3DR.%26aulast%3DBasecke%26aufirst%3DJ.%26aulast%3DRakus%26aufirst%3DD.%26aulast%3DGizak%26aufirst%3DA.%26aulast%3DDemidenko%26aufirst%3DZ.%26aulast%3DCocco%26aufirst%3DL.%26aulast%3DMartelli%26aufirst%3DA.%2BM.%26aulast%3DCervello%26aufirst%3DM.%26atitle%3DGSK-3%2520as%2520potential%2520target%2520for%2520therapeutic%2520intervention%2520in%2520cancer%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D2881%26epage%3D2911%26doi%3D10.18632%2Foncotarget.2037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snider, W. D.</span></span> <span> </span><span class="NLM_article-title">Functions of GSK-3 Signaling in development of the nervous system</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">44</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2011.00044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.3389%2Ffnmol.2011.00044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=22125510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC38XovVyk" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=44&author=W.+Y.+Kimauthor=W.+D.+Snider&title=Functions+of+GSK-3+Signaling+in+development+of+the+nervous+system&doi=10.3389%2Ffnmol.2011.00044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Functions of GSK-3 signaling in development of the nervous system</span></div><div class="casAuthors">Kim, Woo-Yang; Snider, William D.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">Nov.</span>),
    <span class="NLM_cas:pages">44</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Glycogen synthase kinase-3 (GSK-3) is central to multiple intracellular pathways including those activated by Wnt/β-catenin, Sonic Hedgehog, Notch, growth factor/RTK, and G protein-coupled receptor signals.  All of these signals importantly contribute to neural development.  Early attention on GSK-3 signaling in neural development centered on the regulation of neuronal polarity using in vitro paradigms.  However, recent creation of appropriate genetic models has demonstrated the importance of GSK-3 to multiple aspects of neural development including neural progenitor self-renewal, neurogenesis, neuronal migration, neural differentiation, and synaptic development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSTo0OCsFLg7Vg90H21EOLACvtfcHk0lj6nr5wJoYc0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovVyk&md5=eb422d247103891be2e9a4a4e2ad4f9f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2011.00044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2011.00044%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DW.%2BY.%26aulast%3DSnider%26aufirst%3DW.%2BD.%26atitle%3DFunctions%2520of%2520GSK-3%2520Signaling%2520in%2520development%2520of%2520the%2520nervous%2520system%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2011%26volume%3D4%26spage%3D44%26doi%3D10.3389%2Ffnmol.2011.00044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficara, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matheny, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S. H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleary, M. L.</span></span> <span> </span><span class="NLM_article-title">GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis</span>. <i>Canc. Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">597</span>– <span class="NLM_lpage">608</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2010.04.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1016%2Fj.ccr.2010.04.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=20541704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC3cXot1Cgsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=597-608&author=Z.+Wangauthor=M.+Iwasakiauthor=F.+Ficaraauthor=C.+Linauthor=C.+Mathenyauthor=S.+H.+K.+Wongauthor=K.+S.+Smithauthor=M.+L.+Cleary&title=GSK-3+promotes+conditional+association+of+CREB+and+its+coactivators+with+MEIS1+to+facilitate+HOX-mediated+transcription+and+oncogenesis&doi=10.1016%2Fj.ccr.2010.04.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis</span></div><div class="casAuthors">Wang, Zhong; Iwasaki, Masayuki; Ficara, Francesca; Lin, Chenwei; Matheny, Christina; Wong, Stephen H. K.; Smith, Kevin S.; Cleary, Michael L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">597-608</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Acute leukemias induced by MLL chimeric oncoproteins are among the subset of cancers distinguished by a paradoxical dependence on GSK-3 kinase activity for sustained proliferation.  We demonstrate here that GSK-3 maintains the MLL leukemia stem cell transcriptional program by promoting the conditional assocn. of CREB and its coactivators TORC and CBP with homedomain protein MEIS1, a crit. component of the MLL-subordinate program, which in turn facilitates HOX-mediated transcription and transformation.  This mechanism also applies to hematopoietic cells transformed by other HOX genes, including CDX2, which is highly expressed in a majority of acute myeloid leukemias, thus providing a mol. approach based on GSK-3 inhibitory strategies to target HOX-assocd. transcription in a broad spectrum of leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZlG8S2736Z7Vg90H21EOLACvtfcHk0lj6nr5wJoYc0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXot1Cgsbg%253D&md5=6243be5ff831cb1afe592f0e8b7ff5ba</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2010.04.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2010.04.024%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DIwasaki%26aufirst%3DM.%26aulast%3DFicara%26aufirst%3DF.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DMatheny%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DS.%2BH.%2BK.%26aulast%3DSmith%26aufirst%3DK.%2BS.%26aulast%3DCleary%26aufirst%3DM.%2BL.%26atitle%3DGSK-3%2520promotes%2520conditional%2520association%2520of%2520CREB%2520and%2520its%2520coactivators%2520with%2520MEIS1%2520to%2520facilitate%2520HOX-mediated%2520transcription%2520and%2520oncogenesis%26jtitle%3DCanc.%2520Cell%26date%3D2010%26volume%3D17%26spage%3D597%26epage%3D608%26doi%3D10.1016%2Fj.ccr.2010.04.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tullai, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, G. M.</span></span> <span> </span><span class="NLM_article-title">A GSK-3-mediated transcriptional network maintains repression of immediate early genes in quiescent cells</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">3072</span>– <span class="NLM_lpage">3077</span>, <span class="refDoi"> DOI: 10.4161/cc.10.18.17321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.4161%2Fcc.10.18.17321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=21900749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A280%3ADC%252BC3Mfosl2jtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=3072-3077&author=J.+W.+Tullaiauthor=J.+R.+Grahamauthor=G.+M.+Cooper&title=A+GSK-3-mediated+transcriptional+network+maintains+repression+of+immediate+early+genes+in+quiescent+cells&doi=10.4161%2Fcc.10.18.17321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A GSK-3-mediated transcriptional network maintains repression of immediate early genes in quiescent cells</span></div><div class="casAuthors">Tullai John W; Graham Julie R; Cooper Geoffrey M</div><div class="citationInfo"><span class="NLM_cas:title">Cell cycle (Georgetown, Tex.)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3072-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Glycogen synthase kinase-3 (GSK-3) plays a central role in cell survival and proliferation, in part by the regulation of transcription.  Unlike most protein kinases, GSK-3 is active in quiescent cells in the absence of growth factor signaling.  In a recent series of studies, we employed a systems-level approach to understanding the transcription network regulated by GSK-3 in a quiescent cell model.  We identified a group of immediate early genes that were upregulated in quiescent cells solely by the inhibition of GSK-3 in the absence of growth factor stimulation.  Computational analysis of the upstream sequences of these genes identified statistically over-represented binding sites for the transcription factors CREB, NFκB and AP-1, and the roles of these factors in regulating expression of GSK-3 target genes were verified by chromatin immunoprecipitation and RNA interference.  In quiescent cells, GSK-3 inhibits CREB, NFκB and AP-1, thereby maintaining repression of their target genes and contributing to maintenance of cell cycle arrest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTkNpHR0NjEf252AMpI4GK2fW6udTcc2ea5wppUQO02Urntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mfosl2jtQ%253D%253D&md5=b4a96b4b037463eb7eb4928e7dbf3228</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.4161%2Fcc.10.18.17321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.10.18.17321%26sid%3Dliteratum%253Aachs%26aulast%3DTullai%26aufirst%3DJ.%2BW.%26aulast%3DGraham%26aufirst%3DJ.%2BR.%26aulast%3DCooper%26aufirst%3DG.%2BM.%26atitle%3DA%2520GSK-3-mediated%2520transcriptional%2520network%2520maintains%2520repression%2520of%2520immediate%2520early%2520genes%2520in%2520quiescent%2520cells%26jtitle%3DCell%2520Cycle%26date%3D2011%26volume%3D10%26spage%3D3072%26epage%3D3077%26doi%3D10.4161%2Fcc.10.18.17321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugolkov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Zapico, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couch, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billadeau, D. D.</span></span> <span> </span><span class="NLM_article-title">Mutant K-Ras increases GSK-3beta gene expression via an ETS-p300 transcriptional complex in pancreatic cancer</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">3705</span>– <span class="NLM_lpage">3715</span>, <span class="refDoi"> DOI: 10.1038/onc.2011.90</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1038%2Fonc.2011.90" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=21441955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvVOisb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2011&pages=3705-3715&author=J.-S.+Zhangauthor=A.+Koenigauthor=A.+Harrisonauthor=A.+V.+Ugolkovauthor=M.+E.+Fernandez-Zapicoauthor=F.+J.+Couchauthor=D.+D.+Billadeau&title=Mutant+K-Ras+increases+GSK-3beta+gene+expression+via+an+ETS-p300+transcriptional+complex+in+pancreatic+cancer&doi=10.1038%2Fonc.2011.90"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Mutant K-Ras increases GSK-3β gene expression via an ETS-p300 transcriptional complex in pancreatic cancer</span></div><div class="casAuthors">Zhang, J.-S.; Koenig, A.; Harrison, A.; Ugolkov, A. V.; Fernandez-Zapico, M. E.; Couch, F. J.; Billadeau, D. D.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">3705-3715</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Glycogen synthase kinase-3 beta (GSK-3β) is overexpressed in a no. of human malignancies and has been shown to contribute to tumor cell proliferation and survival.  Although regulation of GSK-3β activity has been extensively studied, the mechanisms governing GSK-3β gene expression are still unknown.  Using pancreatic cancer as a model, we find that constitutively active Ras signaling increases GSK-3β gene expression via the canonical mitogen-activated protein kinase signaling pathway.  Anal. of the mechanism revealed that K-Ras regulates the expression of this kinase through two highly conserved E-twenty six (ETS) binding elements within the proximal region.  Furthermore, we demonstrate that mutant K-Ras enhances ETS2 loading onto the promoter, and ETS requires its transcriptional activity to increase GSK-3β gene transcription in pancreatic cancer cells.  Lastly, we show that ETS2 cooperates with p300 histone acetyltransferase to remodel chromatin and promote GSK-3β expression.  Taken together, these results provide a general mechanism for increased expression of GSK-3β in pancreatic cancer and perhaps other cancers, where Ras signaling is deregulated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZqggAKHEZRbVg90H21EOLACvtfcHk0liRMGzgNx3xIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvVOisb0%253D&md5=54915bdecb6740689361f7f61627c044</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fonc.2011.90&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2011.90%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.-S.%26aulast%3DKoenig%26aufirst%3DA.%26aulast%3DHarrison%26aufirst%3DA.%26aulast%3DUgolkov%26aufirst%3DA.%2BV.%26aulast%3DFernandez-Zapico%26aufirst%3DM.%2BE.%26aulast%3DCouch%26aufirst%3DF.%2BJ.%26aulast%3DBilladeau%26aufirst%3DD.%2BD.%26atitle%3DMutant%2520K-Ras%2520increases%2520GSK-3beta%2520gene%2520expression%2520via%2520an%2520ETS-p300%2520transcriptional%2520complex%2520in%2520pancreatic%2520cancer%26jtitle%3DOncogene%26date%3D2011%26volume%3D30%26spage%3D3705%26epage%3D3715%26doi%3D10.1038%2Fonc.2011.90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arioka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi-Yanaga, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomooka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaguri, T.</span></span> <span> </span><span class="NLM_article-title">Anti-tumor effects of differentiation-inducing factor-1 in malignant melanoma: GSK-3-mediated inhibition of cell proliferation and GSK-3-independent suppression of cell migration and invasion</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2017.05.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1016%2Fj.bcp.2017.05.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=28501501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsl2rtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2017&pages=31-48&author=M.+Ariokaauthor=F.+Takahashi-Yanagaauthor=M.+Kuboauthor=K.+Igawaauthor=K.+Tomookaauthor=T.+Sasaguri&title=Anti-tumor+effects+of+differentiation-inducing+factor-1+in+malignant+melanoma%3A+GSK-3-mediated+inhibition+of+cell+proliferation+and+GSK-3-independent+suppression+of+cell+migration+and+invasion&doi=10.1016%2Fj.bcp.2017.05.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-tumor effects of differentiation-inducing factor-1 in malignant melanoma: GSK-3-mediated inhibition of cell proliferation and GSK-3-independent suppression of cell migration and invasion</span></div><div class="casAuthors">Arioka, Masaki; Takahashi-Yanaga, Fumi; Kubo, Momoko; Igawa, Kazunobu; Tomooka, Katsuhiko; Sasaguri, Toshiyuki</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">31-48</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Differentiation-inducing factor-1 (DIF-1) isolated from Dictyostelium discoideum strongly inhibits the proliferation of various mammalian cells through the activation of glycogen synthase kinase-3 (GSK-3).  To evaluate DIF-1 as a novel anti-cancer agent for malignant melanoma, we examd. whether DIF-1 has anti-proliferative, anti-migratory, and anti-invasive effects on melanoma cells using in vitro and in vivo systems.  DIF-1 reduced the expression levels of cyclin D1 and c-Myc by facilitating their degrdn. via GSK-3 in mouse (B16BL6) and human (A2058) malignant melanoma cells, and thereby strongly inhibited their proliferation.  DIF-1 suppressed the canonical Wnt signaling pathway by lowering the expression levels of transcription factor 7-like 2 and β-catenin, key transcription factors in this pathway.  DIF-1 also inhibited cell migration and invasion, reducing the expression of matrix metalloproteinase-2; however, this effect was not dependent on GSK-3 activity.  In a mouse lung tumor formation model, repeated oral administrations of DIF-1 markedly reduced melanoma colony formation in the lung.  These results suggest that DIF-1 inhibits cell proliferation by a GSK-3-dependent mechanism and suppresses cell migration and invasion by a GSK-3-independent mechanism.  Therefore, DIF-1 may have a potential as a novel anti-cancer agent for the treatment of malignant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCpDuiIQ-vWLVg90H21EOLACvtfcHk0liRMGzgNx3xIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsl2rtbw%253D&md5=c8c56bfe0fe9b621e0ab8ce361462cdd</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2017.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2017.05.004%26sid%3Dliteratum%253Aachs%26aulast%3DArioka%26aufirst%3DM.%26aulast%3DTakahashi-Yanaga%26aufirst%3DF.%26aulast%3DKubo%26aufirst%3DM.%26aulast%3DIgawa%26aufirst%3DK.%26aulast%3DTomooka%26aufirst%3DK.%26aulast%3DSasaguri%26aufirst%3DT.%26atitle%3DAnti-tumor%2520effects%2520of%2520differentiation-inducing%2520factor-1%2520in%2520malignant%2520melanoma%253A%2520GSK-3-mediated%2520inhibition%2520of%2520cell%2520proliferation%2520and%2520GSK-3-independent%2520suppression%2520of%2520cell%2520migration%2520and%2520invasion%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2017%26volume%3D138%26spage%3D31%26epage%3D48%26doi%3D10.1016%2Fj.bcp.2017.05.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, J.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shieh, D.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.-J.</span></span> <span> </span><span class="NLM_article-title">GSK-3 inhibitors enhance TRAIL-mediated apoptosis in human gastric adenocarcinoma cells</span>. <i>PloS One</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">e0208094</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0208094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1371%2Fjournal.pone.0208094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=30557366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtlGhs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&author=Y.-Y.+Wuauthor=C.-T.+Hsiehauthor=Y.-M.+Chiuauthor=S.-C.+Chouauthor=J.-T.+Kaoauthor=D.-C.+Shiehauthor=Y.-J.+Lee&title=GSK-3+inhibitors+enhance+TRAIL-mediated+apoptosis+in+human+gastric+adenocarcinoma+cells&doi=10.1371%2Fjournal.pone.0208094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">GSK-3 inhibitors enhance TRAIL-mediated apoptosis in human gastric adenocarcinoma cells</span></div><div class="casAuthors">Wu, Yi-Ying; Hsieh, Chin-Tung; Chiu, Ying-Ming; Chou, Shen-Chieh; Kao, Jung-Ta; Shieh, Dong-Chen; Lee, Yi-Ju</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e0208094</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis has been reported in some cancer cells, including AGS human gastric adenocarcinoma cells.  Reducing this resistance might shed light on the treatment of human gastric adenocarcinoma.  In this study, we examd. whether glycogen synthase kinase-3 (GSK-3) inhibitors can restore TRAIL responsiveness in gastric adenocarcinoma cells.  The effect of two GSK-3 inhibitors, SB-415286, and LiCl, on apoptosis signaling of TRAIL in human gastric adenocarcinoma cell lines and primary gastric epithelial cells was analyzed.  Both inhibitors can sensitize gastric adenocarcinoma cells, but not primary gastric epithelial cells, to TRAIL-induced apoptosis by increasing caspase-8 activity and its downstream signal transmission.  Adding p53 siRNA can downregulate GSK-3 inhibitor-related sensitization to TRAIL-induced apoptosis and caspase-3 activity.  GSK-3 inhibitors strongly activate the phosphorylation of JNK.  Inhibition of JNK leads to earlier and more intense apoptosis, showing that the activation of JNK may provide anti-apoptotic equil. of pro-apoptotic cells.  Our observations indicate that GSK-3 inhibitors can sentize AGS gastric adenocarcinoma cells to TRAIL-induced apoptosis.  Therefore, in certain types of gastric adenocarcinoma, GSK-3 inhibitor might enhance the antitumor activity of TRAIL and mightbe a promising candidate for the treatment of certain types of gastric adenocarcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovD_QbXs_X2LVg90H21EOLACvtfcHk0lgbWl2QA1P3Ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtlGhs7Y%253D&md5=f8f0f0720c678fd05a964752083dc44e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0208094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0208094%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.-Y.%26aulast%3DHsieh%26aufirst%3DC.-T.%26aulast%3DChiu%26aufirst%3DY.-M.%26aulast%3DChou%26aufirst%3DS.-C.%26aulast%3DKao%26aufirst%3DJ.-T.%26aulast%3DShieh%26aufirst%3DD.-C.%26aulast%3DLee%26aufirst%3DY.-J.%26atitle%3DGSK-3%2520inhibitors%2520enhance%2520TRAIL-mediated%2520apoptosis%2520in%2520human%2520gastric%2520adenocarcinoma%2520cells%26jtitle%3DPloS%2520One%26date%3D2018%26volume%3D13%26doi%3D10.1371%2Fjournal.pone.0208094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hur, E.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.-Q.</span></span> <span> </span><span class="NLM_article-title">GSK3 signaling in neural development</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">539</span>– <span class="NLM_lpage">551</span>, <span class="refDoi"> DOI: 10.1038/nrn2870</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1038%2Fnrn2870" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=20648061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptVGisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=539-551&author=E.-M.+Hurauthor=F.-Q.+Zhou&title=GSK3+signaling+in+neural+development&doi=10.1038%2Fnrn2870"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">GSK3 signaling in neural development</span></div><div class="casAuthors">Hur, Eun-Mi; Zhou, Feng-Quan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">539-551</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Recent evidence suggests that glycogen synthase kinase-3 (GSK3) proteins and their upstream and downstream regulators have key roles in many fundamental processes during neurodevelopment.  Disruption of GSK3 signaling adversely affects brain development and is assocd. with several neurodevelopmental disorders.  Here, the authors discuss the mechanisms by which GSK3 activity is regulated in the nervous system and provide an overview of the recent advances in the understanding of how GSK3 signaling controls neurogenesis, neuronal polarization, and axon growth during brain development.  These recent advances suggest that GSK3 is a crucial node that mediates various cellular processes that are controlled by multiple signaling mols., e.g., disrupted in schizophrenia 1 (DISC1), partitioning defective homolog 3 (PAR3), PAR6, and Wnt proteins, that regulate neurodevelopment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiOzmiQawg1rVg90H21EOLACvtfcHk0lgbWl2QA1P3Ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptVGisro%253D&md5=7ad4651b8fd5a97028df1a57be2c4b38</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnrn2870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn2870%26sid%3Dliteratum%253Aachs%26aulast%3DHur%26aufirst%3DE.-M.%26aulast%3DZhou%26aufirst%3DF.-Q.%26atitle%3DGSK3%2520signaling%2520in%2520neural%2520development%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2010%26volume%3D11%26spage%3D539%26epage%3D551%26doi%3D10.1038%2Fnrn2870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Medina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avila, J.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer’s disease</span>. <i>Curr. Pharmaceut. Des.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2790</span>– <span class="NLM_lpage">2798</span>, <span class="refDoi"> DOI: 10.2174/138161210793176581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.2174%2F138161210793176581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=20698823" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=2790-2798&author=M.+Medinaauthor=J.+Avila&title=Glycogen+synthase+kinase-3+%28GSK-3%29+inhibitors+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.2174%2F138161210793176581"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2174%2F138161210793176581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161210793176581%26sid%3Dliteratum%253Aachs%26aulast%3DMedina%26aufirst%3DM.%26aulast%3DAvila%26aufirst%3DJ.%26atitle%3DGlycogen%2520synthase%2520kinase-3%2520%2528GSK-3%2529%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DCurr.%2520Pharmaceut.%2520Des.%26date%3D2010%26volume%3D16%26spage%3D2790%26epage%3D2798%26doi%3D10.2174%2F138161210793176581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo Monte, F.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibitors of GSK-3: structural insights and their application to Alzheimer’s disease models</span>. <i>Int. J. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2012</i></span>,  <span class="NLM_fpage">381029</span>, <span class="refDoi"> DOI: 10.1155/2012/381029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1155%2F2012%2F381029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=22888461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A280%3ADC%252BC38fpvVKmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2012&publication_year=2012&pages=381029&author=T.+Kramerauthor=B.+Schmidtauthor=F.+Lo+Monte&title=Small-molecule+inhibitors+of+GSK-3%3A+structural+insights+and+their+application+to+Alzheimer%E2%80%99s+disease+models&doi=10.1155%2F2012%2F381029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease Models</span></div><div class="casAuthors">Kramer Thomas; Schmidt Boris; Lo Monte Fabio</div><div class="citationInfo"><span class="NLM_cas:title">International journal of Alzheimer's disease</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2012</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">381029</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The world health organization (WHO) estimated that 18 million people are struck by Alzheimer's disease (AD).  The USA, France, Germany, and other countries launched major programmes targeting the identification of risk factors, the improvement of caretaking, and fundamental research aiming to postpone the onset of AD.  The glycogen synthase kinase 3 (GSK-3) is implicated in multiple cellular processes and has been linked to the pathogenesis of several diseases including diabetes mellitus, cancer, and AD.  Inhibition of GSK-3 leads to neuroprotective effects, decreased β-amyloid production, and a reduction in tau hyperphosphorylation, which are all associated with AD.  Various classes of small molecule GSK-3 inhibitors have been published in patents and original publications.  Herein, we present a comprehensive summary of small molecules reported to interact with GSK-3.  We illustrate the interactions of the inhibitors with the active site.  Furthermore, we refer to the biological characterisation in terms of activity and selectivity for GSK-3, elucidate in vivo studies and pre-/clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRgN9KQeV4e1yA3UY9EwTNrfW6udTcc2ea2_o3PVLajVbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38fpvVKmug%253D%253D&md5=100844ec1c85bbf465eeecb27559066d</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1155%2F2012%2F381029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2012%252F381029%26sid%3Dliteratum%253Aachs%26aulast%3DKramer%26aufirst%3DT.%26aulast%3DSchmidt%26aufirst%3DB.%26aulast%3DLo%2BMonte%26aufirst%3DF.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520GSK-3%253A%2520structural%2520insights%2520and%2520their%2520application%2520to%2520Alzheimer%25E2%2580%2599s%2520disease%2520models%26jtitle%3DInt.%2520J.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2012%26volume%3D2012%26spage%3D381029%26doi%3D10.1155%2F2012%2F381029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Llorens-Martín, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurado, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avila, J.</span></span> <span> </span><span class="NLM_article-title">GSK-3beta, a pivotal kinase in Alzheimer disease</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">46</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2014.00046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.3389%2Ffnmol.2014.00046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=24904272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVaqs7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=46&author=M.+Llorens-Mart%C3%ADnauthor=J.+Juradoauthor=F.+Hern%C3%A1ndezauthor=J.+Avila&title=GSK-3beta%2C+a+pivotal+kinase+in+Alzheimer+disease&doi=10.3389%2Ffnmol.2014.00046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">GSK-3β, a pivotal kinase in Alzheimer disease</span></div><div class="casAuthors">Llorens-Martin, Maria; Jurado, Jeronimo; Hernandez, Felix; Avila, Jesus</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">00046</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Alzheimer disease (AD) is the most common form of age-related dementia.  The etiol. of AD is considered to be multifactorial as only a negligible percentage of cases have a familial or genetic origin.  Glycogen synthase kinase-3 (GSK-3) is regarded as a crit. mol. link between the two histopathol. hallmarks of the disease, namely senile plaques and neurofibrillary tangles.  In this review, we summarize current data regarding the involvement of this kinase in several aspects of AD development and progression, as well as key observations highlighting GSK-3 as one of the most relevant targets for AD treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-u6YWBRA8XLVg90H21EOLACvtfcHk0lhPb439h44H9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVaqs7fM&md5=7ea2969c4a89644aebb73701cf7b7d60</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2014.00046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2014.00046%26sid%3Dliteratum%253Aachs%26aulast%3DLlorens-Mart%25C3%25ADn%26aufirst%3DM.%26aulast%3DJurado%26aufirst%3DJ.%26aulast%3DHern%25C3%25A1ndez%26aufirst%3DF.%26aulast%3DAvila%26aufirst%3DJ.%26atitle%3DGSK-3beta%252C%2520a%2520pivotal%2520kinase%2520in%2520Alzheimer%2520disease%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2014%26volume%3D7%26spage%3D46%26doi%3D10.3389%2Ffnmol.2014.00046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MacAulay, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doble, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansotia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinclair, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drucker, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodgett, J. R.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism</span>. <i>Cell Metabol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2007.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1016%2Fj.cmet.2007.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=17908561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1Sjsr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=329-337&author=K.+MacAulayauthor=B.+W.+Dobleauthor=S.+Patelauthor=T.+Hansotiaauthor=E.+M.+Sinclairauthor=D.+J.+Druckerauthor=A.+Nagyauthor=J.+R.+Woodgett&title=Glycogen+synthase+kinase+3alpha-specific+regulation+of+murine+hepatic+glycogen+metabolism&doi=10.1016%2Fj.cmet.2007.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase 3α-specific regulation of murine hepatic glycogen metabolism</span></div><div class="casAuthors">MacAulay, Katrina; Doble, Bradley W.; Patel, Satish; Hansotia, Tanya; Sinclair, Elaine M.; Drucker, Daniel J.; Nagy, Andras; Woodgett, James R.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">329-337</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Glycogen synthase kinase 3 comprises two isoforms (GSK-3α and GSK-3β) that are implicated in type II diabetes, neurodegeneration, and cancer.  GSK-3 activity is elevated in human and rodent models of diabetes, and various GSK-3 inhibitors improve glucose tolerance and insulin sensitivity in rodent models of obesity and diabetes.  Here, we report the generation of mice lacking GSK-3α.  Unlike GSK-3β mutants, which die before birth, GSK-3α knockout (GSK-3α KO) animals are viable but display enhanced glucose and insulin sensitivity accompanied by reduced fat mass.  Fasted and glucose-stimulated hepatic glycogen content was enhanced in GSK-3α KO mice, whereas muscle glycogen was unaltered.  Insulin-stimulated protein kinase B (PKB/Akt) and GSK-3β phosphorylation was higher in GSK-3α KO livers compared to wild-type littermates, and IRS-1 expression was markedly increased.  We conclude that GSK-3 isoforms exhibit tissue-specific physiol. functions and that GSK-3α KO mice are insulin sensitive, reinforcing the potential of GSK-3 as a therapeutic target for type II diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAu8sNwPv527Vg90H21EOLACvtfcHk0lhPb439h44H9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1Sjsr3F&md5=43b2a915a2e2ca90cca6954ab7f5e2f4</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2007.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2007.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DMacAulay%26aufirst%3DK.%26aulast%3DDoble%26aufirst%3DB.%2BW.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DHansotia%26aufirst%3DT.%26aulast%3DSinclair%26aufirst%3DE.%2BM.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DNagy%26aufirst%3DA.%26aulast%3DWoodgett%26aufirst%3DJ.%2BR.%26atitle%3DGlycogen%2520synthase%2520kinase%25203alpha-specific%2520regulation%2520of%2520murine%2520hepatic%2520glycogen%2520metabolism%26jtitle%3DCell%2520Metabol.%26date%3D2007%26volume%3D6%26spage%3D329%26epage%3D337%26doi%3D10.1016%2Fj.cmet.2007.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hölscher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span> <span> </span><span class="NLM_article-title">GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease</span>. <i>Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1515/rns.2011.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1515%2Frns.2011.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC2cXms1Chtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=1-11&author=C.+Gaoauthor=C.+H%C3%B6lscherauthor=Y.+Liuauthor=L.+Li&title=GSK3%3A+a+key+target+for+the+development+of+novel+treatments+for+type+2+diabetes+mellitus+and+Alzheimer+disease&doi=10.1515%2Frns.2011.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease</span></div><div class="casAuthors">Gao, Chong; Hoelscher, Christian; Liu, Yueze; Li, Lin</div><div class="citationInfo"><span class="NLM_cas:title">Reviews in the Neurosciences (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-11</span>CODEN:
                <span class="NLM_cas:coden">RNEUEO</span>;
        ISSN:<span class="NLM_cas:issn">0334-1763</span>.
    
            (<span class="NLM_cas:orgname">Walter de Gruyter GmbH</span>)
        </div><div class="casAbstract">As a constitutively active kinase, glycogen synthase kinase 3 (GSK3) is a kinase which regulates body metab. by phosphorylation of glycogen synthase (GS) and other substrates.  Considerable evidence suggests that GSK3 is involved in the common pathol. underlying Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM).  The overexpression or overactivation of GSK3 could induce a series of pathol. changes, most of which are hallmarks of AD and T2DM.  Therefore, GSK3 could be a novel target to treat these two age-dependent diseases.  The inhibition of this kinase can prevent the aggregation of β-amyloid (Aβ) and hyperphosphorylation of tau protein.  GSK3 inhibition can also be a promising strategy to ameliorate neurodegenerative developments.  Its potential assocn. with memory formation has been shown in electrophysiol. and behavioral expts.  The neuroprotective effects of novel drugs developed to treat T2DM, glucagon-like peptide 1 (GLP-1) and its long-lasting analogs, have a possible link to GSK3 modification.  Recent investigations of the interaction between the phosphatidylinositol 3 kinase (PI3K) signaling pathway and the protective effect of novel GPL-1 receptor agonist geniposide on PC12 cells support this theory.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj-xIygR59CrVg90H21EOLACvtfcHk0liEeM5LDX_EkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXms1Chtrs%253D&md5=7cc38766de07ecbe784755569c712bd5</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1515%2Frns.2011.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252Frns.2011.061%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DC.%26aulast%3DH%25C3%25B6lscher%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%26atitle%3DGSK3%253A%2520a%2520key%2520target%2520for%2520the%2520development%2520of%2520novel%2520treatments%2520for%2520type%25202%2520diabetes%2520mellitus%2520and%2520Alzheimer%2520disease%26jtitle%3DRev.%2520Neurosci.%26date%3D2012%26volume%3D23%26spage%3D1%26epage%3D11%26doi%3D10.1515%2Frns.2011.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jope, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuskaitis, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beurel, E.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics</span>. <i>Neurochem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">595</span>, <span class="refDoi"> DOI: 10.1007/s11064-006-9128-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1007%2Fs11064-006-9128-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=16944320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtlynu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2007&pages=577-595&author=R.+S.+Jopeauthor=C.+J.+Yuskaitisauthor=E.+Beurel&title=Glycogen+synthase+kinase-3+%28GSK3%29%3A+inflammation%2C+diseases%2C+and+therapeutics&doi=10.1007%2Fs11064-006-9128-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen Synthase Kinase-3 (GSK3): Inflammation, Diseases, and Therapeutics</span></div><div class="casAuthors">Jope, Richard S.; Yuskaitis, Christopher J.; Beurel, Eleonore</div><div class="citationInfo"><span class="NLM_cas:title">Neurochemical Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4-5</span>),
    <span class="NLM_cas:pages">577-595</span>CODEN:
                <span class="NLM_cas:coden">NEREDZ</span>;
        ISSN:<span class="NLM_cas:issn">0364-3190</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Deciphering what governs inflammation and its effects on tissues is vital for understanding many pathologies.  The recent discovery that glycogen synthase kinase-3 (GSK3) promotes inflammation reveals a new component of its well-documented actions in several prevalent diseases which involve inflammation, including mood disorders, Alzheimer's disease, diabetes, and cancer.  Involvement in such disparate conditions stems from the widespread influences of GSK3 on many cellular functions, with this review focusing on its regulation of inflammatory processes.  GSK3 promotes the prodn. of inflammatory mols. and cell migration, which together make GSK3 a powerful regulator of inflammation, while GSK3 inhibition provides protection from inflammatory conditions in animal models.  The involvement of GSK3 and inflammation in these diseases are highlighted.  Thus, GSK3 may contribute not only to primary pathologies in these diseases, but also to the assocd. inflammation, suggesting that GSK3 inhibitors may have multiple effects influencing these conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_YzT_EaqXUbVg90H21EOLACvtfcHk0liEeM5LDX_EkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtlynu7w%253D&md5=c417ca3168b0b216eb1be89beffc3cef</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1007%2Fs11064-006-9128-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11064-006-9128-5%26sid%3Dliteratum%253Aachs%26aulast%3DJope%26aufirst%3DR.%2BS.%26aulast%3DYuskaitis%26aufirst%3DC.%2BJ.%26aulast%3DBeurel%26aufirst%3DE.%26atitle%3DGlycogen%2520synthase%2520kinase-3%2520%2528GSK3%2529%253A%2520inflammation%252C%2520diseases%252C%2520and%2520therapeutics%26jtitle%3DNeurochem.%2520Res.%26date%3D2007%26volume%3D32%26spage%3D577%26epage%3D595%26doi%3D10.1007%2Fs11064-006-9128-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osolodkin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palyulin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zefirov, N.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase 3 as an anticancer drug target: novel experimental findings and trends in the design of inhibitors</span>. <i>Curr. Pharmaceut. Des.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">665</span>, <span class="refDoi"> DOI: 10.2174/13816128130407</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.2174%2F1381612811306040665" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=665&author=D.+Osolodkinauthor=V.+Palyulinauthor=N.+Zefirov&title=Glycogen+synthase+kinase+3+as+an+anticancer+drug+target%3A+novel+experimental+findings+and+trends+in+the+design+of+inhibitors&doi=10.2174%2F13816128130407"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.2174%2F1381612811306040665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612811306040665%26sid%3Dliteratum%253Aachs%26aulast%3DOsolodkin%26aufirst%3DD.%26aulast%3DPalyulin%26aufirst%3DV.%26aulast%3DZefirov%26aufirst%3DN.%26atitle%3DGlycogen%2520synthase%2520kinase%25203%2520as%2520an%2520anticancer%2520drug%2520target%253A%2520novel%2520experimental%2520findings%2520and%2520trends%2520in%2520the%2520design%2520of%2520inhibitors%26jtitle%3DCurr.%2520Pharmaceut.%2520Des.%26date%3D2012%26volume%3D19%26spage%3D665%26doi%3D10.2174%2F13816128130407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Momcilovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishbein, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graeber, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parlati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walser, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gricowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibarra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phelps, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. John, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernthal, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubinett, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadeghi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christofk, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackelford, D. B.</span></span> <span> </span><span class="NLM_article-title">The GSK3 signaling axis regulates adaptive glutamine metabolism in lung squamous cell carcinoma</span>. <i>Canc. Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">905</span>– <span class="NLM_lpage">921</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2018.04.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1016%2Fj.ccell.2018.04.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=29763624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsFCnsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2018&pages=905-921&author=M.+Momcilovicauthor=S.+T.+Baileyauthor=J.+T.+Leeauthor=M.+C.+Fishbeinauthor=D.+Braasauthor=J.+Goauthor=T.+G.+Graeberauthor=F.+Parlatiauthor=S.+Demoauthor=R.+Liauthor=T.+C.+Walserauthor=M.+Gricowskiauthor=R.+Shumanauthor=J.+Ibarraauthor=D.+Fridmanauthor=M.+E.+Phelpsauthor=K.+Badranauthor=M.+St.+Johnauthor=N.+M.+Bernthalauthor=N.+Federmanauthor=J.+Yanagawaauthor=S.+M.+Dubinettauthor=S.+Sadeghiauthor=H.+R.+Christofkauthor=D.+B.+Shackelford&title=The+GSK3+signaling+axis+regulates+adaptive+glutamine+metabolism+in+lung+squamous+cell+carcinoma&doi=10.1016%2Fj.ccell.2018.04.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma</span></div><div class="casAuthors">Momcilovic, Milica; Bailey, Sean T.; Lee, Jason T.; Fishbein, Michael C.; Braas, Daniel; Go, James; Graeber, Thomas G.; Parlati, Francesco; Demo, Susan; Li, Rui; Walser, Tonya C.; Gricowski, Michael; Shuman, Robert; Ibarra, Julio; Fridman, Deborah; Phelps, Michael E.; Badran, Karam; St. John, Maie; Bernthal, Nicholas M.; Federman, Noah; Yanagawa, Jane; Dubinett, Steven M.; Sadeghi, Saman; Christofk, Heather R.; Shackelford, David B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">905-921.e5</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Altered metab. is a hallmark of cancer growth, forming the conceptual basis for development of metabolic therapies as cancer treatments.  We performed in vivo metabolic profiling and mol. anal. of lung squamous cell carcinoma (SCC) to identify metabolic nodes for therapeutic targeting.  Lung SCCs adapt to chronic mTOR inhibition and suppression of glycolysis through the GSK3α/β signaling pathway, which upregulates glutaminolysis.  Phospho-GSK3α/β protein levels are predictive of response to single-therapy mTOR inhibition while combinatorial treatment with the glutaminase inhibitor CB-839 effectively overcomes therapy resistance.  In addn., we identified a conserved metabolic signature in a broad spectrum of hypermetabolic human tumors that may be predictive of patient outcome and response to combined metabolic therapies targeting mTOR and glutaminase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX7uLIrnPF27Vg90H21EOLACvtfcHk0ljBRnMDgvoYRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsFCnsLY%253D&md5=4539f1b8727ec7d4d34332756c1ffca7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2018.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2018.04.002%26sid%3Dliteratum%253Aachs%26aulast%3DMomcilovic%26aufirst%3DM.%26aulast%3DBailey%26aufirst%3DS.%2BT.%26aulast%3DLee%26aufirst%3DJ.%2BT.%26aulast%3DFishbein%26aufirst%3DM.%2BC.%26aulast%3DBraas%26aufirst%3DD.%26aulast%3DGo%26aufirst%3DJ.%26aulast%3DGraeber%26aufirst%3DT.%2BG.%26aulast%3DParlati%26aufirst%3DF.%26aulast%3DDemo%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DWalser%26aufirst%3DT.%2BC.%26aulast%3DGricowski%26aufirst%3DM.%26aulast%3DShuman%26aufirst%3DR.%26aulast%3DIbarra%26aufirst%3DJ.%26aulast%3DFridman%26aufirst%3DD.%26aulast%3DPhelps%26aufirst%3DM.%2BE.%26aulast%3DBadran%26aufirst%3DK.%26aulast%3DSt.%2BJohn%26aufirst%3DM.%26aulast%3DBernthal%26aufirst%3DN.%2BM.%26aulast%3DFederman%26aufirst%3DN.%26aulast%3DYanagawa%26aufirst%3DJ.%26aulast%3DDubinett%26aufirst%3DS.%2BM.%26aulast%3DSadeghi%26aufirst%3DS.%26aulast%3DChristofk%26aufirst%3DH.%2BR.%26aulast%3DShackelford%26aufirst%3DD.%2BB.%26atitle%3DThe%2520GSK3%2520signaling%2520axis%2520regulates%2520adaptive%2520glutamine%2520metabolism%2520in%2520lung%2520squamous%2520cell%2520carcinoma%26jtitle%3DCanc.%2520Cell%26date%3D2018%26volume%3D33%26spage%3D905%26epage%3D921%26doi%3D10.1016%2Fj.ccell.2018.04.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sahin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eturi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Souza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pamarthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavora, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giles, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carneiro, B. A.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses</span>. <i>Canc. Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1047</span>– <span class="NLM_lpage">1056</span>, <span class="refDoi"> DOI: 10.1080/15384047.2019.1595283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1080%2F15384047.2019.1595283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=30975030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnt1Cls74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1047-1056&author=I.+Sahinauthor=A.+Eturiauthor=A.+De+Souzaauthor=S.+Pamarthyauthor=F.+Tavoraauthor=F.+J.+Gilesauthor=B.+A.+Carneiro&title=Glycogen+synthase+kinase-3+beta+inhibitors+as+novel+cancer+treatments+and+modulators+of+antitumor+immune+responses&doi=10.1080%2F15384047.2019.1595283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses</span></div><div class="casAuthors">Sahin, Ilyas; Eturi, Aditya; De Souza, Andre; Pamarthy, Sahithi; Tavora, Fabio; Giles, Francis J.; Carneiro, Benedito A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1047-1056</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1555-8576</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  As a kinase at the crossroads of numerous metabolic and cell growth signaling pathways, glycogen synthase kinase-3 beta (GSK-3β) is a highly desirable therapeutic target in cancer.  Despite its involvement in pathways assocd. with the pathogenesis of several malignancies, no selective GSK-3β inhibitor has been approved for the treatment of cancer.  The regulatory role of GSK-3β in apoptosis, cell cycle, DNA repair, tumor growth, invasion, and metastasis reflects the therapeutic relevance of this target and provides the rationale for drug combinations.  Emerging data on GSK-3β as a mediator of anticancer immune response also highlight the potential clin. applications of novel selective GSK-3β inhibitors that are entering clin. studies.  This manuscript reviews the preclin. and early clin. results with GSK-3β inhibitors and delineates the developmental therapeutics landscape for this potentially important target in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrksdIiVuC4KLVg90H21EOLACvtfcHk0ljBRnMDgvoYRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnt1Cls74%253D&md5=e23cc7a6b913c192bcbc6afebcdc1314</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1080%2F15384047.2019.1595283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384047.2019.1595283%26sid%3Dliteratum%253Aachs%26aulast%3DSahin%26aufirst%3DI.%26aulast%3DEturi%26aufirst%3DA.%26aulast%3DDe%2BSouza%26aufirst%3DA.%26aulast%3DPamarthy%26aufirst%3DS.%26aulast%3DTavora%26aufirst%3DF.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DCarneiro%26aufirst%3DB.%2BA.%26atitle%3DGlycogen%2520synthase%2520kinase-3%2520beta%2520inhibitors%2520as%2520novel%2520cancer%2520treatments%2520and%2520modulators%2520of%2520antitumor%2520immune%2520responses%26jtitle%3DCanc.%2520Biol.%2520Ther.%26date%3D2019%26volume%3D20%26spage%3D1047%26epage%3D1056%26doi%3D10.1080%2F15384047.2019.1595283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudd, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and its therapeutic implications</span>. <i>Semin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">101295</span>, <span class="refDoi"> DOI: 10.1016/j.smim.2019.101295</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1016%2Fj.smim.2019.101295" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=31604533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFCms7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2019&pages=101295&author=J.+Kruegerauthor=C.+E.+Ruddauthor=A.+Taylor&title=Glycogen+synthase+3+%28GSK-3%29+regulation+of+PD-1+expression+and+its+therapeutic+implications&doi=10.1016%2Fj.smim.2019.101295"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications</span></div><div class="casAuthors">Krueger, Janna; Rudd, Christopher E.; Taylor, Alison</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">101295</span>CODEN:
                <span class="NLM_cas:coden">SEIME2</span>;
        ISSN:<span class="NLM_cas:issn">1044-5323</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The past few years have witnessed exciting progress in the application of immune check-point blockade (ICB) for the treatment of various human cancers.  ICB was first used against cytotoxic T-lymphocyte-assocd. protein 4 (CTLA-4) to demonstrate durable anti-tumor responses followed by ICB against programmed cell death-1 (PD-1) or its ligand, PD-L1.  Present approaches involve the use of combinations of blocking antibodies against CTLA-4, PD-1 and other inhibitory receptors (IRs) such as TIM3, TIGIT and LAG3.  Despite this success, most patients are not cured by ICB therapy and there are limitations to the use of antibodies including cost, tumor penetration, the accessibility of receptors, and clearance from the cell surface as well as inflammatory and autoimmune complications.  Recently, we demonstrated that the down-regulation or inhibition of glycogen synthase kinase 3 (GSK-3) down-regulates PD-1 expression in infectious diseases and cancer (Taylor et al., 2016 Immunity 44, 274-86; 2018 Cancer Research 78, 706-717; Krueger and Rudd 2018 Immunity 46, 529-531).  In this Review, we outline the use of small mol. inhibitors (SMIs) that target intracellular pathways for co-receptor blockade in cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMPDRi02HZSLVg90H21EOLACvtfcHk0lh-4Br0GgjcoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFCms7bI&md5=cdf8db1fc481008c5a50f00fbf2e7578</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.smim.2019.101295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.smim.2019.101295%26sid%3Dliteratum%253Aachs%26aulast%3DKrueger%26aufirst%3DJ.%26aulast%3DRudd%26aufirst%3DC.%2BE.%26aulast%3DTaylor%26aufirst%3DA.%26atitle%3DGlycogen%2520synthase%25203%2520%2528GSK-3%2529%2520regulation%2520of%2520PD-1%2520expression%2520and%2520its%2520therapeutic%2520implications%26jtitle%3DSemin.%2520Immunol.%26date%3D2019%26volume%3D42%26spage%3D101295%26doi%3D10.1016%2Fj.smim.2019.101295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudd, C. E.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase 3 inactivation compensates for the lack of CD28 in the priming of CD8(+) cytotoxic T-Cells: implications for anti-PD-1 immunotherapy</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1653</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2017.01653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.3389%2Ffimmu.2017.01653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=29312284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFOgsrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1653&author=A.+Taylorauthor=C.+E.+Rudd&title=Glycogen+synthase+kinase+3+inactivation+compensates+for+the+lack+of+CD28+in+the+priming+of+CD8%28%2B%29+cytotoxic+T-Cells%3A+implications+for+anti-PD-1+immunotherapy&doi=10.3389%2Ffimmu.2017.01653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase 3 inactivation compensates for the lack of CD28 in the priming of CD8+ cytotoxic T-cells: implications for anti-PD-1 immunotherapy</span></div><div class="casAuthors">Taylor, Alison; Rudd, Christopher E.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1653/1-1653/9</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The rescue of exhausted CD8+ cytolytic T-cells (CTLs) by anti-Programmed Cell Death-1 (anti-PD-1) blockade has been found to require CD28 expression.  At the same time, we have shown that the inactivation of the serine/threonine kinase glycogen synthase kinase (GSK)-3α/β with small-interfering RNAs (siRNAs) and small mol. inhibitors (SMIs) specifically down-regulates PD-1 expression for enhanced CD8+ CTL function and clearance of tumors and viral infections.  Despite this, it has been unclear whether the GSK-3α/β pathway accounts for CD28 costimulation of CD8+ CTL function.  In this article, we show that inactivation of GSK-3α/β through siRNA or by SMIs during priming can substitute CD28 co-stimulation in the potentiation of cytotoxic CD8+ CTL function against the EL-4 lymphoma cells expressing OVA peptide.  The effect was seen using several structurally distinct GSK-3 SMIs and was accompanied by an increase in Lamp-1 and GZMB expression.  Conversely, CD28 crosslinking obviated the need for GSK-3α/β inhibition in its enhancement of CTL function.  Our findings support a model where GSK-3 is the central cosignal for CD28 priming of CD8+ CTLs in anti-PD-1 immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL4BaOmVL5gbVg90H21EOLACvtfcHk0lh-4Br0GgjcoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFOgsrrM&md5=d9f9ec8f4dd3ba2d11f170068d77f09b</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2017.01653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2017.01653%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DRudd%26aufirst%3DC.%2BE.%26atitle%3DGlycogen%2520synthase%2520kinase%25203%2520inactivation%2520compensates%2520for%2520the%2520lack%2520of%2520CD28%2520in%2520the%2520priming%2520of%2520CD8%2528%252B%2529%2520cytotoxic%2520T-Cells%253A%2520implications%2520for%2520anti-PD-1%2520immunotherapy%26jtitle%3DFront.%2520Immunol.%26date%3D2017%26volume%3D8%26spage%3D1653%26doi%3D10.3389%2Ffimmu.2017.01653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jellusova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cato, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apgar, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramezani-Rad, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conner, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benschop, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodgett, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rickert, R. C.</span></span> <span> </span><span class="NLM_article-title">GSK3 is a metabolic checkpoint regulator in B cells</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">303</span>, <span class="refDoi"> DOI: 10.1038/ni.3664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1038%2Fni.3664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=28114292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFeiur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=303&author=J.+Jellusovaauthor=M.+H.+Catoauthor=J.+R.+Apgarauthor=P.+Ramezani-Radauthor=C.+R.+Leungauthor=C.+Chenauthor=A.+D.+Richardsonauthor=E.+M.+Connerauthor=R.+J.+Benschopauthor=J.+R.+Woodgettauthor=R.+C.+Rickert&title=GSK3+is+a+metabolic+checkpoint+regulator+in+B+cells&doi=10.1038%2Fni.3664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Gsk3 is a metabolic checkpoint regulator in B cells</span></div><div class="casAuthors">Jellusova, Julia; Cato, Matthew H.; Apgar, John R.; Ramezani-Rad, Parham; Leung, Charlotte R.; Chen, Cindi; Richardson, Adam D.; Conner, Elaine M.; Benschop, Robert J.; Woodgett, James R.; Rickert, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">303-312</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">B cells predominate in a quiescent state until an antigen is encountered, which results in rapid growth, proliferation and differentiation of the B cells.  These distinct cell states are probably accompanied by differing metabolic needs, yet little is known about the metabolic control of B cell fate.  Here we show that glycogen synthase kinase 3 (Gsk3) is a metabolic sensor that promotes the survival of naive recirculating B cells by restricting cell mass accumulation.  In antigen-driven responses, Gsk3 was selectively required for regulation of B cell size, mitochondrial biogenesis, glycolysis and prodn. of reactive oxygen species (ROS), in a manner mediated by the co-stimulatory receptor CD40.  Gsk3 was required to prevent metabolic collapse and ROS-induced apoptosis after glucose became limiting, functioning in part by repressing growth dependent on the myelocytomatosis oncoprotein c-Myc.  Notably, we found that Gsk3 was required for the generation and maintenance of germinal center B cells, which require high glycolytic activity to support growth and proliferation in a hypoxic microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQVB5dTbAtxbVg90H21EOLACvtfcHk0lh-4Br0GgjcoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFeiur8%253D&md5=aee3859537ff7c5f59a78cc90ea29318</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fni.3664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.3664%26sid%3Dliteratum%253Aachs%26aulast%3DJellusova%26aufirst%3DJ.%26aulast%3DCato%26aufirst%3DM.%2BH.%26aulast%3DApgar%26aufirst%3DJ.%2BR.%26aulast%3DRamezani-Rad%26aufirst%3DP.%26aulast%3DLeung%26aufirst%3DC.%2BR.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DRichardson%26aufirst%3DA.%2BD.%26aulast%3DConner%26aufirst%3DE.%2BM.%26aulast%3DBenschop%26aufirst%3DR.%2BJ.%26aulast%3DWoodgett%26aufirst%3DJ.%2BR.%26aulast%3DRickert%26aufirst%3DR.%2BC.%26atitle%3DGSK3%2520is%2520a%2520metabolic%2520checkpoint%2520regulator%2520in%2520B%2520cells%26jtitle%3DNat.%2520Immunol.%26date%3D2017%26volume%3D18%26spage%3D303%26doi%3D10.1038%2Fni.3664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakesh, K. P.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3beta inhibitors: A critical review</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">448</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.12.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1016%2Fj.ejmech.2018.12.073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=30616053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvVGgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2019&pages=448-470&author=M.+Xuauthor=S.+L.+Wangauthor=L.+Zhuauthor=P.+Y.+Wuauthor=W.+B.+Daiauthor=K.+P.+Rakesh&title=Structure-activity+relationship+%28SAR%29+studies+of+synthetic+glycogen+synthase+kinase-3beta+inhibitors%3A+A+critical+review&doi=10.1016%2Fj.ejmech.2018.12.073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3β inhibitors: A critical review</span></div><div class="casAuthors">Xu, M.; Wang, S. L.; Zhu, L.; Wu, P. Y.; Dai, W. B.; Rakesh, K. P.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">448-470</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Glycogen Synthase Kinase-3 (GSK-3) is a constitutively dynamic, omnipresent serine/threonine protein kinase regularly called as a "multi-tasking kinase" due to its pliable function in diverse signaling pathways.  It exists in two isoforms i.e., GSK-3α and GSK-3β.  Inhibition of GSK-3 may be useful in curing various diseases such as Alzheimer's disease, type II diabetes, mood disorders, cancers, chronic inflammatory agents, stroke, bipolar disorders and so on, but the approach poses significant challenges.  Lithium was the first GSK-3β inhibitor to be used for therapeutic outcome and has been effectively used for many years.  In recent years, a large no. of structurally diverse potent GSK-3β inhibitors are reported.  The present review focuses on the recent developments in the area of medicinal chem. to explore the diverse chem. structures of potent GSK-3β inhibitors and also describes its structure-activity relationships (SAR) and mol. binding interactions of favorable applicability in various diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp72bJHjANYA7Vg90H21EOLACvtfcHk0ljGN0_XI-HsAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvVGgug%253D%253D&md5=3ee6633bf8aea71b4eec73979f2f39c9</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.12.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.12.073%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DS.%2BL.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DP.%2BY.%26aulast%3DDai%26aufirst%3DW.%2BB.%26aulast%3DRakesh%26aufirst%3DK.%2BP.%26atitle%3DStructure-activity%2520relationship%2520%2528SAR%2529%2520studies%2520of%2520synthetic%2520glycogen%2520synthase%2520kinase-3beta%2520inhibitors%253A%2520A%2520critical%2520review%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D164%26spage%3D448%26epage%3D470%26doi%3D10.1016%2Fj.ejmech.2018.12.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, F. J.</span></span> <span> </span><span class="NLM_article-title">First non-ATP competitive glycogen synthase kinase 3β (GSK-3β) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of alzheimer’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1292</span>– <span class="NLM_lpage">1299</span>, <span class="refDoi"> DOI: 10.1021/jm011020u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm011020u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtFCgu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=1292-1299&author=A.+Martinezauthor=M.+Alonsoauthor=A.+Castroauthor=C.+P%C3%A9rezauthor=F.+J.+Moreno&title=First+non-ATP+competitive+glycogen+synthase+kinase+3%CE%B2+%28GSK-3%CE%B2%29+inhibitors%3A+thiadiazolidinones+%28TDZD%29+as+potential+drugs+for+the+treatment+of+alzheimer%E2%80%99s+disease&doi=10.1021%2Fjm011020u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">First Non-ATP Competitive Glycogen Synthase Kinase 3β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease</span></div><div class="casAuthors">Martinez, Ana; Alonso, Mercedes; Castro, Ana; Perez, Concepcion; Moreno, Francisco J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1292-1299</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glycogen synthase kinase 3β (GSK-3β) has a central role in Alzheimer's disease (AD).  Selective inhibitors which avoid τ hyperphosphorylation may represent an effective therapeutic approach to the pharmacotherapy of AD and other neurodegenerative disorders.  The synthesis, biol. evaluation, and SAR of some thiadiazolidinones (TDZD) as the first non-ATP competitive inhibitor of GSK-3β.  Their synthesis is based on the reactivity of sulfenyl chlorides.  In GSK-3β assays, TDZD derivs. showed IC50 values in the micromolar range, whereas in other protein kinase assays they were devoid of any inhibitory activity.  SAR studies allowed the identification of the key structural features.  Finally, a possible enzymic binding mode is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofQZkRe2BHh7Vg90H21EOLACvtfcHk0ljGN0_XI-HsAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtFCgu70%253D&md5=a364133d1035bee183c58ad30ac140f8</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm011020u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm011020u%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DAlonso%26aufirst%3DM.%26aulast%3DCastro%26aufirst%3DA.%26aulast%3DP%25C3%25A9rez%26aufirst%3DC.%26aulast%3DMoreno%26aufirst%3DF.%2BJ.%26atitle%3DFirst%2520non-ATP%2520competitive%2520glycogen%2520synthase%2520kinase%25203%25CE%25B2%2520%2528GSK-3%25CE%25B2%2529%2520inhibitors%253A%2520thiadiazolidinones%2520%2528TDZD%2529%2520as%2520potential%2520drugs%2520for%2520the%2520treatment%2520of%2520alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D1292%26epage%3D1299%26doi%3D10.1021%2Fjm011020u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conde, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, F. J.</span></span> <span> </span><span class="NLM_article-title">Thienyl and phenyl α-halomethyl ketones: new inhibitors of glycogen synthase kinase (GSK-3β) from a library of compounds searching</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">4631</span>– <span class="NLM_lpage">4633</span>, <span class="refDoi"> DOI: 10.1021/jm034108b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm034108b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BD3sXntlyqtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=4631-4633&author=S.+Condeauthor=D.+I.+P%C3%A9rezauthor=A.+Mart%C3%ADnezauthor=C.+Perezauthor=F.+J.+Moreno&title=Thienyl+and+phenyl+%CE%B1-halomethyl+ketones%3A+new+inhibitors+of+glycogen+synthase+kinase+%28GSK-3%CE%B2%29+from+a+library+of+compounds+searching&doi=10.1021%2Fjm034108b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Thienyl and Phenyl α-Halomethyl Ketones: New Inhibitors of Glycogen Synthase Kinase (GSK-3β) from a Library of Compound Searching</span></div><div class="casAuthors">Conde, Santiago; Perez, Daniel I.; Martinez, Ana; Perez, Concepcion; Moreno, Francisco J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4631-4633</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glycogen synthase kinase (GSK-3β) plays a crucial role in Alzheimer's disease (AD).  Its inhibition is a valid approach to the treatment of AD.  In this initial letter, some thienyl and Ph α-halomethyl ketones are described as new non-ATP competitive inhibitors of GSK-3β.  They are considered as lead compds. for designing and synthesizing new series, to carry out SAR studies, clear up the mechanism of action, and, in general, evaluate their therapeutical usefulness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiiPuuJrm3WbVg90H21EOLACvtfcHk0lje_MoDABHdeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXntlyqtbc%253D&md5=0e54107efbdf7e644679ad55beba574c</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm034108b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm034108b%26sid%3Dliteratum%253Aachs%26aulast%3DConde%26aufirst%3DS.%26aulast%3DP%25C3%25A9rez%26aufirst%3DD.%2BI.%26aulast%3DMart%25C3%25ADnez%26aufirst%3DA.%26aulast%3DPerez%26aufirst%3DC.%26aulast%3DMoreno%26aufirst%3DF.%2BJ.%26atitle%3DThienyl%2520and%2520phenyl%2520%25CE%25B1-halomethyl%2520ketones%253A%2520new%2520inhibitors%2520of%2520glycogen%2520synthase%2520kinase%2520%2528GSK-3%25CE%25B2%2529%2520from%2520a%2520library%2520of%2520compounds%2520searching%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D4631%26epage%3D4633%26doi%3D10.1021%2Fjm034108b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perez, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conde, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wandosell, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelpí, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luque, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez, A.</span></span> <span> </span><span class="NLM_article-title">irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">6914</span>– <span class="NLM_lpage">6925</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2009.08.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1016%2Fj.bmc.2009.08.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=19747834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFamsbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=6914-6925&author=D.+I.+Perezauthor=S.+Condeauthor=C.+P%C3%A9rezauthor=C.+Gilauthor=D.+Simonauthor=F.+Wandosellauthor=F.+J.+Morenoauthor=J.+L.+Gelp%C3%ADauthor=F.+J.+Luqueauthor=A.+Mart%C3%ADnez&title=irreversible+glycogen+synthase+kinase+3+inhibitors+as+useful+pharmacological+tools&doi=10.1016%2Fj.bmc.2009.08.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools</span></div><div class="casAuthors">Perez, Daniel I.; Conde, Santiago; Perez, Concepcion; Gil, Carmen; Simon, Diana; Wandosell, Francisco; Moreno, Francisco J.; Gelpi, Jose L.; Luque, Francisco J.; Martinez, Ana</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6914-6925</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Thienylhalomethylketones, whose chem., biol., and pharmaceutical data are here reported, are the first irreversible inhibitors of GSK-3β described to date.  Their inhibitory activity is likely related to the cysteine residue present in the ATP-binding site, which is proposed as a relevant residue for modulation of GSK-3 activity.  The good cell permeability of the compds. allows them to be used in different cell models.  Overall, the results presented here support the potential use of halomethylketones as pharmacol. tools for the study of GSK-3β functions and suggest a new mechanism for GSK-3β inhibition that may be considered for further drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVCmgufk4pSrVg90H21EOLACvtfcHk0lje_MoDABHdeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFamsbvF&md5=bc84d34e0bec0bd9f0c87376ab2b4b3c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2009.08.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2009.08.042%26sid%3Dliteratum%253Aachs%26aulast%3DPerez%26aufirst%3DD.%2BI.%26aulast%3DConde%26aufirst%3DS.%26aulast%3DP%25C3%25A9rez%26aufirst%3DC.%26aulast%3DGil%26aufirst%3DC.%26aulast%3DSimon%26aufirst%3DD.%26aulast%3DWandosell%26aufirst%3DF.%26aulast%3DMoreno%26aufirst%3DF.%2BJ.%26aulast%3DGelp%25C3%25AD%26aufirst%3DJ.%2BL.%26aulast%3DLuque%26aufirst%3DF.%2BJ.%26aulast%3DMart%25C3%25ADnez%26aufirst%3DA.%26atitle%3Dirreversible%2520glycogen%2520synthase%2520kinase%25203%2520inhibitors%2520as%2520useful%2520pharmacological%2520tools%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D6914%26epage%3D6925%26doi%3D10.1016%2Fj.bmc.2009.08.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">del
Ser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinwachs, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gertz, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andres, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Carrillo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vericat, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redondo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leon, T.</span></span> <span> </span><span class="NLM_article-title">Treatment of Alzheimer’s disease with the GSK-3 inhibitor tideglusib: a pilot study</span>. <i>J. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">215</span>, <span class="refDoi"> DOI: 10.3233/JAD-2012-120805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.3233%2FJAD-2012-120805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=22936007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslGrurjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=205-215&author=T.+del%0ASerauthor=K.+C.+Steinwachsauthor=H.+J.+Gertzauthor=M.+V.+Andresauthor=B.+Gomez-Carrilloauthor=M.+Medinaauthor=J.+A.+Vericatauthor=P.+Redondoauthor=D.+Fleetauthor=T.+Leon&title=Treatment+of+Alzheimer%E2%80%99s+disease+with+the+GSK-3+inhibitor+tideglusib%3A+a+pilot+study&doi=10.3233%2FJAD-2012-120805"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of Alzheimer's Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study</span></div><div class="casAuthors">del Ser, Teodoro; Steinwachs, Klaus C.; Gertz, Hermann J.; Andres, Maria V.; Gomez-Carrillo, Belen; Medina, Miguel; Vericat, Joan A.; Redondo, Pilar; Fleet, David; Leon, Teresa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">205-215</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">This pilot, double-blind, placebo-controlled, randomized, escalating dose trial explored the safety and efficacy of tideglusib, an inhibitor of glycogen synthase kinase-3, in Alzheimer's disease (AD) patients.  Thirty mild-moderate AD patients on cholinesterase inhibitor treatment were administered escalating doses (400, 600, 800, 1,000 mg) of tideglusib or placebo (ratio 2 : 1) for 4, 4, 6, and 6 wk, resp.  The primary objective was to evaluate the safety and tolerability of tideglusib with strict criteria for drug escalation or withdrawal.  Mini-Mental Status Examn. (MMSE), Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog+), word fluency, Geriatric Depression Scale (GDS), and a final Global Clin. Assessment (GCA) were assessed as secondary objectives.  Treatment was well tolerated.  Adverse events were as frequent in active and placebo groups, except for some moderate, asymptomatic, and fully reversible increases (>2.5 × ULN) of serum transaminases in 6 active cases (p = 0.001).  Tideglusib produced pos. trends in MMSE, ADAS-cog, GDS, and GCA without statistical significance in this small sample.  Responders in MMSE were significantly higher in the active group (p = 0.05).  Patients escalated up to 1000 mg/day had a benefit of 1.68 points in the MMSE and 4.72 points in the ADAS-cog+ when compared to placebo.  This small pilot study provides valuable safety and efficacy ests. for the treatment of AD patients with tideglusib, currently being confirmed in a larger clin. trial.  Due to escalating doses and the small sample size, this trial provides insufficient evidence to support or reject a benefit of tideglusib in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrETLaPrOao1rVg90H21EOLACvtfcHk0lhNTPipoU17tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslGrurjE&md5=7a75de640f08ff234d4e3f50838c4967</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.3233%2FJAD-2012-120805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-2012-120805%26sid%3Dliteratum%253Aachs%26aulast%3Ddel%2BSer%26aufirst%3DT.%26aulast%3DSteinwachs%26aufirst%3DK.%2BC.%26aulast%3DGertz%26aufirst%3DH.%2BJ.%26aulast%3DAndres%26aufirst%3DM.%2BV.%26aulast%3DGomez-Carrillo%26aufirst%3DB.%26aulast%3DMedina%26aufirst%3DM.%26aulast%3DVericat%26aufirst%3DJ.%2BA.%26aulast%3DRedondo%26aufirst%3DP.%26aulast%3DFleet%26aufirst%3DD.%26aulast%3DLeon%26aufirst%3DT.%26atitle%3DTreatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%2520with%2520the%2520GSK-3%2520inhibitor%2520tideglusib%253A%2520a%2520pilot%2520study%26jtitle%3DJ.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2013%26volume%3D33%26spage%3D205%26epage%3D215%26doi%3D10.3233%2FJAD-2012-120805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tolosa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litvan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Höglinger, G. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrés, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gómez-Carrillo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">León, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Ser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Investigators, T.</span></span> <span> </span><span class="NLM_article-title">A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy</span>. <i>Mov. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">470</span>– <span class="NLM_lpage">478</span>, <span class="refDoi"> DOI: 10.1002/mds.25824</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1002%2Fmds.25824" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=24532007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvFSmtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2014&pages=470-478&author=E.+Tolosaauthor=I.+Litvanauthor=G.+U.+H%C3%B6glingerauthor=D.+Burnauthor=A.+Leesauthor=M.+V.+Andr%C3%A9sauthor=B.+G%C3%B3mez-Carrilloauthor=T.+Le%C3%B3nauthor=T.+Del+Serauthor=T.+Investigators&title=A+phase+2+trial+of+the+GSK-3+inhibitor+tideglusib+in+progressive+supranuclear+palsy&doi=10.1002%2Fmds.25824"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy</span></div><div class="casAuthors">Tolosa, Eduardo; Litvan, Irene; Hoeglinger, Guenter U.; Burn, David; Lees, Andrew; Andres, Maria V.; Gomez-Carrillo, Belen; Leon, Teresa; del Ser, Teodoro</div><div class="citationInfo"><span class="NLM_cas:title">Movement Disorders</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">470-478</span>CODEN:
                <span class="NLM_cas:coden">MOVDEA</span>;
        ISSN:<span class="NLM_cas:issn">0885-3185</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">It is believed that glycogen synthase kinase-3 (GSK-3) hyperphosphorylates tau protein in progressive supranuclear palsy (PSP).  The Tau Restoration on PSP (TAUROS) study was a double-blind, placebo-controlled, randomized trial to assess the efficacy, safety, and tolerability of tideglusib, a GSK-3 inhibitor, as potential treatment for PSP.  The study enrolled 146 PSP patients with mild-to-moderate disease who were randomized to receive once-daily 600 mg tideglusib, 800 mg tideglusib, or placebo (ratio, 2:2:1) administered orally over 52 wk.  The primary endpoint was the change from baseline to week 52 on the PSP rating scale.  Secondary endpoints were safety and tolerability of tideglusib, changes in motor function (the Timed Up and Go Test), cognition (Dementia Rating Scale-2, Frontal Assessment Battery, verbal fluency), apathy (Starkstein scale), activities of daily living (Schwab and England scale; Unified Parkinson's Disease Rating Scale, part II), quality of life (EuroQol), and Global Clin. Assessment.  Brain atrophy on magnetic resonance imaging and several biomarkers in plasma and cerebrospinal fluid also were examd.  No significant differences were detected in the primary or secondary endpoints at week 52 between placebo and either dose of tideglusib.  Tideglusib was safe, with the exception of some asymptomatic, transient, and reversible transaminase elevations (mainly alanine aminotransferase) in 9% of patients, and diarrhea in 13% of patients.  Tideglusib was generally well tolerated but it did not show clin. efficacy in patients with mild-to-moderate PSP. © 2014 International Parkinson and Movement Disorder Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgJLeCmPA9ULVg90H21EOLACvtfcHk0lhNTPipoU17tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvFSmtL8%253D&md5=4b7899d99427a60b8edae580355a740d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fmds.25824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.25824%26sid%3Dliteratum%253Aachs%26aulast%3DTolosa%26aufirst%3DE.%26aulast%3DLitvan%26aufirst%3DI.%26aulast%3DH%25C3%25B6glinger%26aufirst%3DG.%2BU.%26aulast%3DBurn%26aufirst%3DD.%26aulast%3DLees%26aufirst%3DA.%26aulast%3DAndr%25C3%25A9s%26aufirst%3DM.%2BV.%26aulast%3DG%25C3%25B3mez-Carrillo%26aufirst%3DB.%26aulast%3DLe%25C3%25B3n%26aufirst%3DT.%26aulast%3DDel%2BSer%26aufirst%3DT.%26aulast%3DInvestigators%26aufirst%3DT.%26atitle%3DA%2520phase%25202%2520trial%2520of%2520the%2520GSK-3%2520inhibitor%2520tideglusib%2520in%2520progressive%2520supranuclear%2520palsy%26jtitle%3DMov.%2520Disord.%26date%3D2014%26volume%3D29%26spage%3D470%26epage%3D478%26doi%3D10.1002%2Fmds.25824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovestone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hüll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinne, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huppertz, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrés, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gómez-Carrillo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">León, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">del Ser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">investigators, A.</span></span> <span> </span><span class="NLM_article-title">A phase II trial of tideglusib in Alzheimer’s disease</span>. <i>J. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.3233/jad-141959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.3233%2FJAD-141959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=25537011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjslOltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2015&pages=75-88&author=S.+Lovestoneauthor=M.+Boadaauthor=B.+Duboisauthor=M.+H%C3%BCllauthor=J.+O.+Rinneauthor=H.-J.+Huppertzauthor=M.+Caleroauthor=M.+V.+Andr%C3%A9sauthor=B.+G%C3%B3mez-Carrilloauthor=T.+Le%C3%B3nauthor=T.+del+Serauthor=A.+investigators&title=A+phase+II+trial+of+tideglusib+in+Alzheimer%E2%80%99s+disease&doi=10.3233%2Fjad-141959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase II Trial of Tideglusib in Alzheimer's Disease</span></div><div class="casAuthors">Lovestone, Simon; Boada, Merce; Dubois, Bruno; Huell, Michael; Rinne, Juha O.; Huppertz, Hans-Juergen; Calero, Miguel; Andres, Maria V.; Gomez-Carrillo, Belen; Leon, Teresa; del Ser, Teodoro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-88</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">Background: The ARGO study was a phase II, double-blind, placebo controlled, four parallel arm trial of tideglusib in Alzheimer's disease (AD).  Objective: To prove the clin. efficacy of an inhibitor of glycogen synthase kinase-3 (GSK-3), in AD.  Methods: Mild to moderate (Mini-Mental State Examn. (MMSE) score, 14-26) AD patients on cholinesterase inhibitor and/or memantine treatment were administered tideglusib or placebo for 26 wk.  The ADAS-cog15 was the primary efficacy measure; function, cognition, behavior, and quality of life were assessed as secondary measures; cerebral atrophy in MRI and the levels of tau, amyloid-β, and BACE1 in cerebrospinal fluid (CSF) were exploratory endpoints.  Results: 306 AD patients were randomized to active (1000 mg QD: n = 86, 1000 mg QOD: n = 90, and 500 mg QD: n = 50) or placebo (n = 85) in 55 sites in four European countries.  There were no statistically significant differences between either active and placebo arms in the efficacy variables.  However, BACE1 in CSF significantly decreased with treatment in a small subgroup of patients.  Participants with mild AD in the 500 mg QD group showed significant responses on ADAS-cog15, MMSE, and word fluency.  Diarrhea (14-18% in active, 11% placebo) and dose-dependent, mild to moderate, and fully reversible transaminase increase (9-16% in active, 3.5% placebo) were the most frequent adverse events.  Conclusions: Short term (26 wk) tideglusib was acceptably safe but produced no clin. benefit in this trial.  However, given the non-linear dose response, esp. in mildly affected patients, further dose finding studies in early disease stages and for longer duration are warranted to examine GSK-3 inhibition in AD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGru-ZlfznWkUbVg90H21EOLACvtfcHk0lgReA-bG3wsOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjslOltb8%253D&md5=7a342ad28ad2cfbbc3dc768849fb73ef</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.3233%2FJAD-141959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-141959%26sid%3Dliteratum%253Aachs%26aulast%3DLovestone%26aufirst%3DS.%26aulast%3DBoada%26aufirst%3DM.%26aulast%3DDubois%26aufirst%3DB.%26aulast%3DH%25C3%25BCll%26aufirst%3DM.%26aulast%3DRinne%26aufirst%3DJ.%2BO.%26aulast%3DHuppertz%26aufirst%3DH.-J.%26aulast%3DCalero%26aufirst%3DM.%26aulast%3DAndr%25C3%25A9s%26aufirst%3DM.%2BV.%26aulast%3DG%25C3%25B3mez-Carrillo%26aufirst%3DB.%26aulast%3DLe%25C3%25B3n%26aufirst%3DT.%26aulast%3Ddel%2BSer%26aufirst%3DT.%26aulast%3Dinvestigators%26aufirst%3DA.%26atitle%3DA%2520phase%2520II%2520trial%2520of%2520tideglusib%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2015%26volume%3D45%26spage%3D75%26epage%3D88%26doi%3D10.3233%2Fjad-141959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, Y.</span></span> <span> </span><span class="NLM_article-title">An efficient one-pot procedure for the synthesis of 1,5-benzothiazepinones catalyzed by tetrabutylammonium fluoride (TBAF)</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3743</span>– <span class="NLM_lpage">3745</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2016.07.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1016%2Fj.tetlet.2016.07.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Shs73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2016&pages=3743-3745&author=P.+Zhangauthor=D.+Yeauthor=Y.+Chu&title=An+efficient+one-pot+procedure+for+the+synthesis+of+1%2C5-benzothiazepinones+catalyzed+by+tetrabutylammonium+fluoride+%28TBAF%29&doi=10.1016%2Fj.tetlet.2016.07.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">An efficient one-pot procedure for the synthesis of 1,5-benzothiazepinones catalyzed by tetrabutylammonium fluoride (TBAF)</span></div><div class="casAuthors">Zhang, Peng; Ye, Deyong; Chu, Yong</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">3743-3745</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A practical and efficient method for the prepn. of 1,5-benzothiazepinones I (R = H, Me, 2-thienyl, Ph, 4-BrC6H4, etc.) in good yields has been developed from o-aminothiophenol and the corresponding α,β-unsatd. carboxylic acids RCH:CHCO2H using tetrabutylammonium fluoride (TBAF) as a catalyst.  This study not only expands the previous work on the substrate scope but also provides more understanding of the chem. of such drug scaffolds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplZl4XgkBZWrVg90H21EOLACvtfcHk0lgReA-bG3wsOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Shs73P&md5=c9bac27bcd201e63067f2bb366090bb0</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2016.07.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2016.07.012%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DYe%26aufirst%3DD.%26aulast%3DChu%26aufirst%3DY.%26atitle%3DAn%2520efficient%2520one-pot%2520procedure%2520for%2520the%2520synthesis%2520of%25201%252C5-benzothiazepinones%2520catalyzed%2520by%2520tetrabutylammonium%2520fluoride%2520%2528TBAF%2529%26jtitle%3DTetrahedron%2520Lett.%26date%3D2016%26volume%3D57%26spage%3D3743%26epage%3D3745%26doi%3D10.1016%2Fj.tetlet.2016.07.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molnár, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szendrei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keserü, G. M.</span></span> <span> </span><span class="NLM_article-title">A high throughput luminescent assay for glycogen synthase kinase-3beta inhibitors</span>. <i>Assay Drug Dev. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1089/adt.2006.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1089%2Fadt.2006.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=17355201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BD2sXislCktbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2007&pages=75-84&author=A.+Bakiauthor=A.+Bielikauthor=L.+Moln%C3%A1rauthor=G.+Szendreiauthor=G.+M.+Keser%C3%BC&title=A+high+throughput+luminescent+assay+for+glycogen+synthase+kinase-3beta+inhibitors&doi=10.1089%2Fadt.2006.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A High Throughput Luminescent Assay for Glycogen Synthase Kinase-3β Inhibitors</span></div><div class="casAuthors">Baki, Andrea; Bielik, Attila; Molnar, Laszlo; Szendrei, Gyoergyi; Keserue, Gyoergy M.</div><div class="citationInfo"><span class="NLM_cas:title">Assay and Drug Development Technologies</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-84</span>CODEN:
                <span class="NLM_cas:coden">ADDTAR</span>;
        ISSN:<span class="NLM_cas:issn">1540-658X</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">A high throughput luminescent assay based on the Kinase-Glo system (Promega, Madison, WI) has been developed for screening against glycogen synthase kinase-3β (GSK-3β).  Careful optimization of assay parameters allowed us to develop a robust, reproducible, and sensitive assay.  Its usefulness has been demonstrated in a high throughput screening run when screening 55,000 compds.  This campaign yielded five chem. classes of hits, including several highly potent GSK-3β inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYXSuULTtzHLVg90H21EOLACvtfcHk0lgReA-bG3wsOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXislCktbg%253D&md5=d9e594ab3d34af353b12b53eb41e43cb</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1089%2Fadt.2006.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fadt.2006.029%26sid%3Dliteratum%253Aachs%26aulast%3DBaki%26aufirst%3DA.%26aulast%3DBielik%26aufirst%3DA.%26aulast%3DMoln%25C3%25A1r%26aufirst%3DL.%26aulast%3DSzendrei%26aufirst%3DG.%26aulast%3DKeser%25C3%25BC%26aufirst%3DG.%2BM.%26atitle%3DA%2520high%2520throughput%2520luminescent%2520assay%2520for%2520glycogen%2520synthase%2520kinase-3beta%2520inhibitors%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2007%26volume%3D5%26spage%3D75%26epage%3D84%26doi%3D10.1089%2Fadt.2006.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piloto, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somervaille, T. C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleary, M. L.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase 3 in MLL leukemia maintenance and targeted therapy</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>455</i></span>,  <span class="NLM_fpage">1205</span>– <span class="NLM_lpage">1209</span>, <span class="refDoi"> DOI: 10.1038/nature07284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1038%2Fnature07284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=18806775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlSku7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=1205-1209&author=Z.+Wangauthor=K.+S.+Smithauthor=M.+Murphyauthor=O.+Pilotoauthor=T.+C.+P.+Somervailleauthor=M.+L.+Cleary&title=Glycogen+synthase+kinase+3+in+MLL+leukemia+maintenance+and+targeted+therapy&doi=10.1038%2Fnature07284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase 3 in MLL leukemia maintenance and targeted therapy</span></div><div class="casAuthors">Wang, Zhong; Smith, Kevin S.; Murphy, Mark; Piloto, Obdulio; Somervaille, Tim C. P.; Cleary, Michael L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">7217</span>),
    <span class="NLM_cas:pages">1205-1209</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Glycogen synthase kinase 3 (GSK3) is a multifunctional serine/threonine kinase that participates in numerous signalling pathways involved in diverse physiol. processes.  Several of these pathways are implicated in disease pathogenesis, which has prompted efforts to develop GSK3-specific inhibitors for therapeutic applications.  However, before now, there has been no strong rationale for targeting GSK3 in malignancies.  Here we report pharmacol., physiol. and genetic studies that demonstrate an oncogenic requirement for GSK3 in the maintenance of a specific subtype of poor prognosis human leukemia, genetically defined by mutations of the MLL proto-oncogene.  In contrast to its previously characterized roles in suppression of neoplasia-assocd. signalling pathways, GSK3 paradoxically supports MLL leukemia cell proliferation and transformation by a mechanism that ultimately involves destabilization of the cyclin-dependent kinase inhibitor p27Kip1.  Inhibition of GSK3 in a preclin. murine model of MLL leukemia provides promising evidence of efficacy and earmarks GSK3 as a candidate cancer drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-n74Rwvs6drVg90H21EOLACvtfcHk0lgReA-bG3wsOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlSku7bK&md5=fdda58e7cb5c987be7c0a2fe52877c67</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fnature07284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07284%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSmith%26aufirst%3DK.%2BS.%26aulast%3DMurphy%26aufirst%3DM.%26aulast%3DPiloto%26aufirst%3DO.%26aulast%3DSomervaille%26aufirst%3DT.%2BC.%2BP.%26aulast%3DCleary%26aufirst%3DM.%2BL.%26atitle%3DGlycogen%2520synthase%2520kinase%25203%2520in%2520MLL%2520leukemia%2520maintenance%2520and%2520targeted%2520therapy%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D1205%26epage%3D1209%26doi%3D10.1038%2Fnature07284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindeman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symonds, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolnikov, A.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3beta inhibition preserves hematopoietic stem cell activity and inhibits leukemic cell growth</span>. <i>Stem Cell.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1288</span>– <span class="NLM_lpage">1297</span>, <span class="refDoi"> DOI: 10.1634/stemcells.2007-0600</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1634%2Fstemcells.2007-0600" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=18323411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsFCgtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=1288-1297&author=T.+Holmesauthor=T.+A.+O%E2%80%99Brienauthor=R.+Knightauthor=R.+Lindemanauthor=S.+Shenauthor=E.+Songauthor=G.+Symondsauthor=A.+Dolnikov&title=Glycogen+synthase+kinase-3beta+inhibition+preserves+hematopoietic+stem+cell+activity+and+inhibits+leukemic+cell+growth&doi=10.1634%2Fstemcells.2007-0600"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase-3β inhibition preserves hematopoietic stem cell activity and inhibits leukemic cell growth</span></div><div class="casAuthors">Holmes, Tiffany; O'Brien, Tracey A.; Knight, Robert; Lindeman, Robert; Shen, Sylvie; Song, Emma; Symonds, Geoff; Dolnikov, Alla</div><div class="citationInfo"><span class="NLM_cas:title">Stem Cells (Durham, NC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1288-1297</span>CODEN:
                <span class="NLM_cas:coden">STCEEJ</span>;
        ISSN:<span class="NLM_cas:issn">1066-5099</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">Ex vivo expansion of cord blood cells generally results in reduced stem cell activity in vivo.  Glycogen synthase kinase-3β (GSK-3β) regulates the degrdn. of β-catenin, a crit. regulator of hematopoietic stem cells (HSCs).  Here we show that GSK-3β inhibition activates β-catenin in cord blood CD34+ cells and upregulates β-catenin transcriptional targets c-myc and HoxB4, both known to regulate HSC self-renewal.  GSK-3β inhibition resulted in delayed ex vivo expansion of CD34+ cells, yet enhanced the preservation of stem cell activity as tested in long-term culture with bone marrow stroma.  Delayed cell cycling, reduced apoptosis, and increased adherence of hematopoietic progenitor cells to bone marrow stroma were obsd. in these long-term cultures treated with GSK-3β inhibitor.  This improved adherence to stroma was mediated via upregulation of CXCR4.  In addn., GSK-3β inhibition preserved severe combined immunodeficiency (SCID) repopulating cells as tested in the nonobese diabetic/SCID mouse model.  Our data suggest the involvement of GSK-3β inhibition in the preservation of HSC and their interaction with the bone marrow environment.  Methods for the inhibition of GSK-3β may be developed for clin. ex vivo expansion of HSC for transplantation.  In addn., GSK-3β inhibition suppressed leukemic cell growth via the induction of apoptosis mediated by the down-regulation of survivin.  Modulators of GSK-3β may increase the range of novel drugs that specifically kill leukemic cells while sparing normal stem cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhyjEN8EYUhLVg90H21EOLACvtfcHk0lgYYLEdxihBjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsFCgtLk%253D&md5=1835e5518b6580e843b55cdafd494602</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1634%2Fstemcells.2007-0600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Fstemcells.2007-0600%26sid%3Dliteratum%253Aachs%26aulast%3DHolmes%26aufirst%3DT.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DT.%2BA.%26aulast%3DKnight%26aufirst%3DR.%26aulast%3DLindeman%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DE.%26aulast%3DSymonds%26aufirst%3DG.%26aulast%3DDolnikov%26aufirst%3DA.%26atitle%3DGlycogen%2520synthase%2520kinase-3beta%2520inhibition%2520preserves%2520hematopoietic%2520stem%2520cell%2520activity%2520and%2520inhibits%2520leukemic%2520cell%2520growth%26jtitle%3DStem%2520Cell.%26date%3D2008%26volume%3D26%26spage%3D1288%26epage%3D1297%26doi%3D10.1634%2Fstemcells.2007-0600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kretzschmar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roolf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langhammer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekora, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pews-Davtyan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frech, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenloffel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junghanss, C.</span></span> <span> </span><span class="NLM_article-title">The novel arylindolylmaleimide PDA-66 displays pronounced antiproliferative effects in acute lymphoblastic leukemia cells</span>. <i>BMC Canc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">71</span>, <span class="refDoi"> DOI: 10.1186/1471-2407-14-71</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1186%2F1471-2407-14-71" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=24502201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVymtLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=71&author=C.+Kretzschmarauthor=C.+Roolfauthor=T.+S.+Langhammerauthor=A.+Sekoraauthor=A.+Pews-Davtyanauthor=M.+Bellerauthor=M.+J.+Frechauthor=C.+Eisenloffelauthor=A.+Rolfsauthor=C.+Junghanss&title=The+novel+arylindolylmaleimide+PDA-66+displays+pronounced+antiproliferative+effects+in+acute+lymphoblastic+leukemia+cells&doi=10.1186%2F1471-2407-14-71"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The novel arylindolylmaleimide PDA-66 displays pronounced antiproliferative effects in acute lymphoblastic leukemia cells</span></div><div class="casAuthors">Kretzschmar, Christin; Roolf, Catrin; Langhammer, Tina-Susann; Sekora, Anett; Pews-Davtyan, Anahit; Beller, Matthias; Frech, Moritz J.; Eisenloeffel, Christian; Rolfs, Arndt; Junghanss, Christian</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">71/1-71/9</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Prognosis of adult patients suffering from acute lymphoblastic leukemia (ALL) is still unsatisfactory.  Targeted therapy via inhibition of deregulated signaling pathways appears to be a promising therapeutic option for the treatment of ALL.  Herein, we evaluated the influence of a novel arylindolylmaleimide (PDA-66), a potential GSK3β inhibitor, on several ALL cell lines.  Methods: ALL cell lines (SEM, RS4;11, Jurkat and MOLT4) were exposed to different concns. of PDA-66.  Subsequently, proliferation, metabolic activity, apoptosis and necrosis, cell cycle distribution and protein expression of Wnt and PI3K/Akt signaling pathways were analyzed at different time points.  Results: PDA-66 inhibited the proliferation of ALL cells significantly by redn. of metabolic activity.  The 72 h IC50 values ranged between 0.41 to 1.28 μM PDA-66.  Addnl., caspase activated induction of apoptosis could be detected in the analyzed cell lines.  PDA-66 influenced the cell cycle distribution of ALL cell lines differently.  While RS4;11 and MOLT4 cells were found to be arrested in G2 phase, SEM cells showed an increased cell cycle in G0/1 phase.  Conclusion: PDA-66 displays significant antileukemic activity in ALL cells and classifies as candidate for further evaluation as a potential drug in targeted therapy of ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYuSa5oVmUyLVg90H21EOLACvtfcHk0ljdFpwDaUKR2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVymtLzE&md5=baf0f5cb99b4b2e8a58e3bb3851f4015</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-14-71&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-14-71%26sid%3Dliteratum%253Aachs%26aulast%3DKretzschmar%26aufirst%3DC.%26aulast%3DRoolf%26aufirst%3DC.%26aulast%3DLanghammer%26aufirst%3DT.%2BS.%26aulast%3DSekora%26aufirst%3DA.%26aulast%3DPews-Davtyan%26aufirst%3DA.%26aulast%3DBeller%26aufirst%3DM.%26aulast%3DFrech%26aufirst%3DM.%2BJ.%26aulast%3DEisenloffel%26aufirst%3DC.%26aulast%3DRolfs%26aufirst%3DA.%26aulast%3DJunghanss%26aufirst%3DC.%26atitle%3DThe%2520novel%2520arylindolylmaleimide%2520PDA-66%2520displays%2520pronounced%2520antiproliferative%2520effects%2520in%2520acute%2520lymphoblastic%2520leukemia%2520cells%26jtitle%3DBMC%2520Canc.%26date%3D2014%26volume%3D14%26spage%3D71%26doi%3D10.1186%2F1471-2407-14-71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span> <span> </span><span class="NLM_article-title">Lithium exacerbates hepatic ischemia/reperfusion injury by inhibiting GSK-3beta/NF-kappaB-mediated protective signaling in mice</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>697</i></span>,  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2012.09.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1016%2Fj.ejphar.2012.09.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=23051669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFymurbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=697&publication_year=2012&pages=117-125&author=Y.+Xiaauthor=J.+Raoauthor=A.+Yaoauthor=F.+Zhangauthor=G.+Liauthor=X.+Wangauthor=L.+Lu&title=Lithium+exacerbates+hepatic+ischemia%2Freperfusion+injury+by+inhibiting+GSK-3beta%2FNF-kappaB-mediated+protective+signaling+in+mice&doi=10.1016%2Fj.ejphar.2012.09.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Lithium exacerbates hepatic ischemia/reperfusion injury by inhibiting GSK-3β/NF-κB-mediated protective signaling in mice</span></div><div class="casAuthors">Xia, Yongxiang; Rao, Jianhua; Yao, Aihua; Zhang, Feng; Li, Guoqiang; Wang, Xuehao; Lu, Ling</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">697</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">117-125</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Lithium (an inhibitor of GSK-3β activity) has beneficial effects on ischemia/reperfusion (I/R) injury in the central nervous system, heart and kidney.  However, the role of lithium in hepatic I/R injury is unknown.  The aim of this study was to assess the effects of lithium on hepatic I/R injury in a mouse model of partial hepatic I/R.  Previous studies showed that lithium chloride (LiCl) can phosphorylate residue Ser9, inhibit GSK-3β activity, and improve I/R injury in other organs.  In the present study, mice were pretreated with either vehicle or LiCl, which had similar effects on GSK-3β activity.  Surprisingly, treatment with LiCl significantly exacerbated hepatic I/R injury, which was detd. by serol. and histol. analyses.  Acute and chronic LiCl treatment caused serious damage in hepatic I/R injury, including increased apoptosis and oxidative stress.  To gain insight into the mechanism involved in this damage, the activity of nuclear factor-κB (NF-κB) (GSK-3β can regulate the transcriptional complex of NF-κB) was analyzed, which revealed that LiCl treatment significantly down-regulated the activity of NF-κB.  The NF-κB-mediated protective genes were then further evaluated, including anti-apoptotic genes (RAF2, cIAP 2, Bfl-1 and cFLIP) and the antioxidant gene MnSOD.  The expression of these protective genes was obviously suppressed compared with the vehicle group.  Taken together, these findings show that lithium exacerbates hepatic I/R injury by suppressing the expression of GSK-3β/NF-κB-mediated protective genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_V3ZvjCOo4LVg90H21EOLACvtfcHk0ljdFpwDaUKR2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFymurbM&md5=e9b581fbe71e3ea7da2ad8900adafc33</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2012.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2012.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DY.%26aulast%3DRao%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DL.%26atitle%3DLithium%2520exacerbates%2520hepatic%2520ischemia%252Freperfusion%2520injury%2520by%2520inhibiting%2520GSK-3beta%252FNF-kappaB-mediated%2520protective%2520signaling%2520in%2520mice%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D697%26spage%3D117%26epage%3D125%26doi%3D10.1016%2Fj.ejphar.2012.09.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, H.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, D.-M.</span></span> <span> </span><span class="NLM_article-title">Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model</span>. <i>Neuroscience</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">572</span>, <span class="refDoi"> DOI: 10.1016/j.neuroscience.2008.06.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1016%2Fj.neuroscience.2008.06.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=18640245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVSgtbjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2008&pages=567-572&author=H.-L.+Fengauthor=Y.+Lengauthor=C.-H.+Maauthor=J.+Zhangauthor=M.+Renauthor=D.-M.+Chuang&title=Combined+lithium+and+valproate+treatment+delays+disease+onset%2C+reduces+neurological+deficits+and+prolongs+survival+in+an+amyotrophic+lateral+sclerosis+mouse+model&doi=10.1016%2Fj.neuroscience.2008.06.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model</span></div><div class="casAuthors">Feng, H.-L.; Leng, Y.; Ma, C.-H.; Zhang, J.; Ren, M.; Chuang, D.-M.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">567-572</span>CODEN:
                <span class="NLM_cas:coden">NRSCDN</span>;
        ISSN:<span class="NLM_cas:issn">0306-4522</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Lithium and valproic acid (VPA) are two primary drugs used to treat bipolar disorder, and have been shown to have neuroprotective properties in vivo and in vitro.  A recent study demonstrated that combined treatment with lithium and VPA elicits synergistic neuroprotective effects against glutamate excitotoxicity in cultured brain neurons, and the synergy involves potentiated inhibition of glycogen synthase kinase-3 (GSK-3) activity through enhanced GSK-3 serine phosphorylation.  We therefore investigated the effects of lithium and VPA cotreatment on the disease symptom onset, survival time and neurol. deficits in cooper zinc superoxide dismutase (SOD1) G93A mutant mice, a commonly used mouse model of amyotrophic lateral sclerosis (ALS).  The G93A ALS mice received twice daily i.p. injections with LiCl (60 mg/kg), VPA (300 mg/kg) or lithium plus VPA, starting from the 30th day after birth and continuing until death.  We found that combined treatment with lithium and VPA produced a greater and more consistent effect in delaying the onset of disease symptoms, prolonging the lifespan and decreasing the neurol. deficit scores, compared with the results of monotreatment with lithium or VPA.  Moreover, lithium in conjunction with VPA was more effective than lithium or VPA alone in enhancing the immunostaining of phospho-GSK-3βSer9 in brain and lumbar spinal cord sections.  To our knowledge, this is the first demonstration of enhanced neuroprotection by a combinatorial approach using mood stabilizers in a mouse ALS model.  Our results suggest that clin. trials using lithium and VPA in combination for ALS patients are a rational strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEQ05OC3y2rrVg90H21EOLACvtfcHk0ljNO9JUk-MwSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVSgtbjL&md5=d2c2256442657088e199a5b2094f9bd7</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroscience.2008.06.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroscience.2008.06.040%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DH.-L.%26aulast%3DLeng%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DC.-H.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DM.%26aulast%3DChuang%26aufirst%3DD.-M.%26atitle%3DCombined%2520lithium%2520and%2520valproate%2520treatment%2520delays%2520disease%2520onset%252C%2520reduces%2520neurological%2520deficits%2520and%2520prolongs%2520survival%2520in%2520an%2520amyotrophic%2520lateral%2520sclerosis%2520mouse%2520model%26jtitle%3DNeuroscience%26date%3D2008%26volume%3D155%26spage%3D567%26epage%3D572%26doi%3D10.1016%2Fj.neuroscience.2008.06.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span> <span> </span><span class="NLM_article-title">In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) in the treatment of acute promyelocytic leukemia: As<sub>2</sub>O<sub>3</sub> induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">1052</span>– <span class="NLM_lpage">1061</span>, <span class="refDoi"> DOI: 10.1182/blood.v88.3.1052.bloodjournal8831052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1182%2Fblood.V88.3.1052.1052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=8704214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADyaK28Xks1Cjur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1996&pages=1052-1061&author=G.+Chenauthor=J.+Zhuauthor=X.+Shiauthor=J.+Niauthor=H.+Zhongauthor=G.+Siauthor=X.+Jinauthor=W.+Tangauthor=X.+Liauthor=S.+Xongauthor=Z.+Shenauthor=G.+Sunauthor=J.+Maauthor=P.+Zhangauthor=T.+Zhangauthor=C.+Gazinauthor=T.+Naoeauthor=S.+Chenauthor=Z.+Wangauthor=Z.+Chen&title=In+vitro+studies+on+cellular+and+molecular+mechanisms+of+arsenic+trioxide+%28As2O3%29+in+the+treatment+of+acute+promyelocytic+leukemia%3A+As2O3+induces+NB4+cell+apoptosis+with+downregulation+of+Bcl-2+expression+and+modulation+of+PML-RAR+alpha%2FPML+proteins&doi=10.1182%2Fblood.v88.3.1052.bloodjournal8831052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins</span></div><div class="casAuthors">Chen, Guo-Qiang; Zhu, Jun; Shi, Xue-Geng; Ni, Jian-Hua; Zhong, Hao-Jie; Si, Gui-Ying; Jin, Xiao-Long; Tang, Wei; Li, Xiu-Shong; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1052-1061</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">Saunders</span>)
        </div><div class="casAbstract">It has been shown recently in China that arsenic trioxide (As2O3) is a very effective treatment for acute promyelocytic leukemia (APL).  APL patients resistant to all-trans retinoic acid (ATRA) and conventional chemotherapy can still respond to As2O3.  In this study, we addressed the possible cellular and mol. mechanisms of this treatment by using NB4 cells as a model.  The results show that: (1) As2O3 triggers relatively specific NB4 cell apoptosis at micromolar concn., as proved by morphol., histogramic related nuclear DNA contents, and DNA gel electrophoresis. (2) As2O3 does not influence bax, bcl-x, c-myc, and p53 gene expression, but downregulates bcl-2 gene expression at both mRNA and protein levels.  (3)As2O3 induces a significant modulation of the PML staining pattern in NB4 cells and HL-60 cells.  The micropunctates characteristic of PML-RARα in NB4 cells disappear after treatment with As2O3, whereas a diffuse PML staining occurs in the perinuclear cytoplasmic region.  In addn., a low percentage of untreated NB4 cells exhibits an accumulation of PML> pos. particles in a compartment of cytoplasm.  The percentage of these cells can be significantly increased after As2O3 treatment.  A similar PML staining pattern is obsd. in apoptotic cells.  (4) ATRA pretreatment does not influence As2O3-induced apoptosis.  These results suggest that induction of cell apoptosis can be one of the mechanisms of the therapeutic effect of As2O3.  Moreover, this apoptosis induction occurs independently of the retinoid pathway and may be mediated, at least partly, through the modulation of bcl-2, as well as PML-RARα and/or PML proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5d7RDGm_BkrVg90H21EOLACvtfcHk0ljNO9JUk-MwSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xks1Cjur0%253D&md5=402dd3dea5e64ebd998c559f3d2dd747</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1182%2Fblood.V88.3.1052.1052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V88.3.1052.1052%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DNi%26aufirst%3DJ.%26aulast%3DZhong%26aufirst%3DH.%26aulast%3DSi%26aufirst%3DG.%26aulast%3DJin%26aufirst%3DX.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXong%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DG.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DGazin%26aufirst%3DC.%26aulast%3DNaoe%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DZ.%26atitle%3DIn%2520vitro%2520studies%2520on%2520cellular%2520and%2520molecular%2520mechanisms%2520of%2520arsenic%2520trioxide%2520%2528As2O3%2529%2520in%2520the%2520treatment%2520of%2520acute%2520promyelocytic%2520leukemia%253A%2520As2O3%2520induces%2520NB4%2520cell%2520apoptosis%2520with%2520downregulation%2520of%2520Bcl-2%2520expression%2520and%2520modulation%2520of%2520PML-RAR%2520alpha%252FPML%2520proteins%26jtitle%3DBlood%26date%3D1996%26volume%3D88%26spage%3D1052%26epage%3D1061%26doi%3D10.1182%2Fblood.v88.3.1052.bloodjournal8831052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flexor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, P.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waxman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanotte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J.-H.</span></span> <span> </span><span class="NLM_article-title">Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">1014</span>– <span class="NLM_lpage">1022</span>, <span class="refDoi"> DOI: 10.1182/blood.v99.3.1014.h80302001014_1014_1022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1182%2Fblood.V99.3.1014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=11807007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtValtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=1014-1022&author=Q.+Zhuauthor=J.-W.+Zhangauthor=H.-Q.+Zhuauthor=Y.-L.+Shenauthor=M.+Flexorauthor=P.-M.+Jiaauthor=Y.+Yuauthor=X.+Caiauthor=S.+Waxmanauthor=M.+Lanotteauthor=S.-J.+Chenauthor=Z.+Chenauthor=J.-H.+Tong&title=Synergic+effects+of+arsenic+trioxide+and+cAMP+during+acute+promyelocytic+leukemia+cell+maturation+subtends+a+novel+signaling+cross-talk&doi=10.1182%2Fblood.v99.3.1014.h80302001014_1014_1022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk</span></div><div class="casAuthors">Zhu, Qi; Zhang, Ji-Wang; Zhu, Hai-Qing; Shen, Yu-Lei; Flexor, Maria; Jia, Pei-Ming; Yu, Yun; Cai, Xun; Waxman, Samuel; Lanotte, Michel; Chen, Sai-Juan; Chen, Zhu; Tong, Jian-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1014-1022</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Acute promyelocytic leukemia (APL) is characterized by the specific chromosome translocation t(15;17) with promyelocytic leukemia-retinoic acid receptor-α (PML-RARA) fusion gene and the ability to undergo terminal differentiation as an effect of all-trans retinoic acid (ATRA).  Recently, arsenic trioxide (As2O3) was identified as an alternative therapy in patients with both ATRA-sensitive and ATRA-resistant APL.  At the cellular level, As2O3 triggers apoptosis and a partial differentiation of APL cells in a dose-dependent manner; both effects are obsd. in vivo among patients with APL and APL animal models.  To further explore the mechanism of As2O3-induced differentiation, the combined effects of arsenic and a no. of other differentiation inducers on APL cell lines (NB4 and NB4-R1) and some fresh APL cells were examd.  The data show that a strong synergy exists between a low concn. of As2O3 (0.25 μM) and the cyclic adenosine monophosphate (cAMP) analog, 8-CPT-cAMP, in fully inducing differentiation of NB4, NB4-R1, and fresh APL cells.  Furthermore, cAMP facilitated the degrdn. of As2O3-mediated fusion protein PML-RARα, a process considered to play a key role in overcoming the differentiation arrest of APL cells.  On the other hand, cAMP could significantly inhibit cell growth by modulating several major players in G1/S transition regulation.  Interestingly, H89, an antagonist of protein kinase A, could block the differentiation-inducing effect of As2O3 potentiated by cAMP.  These results thus support the existence of a novel signaling cross-talk for APL maturation, which may deepen understanding of As2O3-induced differentiation in vivo, and thus furnish insights for new therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdhZXNWJYYTbVg90H21EOLACvtfcHk0liaEb2627t1jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtValtrc%253D&md5=18d70d5b0166d768ddba9b5581775741</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1182%2Fblood.V99.3.1014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V99.3.1014%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DJ.-W.%26aulast%3DZhu%26aufirst%3DH.-Q.%26aulast%3DShen%26aufirst%3DY.-L.%26aulast%3DFlexor%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DP.-M.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DWaxman%26aufirst%3DS.%26aulast%3DLanotte%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DS.-J.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DTong%26aufirst%3DJ.-H.%26atitle%3DSynergic%2520effects%2520of%2520arsenic%2520trioxide%2520and%2520cAMP%2520during%2520acute%2520promyelocytic%2520leukemia%2520cell%2520maturation%2520subtends%2520a%2520novel%2520signaling%2520cross-talk%26jtitle%3DBlood%26date%3D2002%26volume%3D99%26spage%3D1014%26epage%3D1022%26doi%3D10.1182%2Fblood.v99.3.1014.h80302001014_1014_1022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benajiba, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiwer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacher, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gale, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puissant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Back, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pikman, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galinsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeAngelo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robers, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machleidt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermine, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakshminarasimhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemann, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scolnick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegmaier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holson, E. B.</span></span> <span> </span><span class="NLM_article-title">Exploiting an Asp-Glu “switch” in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">eaam8460</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.aam8460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=10.1126%2Fscitranslmed.aam8460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=29515000" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&author=F.+F.+Wagnerauthor=L.+Benajibaauthor=A.+J.+Campbellauthor=M.+Weiwerauthor=J.+R.+Sacherauthor=J.+P.+Galeauthor=L.+Rossauthor=A.+Puissantauthor=G.+Alexeauthor=A.+Conwayauthor=M.+Backauthor=Y.+Pikmanauthor=I.+Galinskyauthor=D.+J.+DeAngeloauthor=R.+M.+Stoneauthor=T.+Kayaauthor=X.+Shiauthor=M.+B.+Robersauthor=T.+Machleidtauthor=J.+Wilkinsonauthor=O.+Hermineauthor=A.+Kungauthor=A.+J.+Steinauthor=D.+Lakshminarasimhanauthor=M.+T.+Hemannauthor=E.+Scolnickauthor=Y.+L.+Zhangauthor=J.+Q.+Panauthor=K.+Stegmaierauthor=E.+B.+Holson&title=Exploiting+an+Asp-Glu+%E2%80%9Cswitch%E2%80%9D+in+glycogen+synthase+kinase+3+to+design+paralog-selective+inhibitors+for+use+in+acute+myeloid+leukemia&doi=10.1126%2Fscitranslmed.aam8460"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aam8460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aam8460%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DF.%2BF.%26aulast%3DBenajiba%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DA.%2BJ.%26aulast%3DWeiwer%26aufirst%3DM.%26aulast%3DSacher%26aufirst%3DJ.%2BR.%26aulast%3DGale%26aufirst%3DJ.%2BP.%26aulast%3DRoss%26aufirst%3DL.%26aulast%3DPuissant%26aufirst%3DA.%26aulast%3DAlexe%26aufirst%3DG.%26aulast%3DConway%26aufirst%3DA.%26aulast%3DBack%26aufirst%3DM.%26aulast%3DPikman%26aufirst%3DY.%26aulast%3DGalinsky%26aufirst%3DI.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DKaya%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DRobers%26aufirst%3DM.%2BB.%26aulast%3DMachleidt%26aufirst%3DT.%26aulast%3DWilkinson%26aufirst%3DJ.%26aulast%3DHermine%26aufirst%3DO.%26aulast%3DKung%26aufirst%3DA.%26aulast%3DStein%26aufirst%3DA.%2BJ.%26aulast%3DLakshminarasimhan%26aufirst%3DD.%26aulast%3DHemann%26aufirst%3DM.%2BT.%26aulast%3DScolnick%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DY.%2BL.%26aulast%3DPan%26aufirst%3DJ.%2BQ.%26aulast%3DStegmaier%26aufirst%3DK.%26aulast%3DHolson%26aufirst%3DE.%2BB.%26atitle%3DExploiting%2520an%2520Asp-Glu%2520%25E2%2580%259Cswitch%25E2%2580%259D%2520in%2520glycogen%2520synthase%2520kinase%25203%2520to%2520design%2520paralog-selective%2520inhibitors%2520for%2520use%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2018%26volume%3D10%26doi%3D10.1126%2Fscitranslmed.aam8460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span> <span> </span><span class="NLM_article-title">Assessing lysine and cysteine reactivities for designing targeted covalent kinase inhibitors</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">6553</span>– <span class="NLM_lpage">6560</span>, <span class="refDoi"> DOI: 10.1021/jacs.8b13248</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.8b13248" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmslSgur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2019&pages=6553-6560&author=R.+Liuauthor=Z.+Yueauthor=C.-C.+Tsaiauthor=J.+Shen&title=Assessing+lysine+and+cysteine+reactivities+for+designing+targeted+covalent+kinase+inhibitors&doi=10.1021%2Fjacs.8b13248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Assessing Lysine and Cysteine Reactivities for Designing Targeted Covalent Kinase Inhibitors</span></div><div class="casAuthors">Liu, Ruibin; Yue, Zhi; Tsai, Cheng-Chieh; Shen, Jana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6553-6560</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Targeted covalent inhibitor design is gaining increasing interest and acceptance.  A typical covalent kinase inhibitor design targets a reactive cysteine; however, this strategy is limited by the low abundance of cysteine and acquired drug resistance from point mutations.  Inspired by the recent development of lysine-targeted chem. probes, we asked if nucleophilic (reactive) catalytic lysines are common on the basis of the published crystal structures of the human kinome.  Using a newly developed pKa prediction tool based on continuous const. pH mol. dynamics, the catalytic lysines of eight unique kinases from various human kinase groups were retrospectively and prospectively predicted to be nucleophilic, when kinase is in the rare DFG-out/αC-out type of conformation.  Importantly, other reactive lysines as well as cysteines at various locations were also identified.  On the basis of the findings, we proposed a new strategy in which selective type II reversible kinase inhibitors are modified to design highly selective, lysine-targeted covalent inhibitors.  Traditional covalent drugs were discovered serendipitously; the presented tool, which can assess the reactivities of any potentially targetable residues, may accelerate the rational discovery of new covalent inhibitors.  Another significant finding of the work is that lysines and cysteines in kinases may adopt neutral and charged states at physiol. pH, resp.  This finding may shift the current paradigm of computational studies of kinases, which assume fixed soln. protonation states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXUZJq48FZTLVg90H21EOLACvtfcHk0liaEb2627t1jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmslSgur8%253D&md5=aab2762e5cbcedae163c38445f48bdd7</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjacs.8b13248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.8b13248%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DYue%26aufirst%3DZ.%26aulast%3DTsai%26aufirst%3DC.-C.%26aulast%3DShen%26aufirst%3DJ.%26atitle%3DAssessing%2520lysine%2520and%2520cysteine%2520reactivities%2520for%2520designing%2520targeted%2520covalent%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2019%26volume%3D141%26spage%3D6553%26epage%3D6560%26doi%3D10.1021%2Fjacs.8b13248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2127</span>– <span class="NLM_lpage">2142</span>, <span class="refDoi"> DOI: 10.1021/jm101340q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101340q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjt1yrtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2127-2142&author=Y.+Wangauthor=J.+Aiauthor=Y.+Wangauthor=Y.+Chenauthor=L.+Wangauthor=G.+Liuauthor=M.+Gengauthor=A.+Zhang&title=Synthesis+and+c-Met+kinase+inhibition+of+3%2C5-disubstituted+and+3%2C5%2C7-trisubstituted+quinolines%3A+identification+of+3-%284-acetylpiperazin-1-yl%29-5-%283-nitrobenzylamino%29-7-+%28trifluoromethyl%29quinoline+as+a+novel+anticancer+agent&doi=10.1021%2Fjm101340q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and c-Met Kinase Inhibition of 3,5-Disubstituted and 3,5,7-Trisubstituted Quinolines: Identification of 3-(4-Acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a Novel Anticancer Agent</span></div><div class="casAuthors">Wang, Yuanxiang; Ai, Jing; Wang, Ying; Chen, Yi; Wang, Lu; Liu, Gang; Geng, Meiyu; Zhang, Ao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2127-2142</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By use of an improved synthetic strategy, a series of 3,5-disubstituted and 3,5,7-trisubstituted quinolines were readily prepd.  3,5,7-Trisubstituted quinolines I (X = NMe, NCOMe, NEt, O, NSO2-cPr, NSO2Me, NCH2CO2Et) were identified as the most potent c-Met inhibitors with IC50 of less than 1.0 nM.  Compd. I (X = NCOMe)(II) showed the most promising overall PK profile and has high potency and extraordinary selectivity to c-Met against c-Met family member Ron and 12 other tyrosine kinases.  It produced constitutive inhibition of c-Met phosphorylation in c-Met dependent cell lines.  At doses of 100 mg/kg, compd. II showed statistically significant tumor growth inhibition (68-69%) in both NIH-3T3-TPR-Met and U-87 MG human gliobastoma xenograft models.  These results clearly indicated that compd. II is a potent and highly selective c-Met inhibitor.  Its favorable in vitro and in vivo profiles warrant further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaaPLbjIALwbVg90H21EOLACvtfcHk0ljOu-N4GNPB-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjt1yrtbk%253D&md5=b7e0a14f0f710b066051f01bf15397e4</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm101340q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101340q%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DSynthesis%2520and%2520c-Met%2520kinase%2520inhibition%2520of%25203%252C5-disubstituted%2520and%25203%252C5%252C7-trisubstituted%2520quinolines%253A%2520identification%2520of%25203-%25284-acetylpiperazin-1-yl%2529-5-%25283-nitrobenzylamino%2529-7-%2520%2528trifluoromethyl%2529quinoline%2520as%2520a%2520novel%2520anticancer%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2127%26epage%3D2142%26doi%3D10.1021%2Fjm101340q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i94"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02254">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_11020"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02254?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02254</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">HPLC traces for key target compounds and figures for the candidate of <b>4</b>-<b>3</b> including hERG inhibition and exposition curve in mouse plasma (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02254/suppl_file/jm0c02254_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and biological data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02254/suppl_file/jm0c02254_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02254/suppl_file/jm0c02254_si_001.pdf">jm0c02254_si_001.pdf (275.98 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02254/suppl_file/jm0c02254_si_002.csv">jm0c02254_si_002.csv (1.04 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c02254&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c02254%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-11%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c02254" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677afad5ad7e21a6","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
